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PREVENTS THE FORMATION OF AMYLOID FIBRILS
Neeraj Kapoor, Ph.D.
The Rockefeller university, 2010

Nucleobindin 1 (NUCB1) is a widely expressed multi-domain Ca2+binding protein whose precise physiological and biochemical functions are
not well understood. We engineered and heterologously expressed a
soluble form of NUCB1 (sNUCB1) and characterized its biophysical and
biochemical properties.

We show that sNUCB1 exists as a dimer in

solution and that each monomer binds two divalent Ca2+ cations. Ca2+binding causes conformational changes in sNUCB1 as judged by circular
dichroism and fluorescence spectroscopy experiments.

Earlier reports

suggested that NUCB1 might interact with heterotrimeric G protein αsubunits.

We

show

that

dimeric

Ca2+-free

sNUCB1

binds

to

heterologously expressed Gαi1 and that Ca2+-binding inhibits this
interaction. We further show that the binding of sNUCB1 to Gαi1 inhibits
its basal rate of GDP release and slows its rate and extent of GTPγS
uptake. We conclude that sNUCB1 is a Ca2+-dependent guaninenucleotide dissociation inhibitor (GDI) for Gαi1. To our knowledge

sNUCB1 is the first example of a calcium-dependent GDI for
heterotrimeric G proteins.

In addition, we also established novel and unique anti-amyloidogenic
functional ability of sNUCB1. We show that Ca2+-free sNUCB1 can
inhibit fibril formation by highly amyloidogenic human Islet Amyloid
PolyPeptide (hIAPP) and Amyloid-β 42 (Aβ42) peptides, as relevant to
Type-2 Diabetes and Alzheimer’s disease. In addition, we also show that
Ca2+-free sNUCB1 can effectively dissociate amyloid fibrils formed by
both hIAPP and Aβ42. Interestingly, Ca2+ disrupts this unique functional
ability of sNUCB1. In order to circumvent this, we designed and purified a
Ca2+-insentive mutant namely sNUCB1(tetramutant) that is functionally
similar to sNUCB1 even in the presence of excess Ca2+ in the reaction
mixture. Mechanistically, we show that sNUCB1 inhibits fibril formation
by capping the ends of high molecular mass prefibrillar species.
Subsequently, we also isolated a 39-amino-acid long C-terminal (CT)
peptide fragment of NUCB1 namely NUCB1(381-419) which, similar to
sNUCB1, inhibits and disaggregates hIAPP fibrillization. Finally we have
also extended this work to other amyloidogenic proteins namely tau
K19(C322S), a synthetic construct comprising microtubule binding
domain of human tau protein. Specifically, we show that Ca2+-free
sNUCB1 effectively inhibits amyloid fibril formation by tauK19(C322S).
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CHAPTER 1
Nucleobindin 1 is a Calcium Regulated Guanine Nucleotide Dissociation
Inhibitor of Gαi1

1.0 INTRODUCTION
Heterotrimeric guanine nucleotide-binding proteins, G proteins, couple to
heptahelical cell surface G protein-coupled receptors (GPCRs) and
participate in intracellular signaling events. The G protein heterotrimer is
composed of the GTPase Gα subunit and the Gβγ heterodimer. Upon
ligand-mediated activation, GPCRs catalyze the exchange of GDP for
GTP on Gα leading to dissociation of the heterotrimer into Gα•GTP and
Gβγ subunits (1-3). These individual subunits then regulate downstream
signaling cascades involving effector systems like adenylyl cyclases, Ca2+
and K+ channels, phospholipase C isozymes and cyclic nucleotide
phosphodiesterases (4, 5). Thereafter, the intrinsic GTPase activity of Gα
reverts it back to the GDP-bound state, which can reassociate with Gβγ.
This inhibits the interaction of G protein subunits with downstream
effectors, which results in turning-off of the signaling pathways. Hence,
signaling by heterotrimeric G proteins is directly dependent on the lifetime
of the GTP-bound state of Gα. This lifetime is regulated by GTPase
accelerating proteins (GAPs), which catalyze the rapid hydrolysis of the
Gα bound GTP to GDP and by guanine nucleotide dissociation inhibitors
(GDIs), which inhibit the exchange of GDP for GTP in the catalytic
pocket of Gα (6).
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Together, GAPs and GDIs exert a regulatory control on G protein
signaling. In recent years, novel interacting partners of heterotrimeric G
proteins called the regulators of G protein signaling or RGS proteins have
been discovered that possess GAP activity (7, 8). Interestingly, RGS12
and RGS14 in addition to functioning as GAPs, can also act as GDIs (9,
10). In 1999, Lanier and coworkers used yeast two-hybrid analysis to
identify distinct receptor independent activators of G protein signaling or
AGS proteins (11). Several members of this AGS family (AGS3-6) have
been shown to function as GDIs of Gαi subunits (12). The observed GDI
activity of both AGS and RGS proteins towards Gαi/o is attributed to a 19amino-acid consensus sequence called the GoLoco motif (9, 13, 14).
Earlier in 1995, in an independent yeast two-hybrid screen, Mochizuki et
al. established the interaction of a novel Golgi-resident Ca2+-binding
protein Nucleobindin 1 or NUCB1, specifically with the heterotrimeric G
protein α-subunit, Gαi2 (15). Subsequently, Lin et al. demonstrated that
NUCB1 interacts exclusively with the adenylyl cyclase inhibitory (Gαi)
and stimulatory (Gαs) classes of Gα subunits (16). In a recent study it was
shown that overexpression of NUCB1 causes redistribution of only the
Gαi1 subunits and not the Gβγ subunits to the plasma membrane and
regulated secretion granules (17). However, a role of NUCB1 in
modulating Gαi1 activation has not been observed so far.
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NUCB1 is a 55 kDa multi-domain Ca2+-binding protein that was first
identified as a novel B cell growth and differentiation factor associated
with lupus syndrome (18). NUCB1 derives its trivial name, Calnuc, from
its Ca2+-binding and DNA-binding ability (19). The DNA-binding domain
of basic residues (172-218) lies at the N-terminus following the signal
sequence. The Ca2+-binding domain is at the core of the protein sequence
comprising of two EF hand motifs with an intervening acidic region (253316). The Ca2+-binding domain is followed by a leucine zipper domain
(347-389), which has been postulated to induce NUCB1 dimerization (20)
(Fig.1.1). The C-terminal (CT) region following the leucine zipper domain
is predicted to be intrinsically disordered and unstructured (21).
Intriguingly, NUCB1 is strongly conserved from flies to humans (22) and
is widely distributed amongst Golgi (16, 23), nucleus (19, 24),
endoplasmic reticulum (25, 26) and cytoplasm (17). The N-terminal signal
sequence of NUCB1 targets it to different membrane compartments and its
deletion renders NUCB1 cytosolic.

Recently, Brodeur et al. reported the role of NUCB1 in LDLR related
protein 9 (LRP9) trafficking where the cytosolic NUCB1 fraction helps in
LRP9 endosomal sorting and prevents its delivery to lysosomes (27). The
ubiquitous expression of NUCB1 in various cell and tissue types results in
a diverse interactome comprising interacting partners like G protein αsubunits, cyclooxygenases and amyloid precursor protein (16, 26-28).
3

Several classes of Gα subunits have been shown to interact with NUCB1
(16, 26-28). Yeast-two hybrid experiments performed with various
deletion constructs of either Gαi3 or NUCB1 mapped the CT α5 helix
domain of G protein and the acidic region of NUCB1 (264-305) to be
necessary for interaction (29). Immuno-fluorescence based studies showed
that NUCB1 and Gαi protein subunits co-localize on the Golgi lumen and
regulated secretion granules (17). Since Gα subunits are ubiquitously
involved in numerous signal transduction pathways in different tissue
types, their interaction with NUCB1 might regulate downstream signaling
events.

We are interested in understanding the role of α5 helix of G protein α
subunits in regulating nucleotide exchange rates (30-32). Since the α5
helix of Gα is involved in interaction with NUCB1, we characterized and
studied the interaction of NUCB1 with Gαi1 in detail. In the current study,
we present the detailed biophysical and biochemical characterization of
the Ca2+-binding ability and oligomeric state of a heterologously
expressed N-terminally truncated soluble form of NUCB1, termed
sNUCB1 (Fig.1.1). We show that sNUCB1 binds Ca2+ and exists as a
dimer in solution. Ca2+-free sNUCB1 preferentially binds wild-type (WT)
Gαi1 and inhibits its GDP release as demonstrated by several independent
assays. We conclude that sNUCB1 serves as a novel Ca2+-regulated GDI
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of Gαi1. Our findings suggest that NUCB1 is involved in regulating
cytoplasmic G protein signaling and trafficking.
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1.1 MATERIALS AND METHODS
1.1.1 REAGENTS
Guanosine 5’-diphosphate (GDP) sodium salt and guanosine 5’-O-(3thiotriphosphate) (GTPγS) tetralithium salt were purchased from SigmaAldrich (St. Louis, MO). The fluorescent GTPγS analogue, mant (2’,3’-O(N-methyl-anthraniloyl) - GTPγS was purchased from Jena Biosciences
(Jena, Germany) whereas BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-sindacene)-FL-GTPγS was purchased from Molecular Probes (Invitrogen).
The His6-tagged truncation and point mutants of sNUCB1 were generated
by site-directed mutagenesis using the high-fidelity thermostable DNA
polymerase Pfu (Stratagene, CA). All reagents and chemicals used were of
highest available purity.

1.1.2. Heterologous expression of sNUCB1 and heterotrimeric G
protein α-subunit Gα i1
The cDNA clones for human NUCB1 and rat Gαi1 were obtained from
ATCC and cDNA.org respectively. DNA fragment for the soluble form of
NUCB1 or sNUCB1, corresponding to residues 31-461 of the human
NUCB1 protein without the N-terminal signal sequence (residues 1-31)
was

cloned

into

the

pET28a(+)

expression

vector

(Amersham

Biosciences). Similarly the DNA fragment corresponding to full-length
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WT rat Gαi1 subunit (residues 1–354) was cloned into the pET28a(+)
expression vector. The vector was used to transform BL21 (DE3) cells to
express a N-terminal His6-tag protein containing a PreScission protease
site directly after the His6-tag. The expressed construct for sNUCB1
served as a template for introducing site-specific mutations using the
Quick Change system (Stratagene, La Jolla, CA) to generate
sNUCB1(W232A/W333A) or for introducing a missense mutation to
generate the truncated version of the protein, namely sNUCB1(W333Ter).
All proteins were expressed in BL21 (DE3) cells grown in the presence of
50 µg / ml kanamycin. Cells were grown at 37 oC to A600nm of ~ 0.8 and
then induced with 500 µ M isopropylthio-β-D-galactoside (IPTG) (US
Biological). Post induction the culture was grown overnight at 17 oC and
subsequently harvested. The resulting pellets were re-suspended in a
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM βmercaptoethanol, bovine lung aprotinin (20 mg / ml), 2 mM
phenylmethane sulfonyl fluoride (PMSF) and complete EDTA-free
protease inhibitor cocktail tablets (Roche). Thereafter the cells were lysed
and the expressed His6-tag protein was purified from crude extract by
using affinity chromatography using Ni-NTA column pre-equilibrated
with buffer A (50 mM Tris, pH 8.0, 150 mM NaCl, 50 mM βmercaptoethanol) for sNUCB1 and its variants and buffer A’ (50 mM Tris
pH 8.0, 150 mM NaCl, 2 mM MgCl2•6H2O, 10 µM GDP, 50 mM βmercaptoethanol) for WT Gαi1. The bound His6-tag protein was eluted
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from the column by using buffer A or buffer A’ supplemented with 500
mM imidazole. The His6-tag was cleaved by a GST-tagged PreScissionTM
protease, which was subsequently removed from the solution using GSHSepharose column chromatography. In order to remove Ca2+ from
sNUCB1 or its variants, the proteins were extensively dialyzed against
buffer A supplemented with 5 mM EGTA and 1 mM EDTA, which were
also eventually removed through dialysis. Finally, size exclusion
chromatography (SEC) was done using Superdex200 26 / 60 HR column
equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM NaCl) for
sNUCB1 and its variants and equilibrated in buffer S’ (50 mM Tris, pH
8.0, 150 mM NaCl, 2 mM MgCl2.6H2O, 10 µM GDP, 1mM DTT) for WT
Gαi1 to obtain homogenously pure protein. The typical yield for sNUCB1
and its variants was ~ 5-7 mg / L and for WT Gαi1 ~ 12-15 mg / L. The
purity of the proteins was assessed by Coomassie brilliant blue staining
after the proteins were separated through SDS-PAGE. The purity of all
proteins was greater than 95%.

1.1.3 Isothermal Titration Calorimetry (ITC)
ITC was performed at 25 °C (298 K) using a MicroCal VP-ITC
(MicroCal, Northhampton, MA) calorimeter. In order to measure
quantitatively the binding of Ca2+ or WT Gαi1•GDP to sNUCB1, 2 ml of
50 µM sNUCB1 (Ca2+-free) and 700 µl of either 500 µM CaCl2•6H2O
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(prepared in 50 mM Tris, pH 8.0, 150 mM NaCl) or 600 µM WT
Gαi1•GDP (prepared in 50 mM Tris, pH 8.0, 150 mM NaCl, 2 mM
MgCl2.6H2O, 10 µM GDP, 1 mM TCEP) was used and thoroughly
degassed. Contents of the sample cell were stirred continuously at 280 rpm
during the experiment. A typical titration of sNUCB1 involved 50
injections each of 5 µl of CaCl2.6H2O (500 µM) or WT Gαi1•GDP (600
µM) into a sample cell containing 1.4 ml of sNUCB1 (50 µM). The heat
of dilution of the titrant (CaCl2•6H2O or WT Gαi1•GDP) was subtracted
from the titration data for base-line correction. The base line-corrected
data were analyzed with MicroCal OriginTM 6.0 software to determine
the change in enthalpy (ΔH) and association constant (Ka). Thermal
titration data fit showed two-sets of binding sites for Ca2+ to sNUBC1.
Additionally, the data analysis also showed that one WT Gαi1•GDP
subunit interacts with a dimer of Ca2+-free sNUCB1. The parameters were
calculated based on 3 or more independent titration experiments. Each
numerical value reported is the mean ± S.E.M. amongst the independent
data sets.

1.1.4 Size Exclusion Chromatography (SEC)
Complex formation between sNUCB1 and WT Gα i1
Complex formation between sNUCB1 and Gαi1 was monitored using
SEC. 150 µM of sNUCB1 (- Ca2+ / +Ca2+) was incubated with 256 µM
9

Gαi1•(GDP / GTPγS) in 20 mM Tris, pH 8.0, 100 mM NaCl, 10 mM
MgCl2, 10 µM GDP and 1 mM DTT at 30 oC for 20 min with minimal
shaking to enable saturation binding. WT Gαi1 in the GTPγS-bound state
was generated by incubating WT Gαi1•GDP with 5 mM GTPγS for 30 min
at 30 oC to ensure complete exchange of nucleotide. Further the complete
exchange was confirmed by AlF4¯ exchange assay. About 200 µl of the
reaction mixture was injected onto a buffer equilibrated Superdex200 10 /
30 GL column attached to AKTA FPLC (GE Healthcare) and run at 4 oC.
Sample Elution was performed with the incubation buffer at a flow rate of
0.5 ml / min with 0.35 ml fractions collected. Peak fractions were
analyzed through SDS-PAGE followed by Coomassie staining to analyze
the complex formation.

Estimation of sNUCB1 molecular mass using heavy molecular weight
standards
Purified sNUCB1 or the heavy molecular weight standards (GE
Healthcare) were injected onto a Superdex200 10 / 30 GL column preequilibrated with Buffer S and the normalized absorbance of the eluting
peak was plotted. A calibration curve of Kav [(Ve-Vo)/(Vc-Vo)] vs
Log(molecular weight) was plotted, where Ve is the elution volume, Vo is
the column void volume corresponding to the elution of Blue Dextran and
Vc is the geometric column volume. The data were fit to a straight-line
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curve like Y = A + Bx where A = 1.915 and B = 0.311 were obtained from
the fit. Therefore for a Y = Kav value, the corresponding value of
Log(Molecular weight) was obtained to estimate the molecular mass of
sNUCB1 and sNUCB1(W333Ter).

1.1.5 Light Scattering
Multi-angle light scattering (MALS) and Dynamic Light Scattering
(DLS)
The light scattering data were collected using a Superdex200 10 / 30 HR
SEC column (GE Healthcare, Piscataway, NJ), connected to High
Performance Liquid Chromatography System (HPLC), Agilent 1200,
(Agilent Technologies, Wilmington, DE) equipped with an autosampler.
The elution from SEC was monitored by a photodiode array (PDA) UV /
VIS detector (Agilent Technologies, Wilmington, DE), differential
refractometer (OPT-Lab rEx Wyatt Corp., Santa Barbara, CA), static and
dynamic, multiangle laser light scattering (LS) detector (HELEOS II with
QELS capability, Wyatt Corp., Santa Barbara, CA). The SEC-UV / LS /
RI system was equilibrated in buffer (50 mM Tris, pH 8.0, 150 mM NaCl)
for sNUCB1 alone and in buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 10
mM MgCl2, 10 µM GDP, 1 mM DTT) for WT and truncated sNUCB1 / G
protein complex at the flow rate of 1.0 ml / min. Two software packages
were used for data collection and analysis: the Chemstation software
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(Agilent Technologies, Wilmington, DE) controlled the HPLC operation
and data collection from the multi-wavelength UV/VIS detector, while the
ASTRA software (Wyatt Corp., Santa Barbara, CA) collected data from
the refractive index (RI) detector and the LS detectors, and recorded the
UV trace at 280 nm sent from the PDA detector. The weight-average
molecular masses, Mw, were determined across the entire elution profile in
the intervals of 1 s from static LS measurement using ASTRA software as
previously described (33). The approach uses a Rayleigh-Debye-Gans
light scattering model (equation 1), which relates the amount of scattered
light to the concentration and weight average molecular weight of solute
and second virial coefficient:

K ∗c
1
=
+ 2A2c
R(θ ) M w

(1)

where, R(θ) is the intensity of excess scattered light at angle θ, c is the
€
concentration of the solute, Mw is the weight average molecular weight of
the solute, A2 is the second virial coefficient, K* is an optical parameter
equal to 4 π 2 n 2

(dn dc) 2
, where n is the refractive index, dn / dc is the
λ40 N A

refractive index increment for the solute, NA is Avogadro’s number, and

€λ0 is the wavelength of the scattered light.
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DLS measurements were made “on line” at an angle of 100° with a 2 s
collection time. Time resolved scatter intensity fluctuations were analyzed
using ASTRA Software (Wyatt Corp., Santa Barbara, CA), which
implements the cumulants method (34) to determine the time dependence
of diffusive motion also referred to as the intensity correlation function,
G(T), (35):

G(T) = B{1+ α [exp(−DT q 2 t)]2 }

(2)

where, B is the average baseline intensity, α is an instrument-specific
€
is the concentration-dependent translational
correction factor, DT
diffusion constant of the solute, t is a delay time, and q is the scattering
vector equal to

4 πn
sin θ 2 , where n is the refractive index of the solvent,
λ

λ is the wavelength of the scattered light and θ is the scattering angle.

€ 2 describes the relationship between the time dependency of
Equation
fluctuation in scatter intensity and the translational diffusion coefficient.
The value of DT can be used to estimate the apparent hydrodynamic radius
of an equivalent sphere using Stokes-Einstein relationship (equation 3):

Rh =

kT
6πηDT

(3)

where, k is the Boltzmann constant, T is the absolute temperature, and η is
€
the temperature corrected viscosity of the solution.
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Determination of dimerization equilibrium constant from SECUV/LS/RI
The concentration dependent changes in the weight-average molar mass
(Mw) determined for the apex of the eluting peak for sNUBC1 were used
to determine the dimerization constant. The weight-average molar masses
were plotted as a function of protein concentration for sNUCB1; error bars
represent ± 3 % of Mw for concentration above 100 µg / ml; ± 5 % of Mw
for concentration between 1-100 µg / ml and ± 10 % of Mw for
concentration below 1 µg / ml. Lines represent the non-linear least-square
fits to a monomer-dimer association model for sNUCB1 dimerization.

Determination of Kd of complex formation from SEC-UV / LS / RI
The concentration dependent changes in the weight average molar mass
(Mw) determined for the apex of the eluting peak were used to determine
the complexation of Gαi1 with sNUCB1 / sNUCB1(W333Ter). The
weight-average molar mass values were plotted as a function of total
protein concentration for complexation; error bars represent ± 3 % of Mw
for concentration above 100 µg / ml; ± 5 % of Mw for concentration
between 1-100 µg / ml and ± 10 % of Mw for concentration below 1 µg /
ml. Lines represent the non-linear least-square fits to a stimulated
complexation model using Origin 6.0.
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1.1.6 Steady State Fluorescence Spectroscopy
Steady-state Trp fluorescence upon Ca2+-binding
Steady-state fluorescence measurements for sNUCB1 were carried out in a
SPEX τ3 spectrofluorimeter (Jobin-Yvon Instruments, NJ) at 25 °C. The
excitation wavelength was set at 295 nm, while emission spectra were
collected from 310 nm to 460 nm. The excitation and emission slit widths
were 2.5 nm and 5.0 nm, respectively. 178 nM of Ca2+-free sNUCB1
equilibrated in buffer containing 50 mM Tris, pH 8.0, 100 mM NaCl was
incubated with increasing concentrations of Ca2+ with constant stirring for
5 min. Thereafter, Trp emission fluorescence spectra were collected for
each concentration of Ca2+ added.

Quenching of tryptophan fluorescence by small molecule quenchers
The excitation wavelength was set at 295 nm and the emission spectra
were collected from 315-460 nm with the excitation slit and emission slit
width being 2.5 nm and 5 nm, respectively. 333 nM of protein was
equilibrated in buffer containing 50 mM Tris, pH 8.0 and 100 mM NaCl.
In order to study the interaction between the protein and the quenchers,
small aliquots of the quenchers were added incrementally from a
concentrated stock solution. In the case of potassium iodide, a small
quantity of Na2S2O3 (0.1 mM) was added to prevent it from forming free
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triiodide (I3-). The accessibility of Trp was monitored by analyzing the
quenching data using Stern-Volmer equation (equation 4):
F0 / F = 1+ KSV [Q]

(4)

Where F0 and F are the fluorescence intensities in the absence and
presence of quenchers respectively, [Q] is the concentration of the
quenching molecules and KSV is the Stern-Volmer quenching constant. In
the case of purely collisional quenching mechanism, the Stern-Volmer plot
of F0 / F versus [Q] is linear with a slope equal to KSV.

Fluorescence-based mant-GTPγ S (mGTPγ S) binding assays
Steady-state fluorescence measurements experiments were carried out in a
SPEX τ3 spectrofluorimeter (Jobin-Yvon Instruments, NJ) at 25 °C. 15
µM of WT Gαi1 was incubated with 50 µM of sNUCB1(W232A/W333A)
in the reaction buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM
MgCl2 and 1 mM DTT) for 5 min with constant stirring. Thereafter,
mGTPγS (15 µM) was added to the reaction mixture. FRET was
monitored by exciting the intrinsic Trp fluorescence at 295 nm and
measuring the fluorescence emission from 310 nm to 540 nm. In all cases,
blank spectra containing buffer with sNUCB1(W232A/W333A) alone
were subtracted from the final spectra.
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1.1.7 Time based fluorescence spectroscopy
Time-based fluorescence measurements were performed in a SPEX
Fluorolog-2 spectrofluorometer (SPEX Industries, Edison, NJ) at 25oC.
The excitation wavelength was set at 295 nm specifically for Trp residues,
while emission wavelength was set at 340 nm. The excitation and
emission slit width were 5 nm each.

AlF4¯ uptake assay
WT Gαi1 was incubated at 25oC in reaction buffer K (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 2 mM MgCl2 and 1 mM DTT) with increasing
amounts of sNUCB1(W232A/W333A) for 10 mins with constant stirring.
Thereafter for AlF4¯ dependent activation of Gαi1, a premixed solution of
AlCl3¯ (20 mM) and NaF (1 M), respectively, was injected at 180 s. A
time course of enhancement in Trp fluorescence coupled to activation was
monitored

in

the

presence

of

increasing

concentrations

of

sNUCB1(W232A/W333A) in the reaction mixture.

GTPγ S nucleotide exchange assay
WT Gαi1 was incubated at 25 oC with increasing concentration of
sNUCB1(W232A/W333A) in reaction buffer K for 10 min with constant
stirring. The base line fluorescence was monitored for 200 s after which
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GTPγS (20 µM) was injected into the reaction mixture and the relative
increase in intrinsic Trp fluorescence (λex = 295 nm, λem = 340 nm) was
measured

as

a

function

of

time

for

each

concentration

of

sNUCB1(W232A/W333A).

BODIPY-FL-GTPγ S nucleotide exchange assay
WT Gαi1 (20 µM) was incubated at 25oC in reaction buffer K with
increasing concentration of Ca2+-free sNUCB1 for 10 min with constant
stirring. BODIPY -FL-GTPγS (20 µM) was added to the reaction mixture
and the relative increase in intrinsic fluorescence (λex = 485 nm, λem = 512
nm) was measured for each concentration of Ca2+-free sNUCB1 as a
function of time.

BODIPY FL-GTPγ S nucleotide binding assay
WT Gαi1 (20 µM) was incubated alone and with Ca2+-free sNUCB1 (100
µM) at room temperature in reaction buffer K. 10 µl samples were
withdrawn from each reaction mixture at various time points and loaded
onto a pre-equilibrated ZebaTM micro-desalt spin columns to remove the
unbound nucleotide. The columns were spun at 1000 g for 1 min and the
flowthrough collected. The amount of bound nucleotide in each
flowthrough was measured by using BODIPY absorbance at 504 nm (ε =
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80,000 M-1 cm-1). The absorbance at 280 nm was also monitored to ensure
that the same amount of protein was being collected in each flowthrough
sample.

1.1.8 Circular Dichroism (CD) Spectroscopy
Wavelength scan: All CD experiments were performed using an Aviv
62A DS CD spectrophotometer. Far-UV CD spectra were recorded at the
end of each kinetic run. Spectra were recorded over the wavelength range
of 190-250 nm at 1 nm intervals with an averaging time of 3 s using a 0.1
cm path length cell. Background spectrum was subtracted from each of the
collected data sets. Each spectrum obtained was an average of 3 scans.
The recorded spectra in millidegrees of ellipticity was converted to mean
residue ellipticity in deg.cm2dmol-1 using the following equation (equation
5):

[θ ] =

θ
10 × c × l × n

(5)

where [θ] is the mean residue ellipticity in deg*cm2dmol-1, θ is the
€
ellipticity in mdeg, c is the concentration in M, l is the path length in cm
and n is the number of peptide bonds.
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Thermal unfolding: The unfolding of the protein (8 µM) with temperature
was monitored using CD at a wavelength of 222 nm, which is
characteristic of an α-helix. The data points were averaged over 30 s for
every unit increment in temperature. A plot of CD signal versus
temperature was fit to the equation (equation 6):

f (T) =

α N + β N × T + (α D + β D × T) • e
o
−ΔGD−N
(T)
1+ e
RT

o
(T)
−ΔGD−N
RT

(6)

where,

€
o
o
−ΔGD−N
(T) = −ΔH D−N
(Tm ) ∗ (1−

T
T
) − ΔC po ∗{(Tm − T) + T ∗ ln }
Tm
Tm

f(T) is the signal as a function of temperature, T is the temperature, R is
€

the gas constant, αN defines the intercept and βN is the slope of the posttransition region of the curve, αD defines the intercept and βD is the slope
of the pre-transition region of the curve, ΔGo is the free energy change for
the unfolding reaction, ΔHoD-N is the change in enthalpy for unfolding at
the Tm and ΔCpo is the change in heat capacity. Using the above
expressions, Tm, the mid-point transition temperature was estimated along
with the change in enthalpy ∆HoD-N, for the unfolding reaction at that Tm.
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1.1.9 Radioligand [GTPγ 35S] based nucleotide-exchange assay
The effect of Ca2+-free sNUCB1 or Ca2+-free sNUCB1(W333Ter) binding
to WT Gαi1•GDP on the nucleotide exchange was monitored using
[35S]GTPγS exchange assay. 20 µM WT Gαi1•GDP alone or with 100 µM
of Ca2+-free sNUCB1 / sNUCB1(W333Ter) was incubated in Buffer (10
mM Tris pH 7.5, 100 mM NaCl, 2 mM MgCl2, 2 mM DTT) for 20 min at
30 oC. After incubation, [35S]GTPγS solution diluted with GTPγS was
added to the reaction mixtures such that the final GTPγS concentration in
each reaction mixture was 100 µM with an associated radioactivity of 50
nCi / 8 µ l of reaction volume. Thereafter 8 µ l samples (50 nCi) were
withdrawn from each reaction mixture and added to Buffer equilibrated
nitrocellulose filters. Subsequently, the filters were extensively washed
with Wash Buffer (50 mM Tris pH 7.5, 5 mM MgCl2) to remove excess
radioligand. For data analysis the counts were recorded and the value for
buffer alone was subtracted from each reading. Each individual data point
was scaled to the value of radioactivity within 8 µl of reaction volume to
get the pmoles of radioligand bound to WT Gαi1 in each reaction. As a
positive control, the CT GoLoco motif peptide from RGS14 namely
R14GL(496-531) was used in an identical experimental setup.
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1.1.10 Analytical UltraCentrifugation (AUC)
Sedimentation equilibrium studies were carried out at different centrifugal
speeds and protein concentrations for sNUCB1 and sNUCB1(W333Ter).
AUC experiments for sNUCB1 (- / +Ca2+) were done at 25oC with protein
concentrations of 50 µM, 100 µM and 150 µM each at speeds of 20,000
rpm, 30,000 rpm and 40,000 rpm. Similarly for sNUCB1(W333Ter), AUC
experiments were done with 32 µM, 70 µM and 150 µM protein
concentrations each at speeds of 25,000 rpm, 30,000 rpm and 40,000 rpm.
The individual protein samples were run for sufficiently long periods of
time to allow for the equilibrium to generate a time invariant concentration
gradient balanced by diffusion of the macromolecular species. The speeds
were decided based on the molecular weight of the protein. Under no net
transport conditions, the following correlation should be observed between
concentration and the radial distance (36) (equation 7):

Cr = Cro ∗ e

(σ ∗ r) 2 2
(r − ro )
2

where,

€

ω2
σ = M(1− νρ) ∗
RT
Cr is the concentration of macrosolute at any radial distance r, Cro is the

€

concentration of the macrosolute at the reference radial distance r0, ν is the
partial specific volume, ω is the angular velocity, ρ is the density, R is the
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(7)

gas constant, T is the absolute temperature and M is the molecular mass.
The data were analyzed using OptimaTM XL-A/XL-I Data Analysis
Software (Beckman, 2001).
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1.2 RESULTS
1.2.1 Ca2+-binding to EF hand domains of sNUCB1 induces
conformational changes
A soluble form of NUCB1 namely sNUCB1 was engineered, expressed in
E.coli and purified to homogeneity (Figs. 1.1, 1.2A). The domain
architecture of sNUCB1 shows two EF hand Ca2+-binding regions
sandwiched between a N-terminal DNA binding domain and a CT leucine
zipper (20). The thermodynamics of Ca2+-binding to sNUCB1 were
studied using Isothermal Titration Calorimetry (ITC). The Ca2+ binding
was exothermic with ΔH1° = -2.1 ± 0.06 kcal mol-1 and ΔS1° = 16.5 cal
mol-1 K-1 for the first EF hand and ΔH2° = -0.62 ± 0.31 kcal mol-1 and
ΔS2°

= 17.1 cal mol-1 K-1 for Ca2+ binding to the second EF hand,

suggesting a spontaneous uptake of Ca2+ by Ca2+-free sNUCB1. The
recorded data were best fit to a “two-set of binding sites” model giving Kd
values of 6.3 µM and 73.5 µM for Ca2+-binding (Fig. 1.2B). The
difference in binding affinities arises due to the presence of a noncanonical Arg residue substituting for the canonical Gly at the sixth
position of the 12-residue Ca2+-binding loop of the second EF hand. Our
results show that the two EF hands in sNUCB1 bind to Ca2+ differentially
with an order of magnitude difference in their Kd values. In 2004, de Alba
et al. heterologously expressed and purified only the EF hand domain
(228-326) of NUCB1 and also reported two Ca2+-binding sites with
different affinities (21).
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Figure 1.1. Domain architecture of human NUCB1 and engineered
NUCB1 variants

(A) The modular nature of the NUCB1 protein

structure is depicted schematically with its N-terminal signal sequence
(grey square), putative DNA binding domain (green square), two EF hand
loops (magenta rectangles), acidic region (blue oval) and leucine zipper
domain (yellow hexagon). The amino acid residues at domain borders are
numbered.

We engineered a construct for expression in E. coli of a

soluble form of NUCB1 that included an N-terminal hexa-His tag and a
PreScission protease recognition sequence with an intervening spacer
sequence as shown.

Endoprotease cleavage yields a soluble form of

NUCB1 that begins with the amino acid sequence GPHMAS and
continues with the remainder of the native sequence beginning at Gly32.
We refer to this expressed protein construct as soluble NUCB1 or
sNUCB1 throughout the text.

We also constructed a Trp double-

replacement mutant sNUCB1(W232A/W333A) and a truncation mutant
sNUCB1(W333Ter) as shown.
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The EF hand regions undergo conformational changes upon Ca2+-binding,
which can be monitored through change in intrinsic Trp fluorescence of
sNUCB1. sNUCB1 has two Trp residues at position 232 and 333 lying
sequentially before and after the EF hand domain, respectively. Steadystate fluorescence measurements show a blue shift of 15 nm and an
enhancement in fluorescence intensity as more Ca2+ was added to Ca2+free sNUCB1 (Fig. 1.2C). Thus, Ca2+-binding causes a conformational
change in sNUCB1 causing reorientation of the Trp residues from a
solvent exposed polar to a hydrophobic environment. Fluorescence
quenching experiments with acrylamide and iodide were performed to
probe these conformational changes around the Trp residues upon Ca2+
binding. Acrylamide is a diffusible neutral quencher of Trp fluorescence
unaffected by the charges surrounding the fluorophore. I-, on the other
hand, is an anionic quencher for surface exposed fluorophores only (37).
Quenching experiments show that Trp residues are more accessible to
acrylamide than I- for quenching. On binding to Ca2+, acrylamide
quenching decreases much more than I- quenching (Fig. 1.2D). F0 / F vs
quencher concentration gave a straight-line indicative of a dynamic
quenching rather than static quenching. These observations suggest that
conformational changes associated with Ca2+-binding make Trp residues
less accessible by reorienting them into a hydrophobic environment.
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Figure 1.2. Purification and effect of Ca2+-binding to sNUCB1. (A)
The SDS-PAGE analysis of sNUCB1 shows a single band after final step
of purification. The protein band migrates at ~ 51 kDa. sNUCB1 possesses
two Ca2+-binding EF hand motifs. (B) We used isothermal titration
calorimetry (ITC) to measure the Ca2+ binding affinity of sNUCB1.
sNUCB1 presumably binds one Ca2+ cation at each of its two EF hand
domains and a non-linear least squares fit of the calculated values using
the “two-set of sites” model resulted in an excellent fit as shown in the
inset. The calculated dissociation constants for Ca2+-binding to the two
EF hand domains of sNUCB1 are 6.3 ± 0.18 µM and 73.5 ± 0.19 µM. (C)
Ca2+-free sNUCB1 was used for determining the conformational changes
associated with Ca2+-binding to sNUCB1. 178 nM sNUCB1 was titrated
with increasing amounts of Ca2+ while fluorescence emission was
collected from 310 to 460 nm with the excitation set at 295 nm. Black
trace indicates Ca2+-free sNUCB1, while the red, green, navy blue, yellow,
light blue and pink traces represent 1 mM, 2 mM, 5 mM, 7 mM, 10 mM
and 15 mM Ca2+ added to the protein solution. Inset: Change in the
fluorescence intensity is indicated by black circles, while the red circles
indicate the blue shift of the Trp fluorescence. With increasing
concentration of Ca2+, the emission intensity enhanced by 50%, while
there was a 15 nm blue shift on binding to Ca2+ to sNUCB1 indicative of
the movement of Trp residues from a polar environment to a non-polar,
hydrophobic region. (D) We measured the accessibility of Trp residues of
sNUCB1 to small molecule quenchers, acrylamide and iodide, in the
presence and absence of Ca2+. Steady-state fluorescence measurements
were done at 25 °C with the excitation at 295 nm, while the emission
spectra were collected from 315 nm to 460 nm. Stern-Volmer plot was
calculated by taking the emission maxima at 330 nm. The top panel shows
the quenching of sNUCB1 Trp residues in the presence (black trace) and
absence (red trace) of Ca2+. The bottom panel shows quenching of
sNUCB1 Trp residues by ionic quencher iodide in the presence (black
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trace) and absence (red trace) of Ca2+. Fo / F vs quencher concentration
gave a straight line indicative of a dynamic quenching rather than static
quenching. The quenching by acrylamide both in the presence and absence
of Ca2+ was larger than the iodide showing that the two Trp residues are in
different environments. Ca2+-binding to sNUCB1 caused a considerably
greater decrease in the observed acrylamide quenching relative to iodide.
This shows that the conformational change associated with Ca2+-binding
reorients the Trp residues in an environment inaccessible to either
quencher.
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Figure 1.2
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The binding of Ca2+ to an EF hand motif forms an octahedral coordination sphere, which can cause structural rearrangement in the protein
(38). This secondary structural change can in principle be followed by
circular dichroism (CD) spectroscopy. Ca2+-binding to sNUCB1 causes
only a slight increase in helicity. Intriguingly, the far-UV CD spectra of
sNUCB1 show a smooth structural transition from an α-helical secondary
structure at lower concentrations to a predominant β-sheet structure at
higher concentrations. These concentration-dependent structural changes
were observed both in the absence and presence of Ca2+ (Fig. 1.3A).
Furthermore, the thermal unfolding data for sNUCB1 showed an increase
in apparent Tm of 4 oC on binding to Ca2+. The folding of sNUCB1 was
observed to be non-cooperative and irreversible both in the absence and
presence of Ca2+ (Fig. 1.3B). The increase in stabilization on binding to
Ca2+ suggests a structural ordering of sNUCB1.

1.2.2 NUCB1 is a dimer
The domain diagram of NUCB1 reveals the presence of a CT-domain
leucine zipper, which is a canonical structural motif known to cause
dimerization (39) (Fig. 1.1). The oligomeric state of NUCB1 was
evaluated through sedimentation equilibrium experiments using Analytical
Ultra-Centrifugation (AUC). This experiment is insensitive to the shape of
the molecule, and directly reports on the molar mass of the sedimenting
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Figure 1.3. Secondary structure transition in sNUCB1 (- / + Ca2+) with
increasing concentration. Far-UV circular dichroism spectra of (A) Ca2+free or (B) Ca2+-bound sNUCB1 were collected with increasing
concentration. At lower concentrations, i.e. 4 µM (red), 8 µM (green), 16
µM (yellow) and 24 µM (blue), CD spectra show that sNUCB1 is mainly
helical. At 32 µM (pink), the CD spectrum shows a reduction in the helical
content. Higher concentrations of sNUCB1, i.e. 40 µM (cyan), 50 µM
(brown) and 64 µM (orange), show primarily β-sheet secondary structure.
We also monitored thermal unfolding of sNUCB1. (B) Thermal unfolding
transitions of recombinant Ca2+-free (top) and Ca2+-bound (bottom)
sNUCB1 (8 µM) were monitored by recording CD signal at 222 nm at a
heating rate of 1 oC / min. The trace is indicative of a multistep noncooperatively folded protein. The Tm for the Ca2+-bound sNUCB1 is
higher than Tm for the Ca2+-free protein, indicating the enhanced stability
of the protein in the Ca2+-bound state. (C) The CD spectrum for
sNUCB1(W333Ter) at 50 µM concentration displays a majorly helical
secondary structure. In each experiment, the spectrum for buffer (50 mM
Tris pH 8.0, 150 mM NaCl) alone was subtracted from each of the spectra.
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species

characterized

by

Boltzmann

distribution.

Sedimentation

equilibrium measurements were performed with Ca2+-free sNUCB1 for
concentrations varying from 50 µM to 150 µM. The data could be well fit
to a monomer-Nmer model, which gave a molecular mass of ~100 kDa
corresponding to a dimer of sNUCB1 in solution (Fig. 1.4A). AUC
analysis of Ca2+-bound sNUCB1 indicated that it is also primarily dimeric
in solution (Fig. 1.4A, inset). In order to confirm that the dimerization of
sNUCB1 is caused by the leucine zipper domain, a CT truncation mutant,
sNUCB1(W333Ter), lacking the leucine zipper was designed and
heterologously

expressed.

The

far-UV

CD

spectrum

of

sNUCB1(W333Ter) showed an α-helical secondary structure even at high
protein concentrations in contrast to the concentration dependent transition
observed for sNUCB1 (Fig.1.3C). AUC analysis of sNUCB1(W333Ter)
revealed a monomeric species in solution over the concentration range of
32µM to 150µM (Fig. 1.4B). Similar to sNUCB1, the association state of
sNUCB1(W333Ter) was unaffected upon binding to Ca2+. The
experiments with the truncation mutant confirm that the leucine zipper
domain of sNUCB1 is essential for the dimeric state of the protein in
solution.

The thermodynamics of the dimerization of sNUCB1 was further
investigated using Multi-Angle Light Scattering (MALS). In a series of
size-exclusion chromatography (SEC) experiments, Ca2+-free sNUCB1
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was analyzed by gel filtration using a Superdex 200 10/30 HR column.
The eluted protein peak was fractionated and subjected to MALS analysis
at seven different angles to estimate the molecular mass of the eluting
species. As shown in Fig.1.4C, a gradual increase in the weight-average
molecular mass of the eluting species was observed with increasing
concentration of the protein. At concentrations around 10 nM, sNUCB1
exists as a monomer. As the concentration is gradually increased, a
monomer-dimer

equilibrium

is

observed

with

dimeric

sNUCB1

dominating at concentrations greater than 1µM. The data collected at
different angles for each run were fit to a monomer-dimer equilibrium
model giving a dissociation constant, Kd of dimerization, for sNUCB1 of
0.26 ± 0.12 µM. sNUCB1(W333Ter) in MALS measurements continued
to exist as a monomer even at high protein concentrations. Thus the
leucine zipper region is responsible for the dimeric state of sNUCB1 in
solution under physiological conditions.

1.2.3 sNUCB1 is structurally asymmetric with an elongated CT
Ca2+-free sNUCB1 in SEC experiments elutes at a much higher volume
than a globular protein with molecular mass similar to that of a sNUCB1
monomer or a dimer (Fig. 1.4D). A plot of the elution parameter, Kav, vs
log(molecular mass) for a number of globular protein standards was
utilized to estimate an apparent molecular mass of 300 kDa for sNUCB1
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Figure 1.4. sNUCB1 forms a stable non-globular dimer mediated by
its

leucine

zipper

domain.

(A)

We

carried

out

analytical

ultracentrifugation (AUC) experiments to determine the oligomeric state
of sNUCB1 in solution. The sedimentation equilibrium plot for Ca2+-free
sNUCB1 (50 µM monomeric concentration) shows the evolution of a
sample concentration curve resulting from the applied centrifugal force.
The data were fit to a monomer-Nmer equilibrium model, which gave a
measured molecular mass of 98.9 ± 0.41 kDa, consistent with a dimeric
structure for sNUCB1 in solution (the theoretical molecular mass of
monomeric sNUCB1 is ~51 kDa). The inset shows the sedimentation
equilibrium plot for Ca2+-bound sNUCB1, which gave essentially an
identical molecular mass of 99.4 ± 0.78 kDa. Thereafter, (B) AUC
experiments

were

carried

out

on

the

truncation

mutant,

sNUCB1(W333Ter), which lacked the Leucine zipper domain in the Cterminal region of the protein. The AUC sedimentation equilibrium plot
for Ca2+-free sNUCB1(W333Ter) (70 µM monomeric concentration) gave
a molecular mass of 35.2 ± 0.05 kDa, consistent with a monomeric species
in solution (the theoretical molecular mass of sNUCB1(W333Ter) is ~36.8
kDa). (C) We studied the monomer-dimer equilibrium of sNUCB1 with
multi-angle light scattering (MALS) of fractions with increasing protein
concentration collected from Superdex200 10/30 HR size exclusion
chromatography in 50 mM Tris-HCl (pH 8.0), 150 mM NaCl. The weightaverage molecular mass of the complex at a given protein concentration
was determined from a non-linear least-square fit of a collection of values
determined for the apex fractions of each eluting peak. A monomer-dimer
association model of the values as a function of sNUCB1 concentration
gave an apparent dissociation constant (Kd) for dimerization of 0.26 ± 0.12
µM. The error bars indicate the extent of variation in molecular mass
determination originating from the light scattering measurement. (D) SEC
of sNUCB1, heavy molecular weight standards along with known globular
proteins was done using a Superdex200 10/30 HR column. Proteins were
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individually injected onto the column and the elution profile for each
protein was recorded as a function of elution volume. The void volume
(Vo) of the column was derived from the elution of Blue Dextran, whereas
elution volume (Ve) for each protein was obtained from the corresponding
peak for each sample. In order to estimate the molecular mass of sNUCB1
and sNUCB1(W333Ter), a calibration curve was prepared by plotting Kav
[(Ve-Vo)/(Vc-Vo)] vs Log(molecular weight) where Vc is the geometric
volume of the column. The data were fit to a linear equation. The
estimated molecular mass of sNUCB1 and sNUCB1(W333Ter) were
obtained from the plot by using their corresponding Kav values. The
estimated masses suggest that sNUCB1 has a non-globular structure due to
which it elutes at a higher volume compared to globular proteins of similar
masses. We next measured dynamic light scattering (DLS) chromatograms
for (E) sNUCB1 and (F) sNUCB1(W333Ter). Each protein sample was
injected onto a Superdex200 10/30 HR column and the refractive index
detector was used to analyze the protein peak. The change in refractive
index as a function of protein concentration was used to compute the
molecular mass as shown in green for sNUCB1 and red for
sNUCB1(W333Ter). The molecular mass corresponds to a dimer for
sNUCB1 and a monomer for sNUCB1(W333Ter). The insets show the
correlation functions as each protein diffuses through the solution in the
DLS experiment. The diffusion coefficient from the correlation function
gives the hydrodynamic radius (Rh) using Stokes equation. The computed
Rh values were 6.2 nm and 3.03 nm for sNUCB1 and sNUCB1(W333Ter),
respectively.
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Figure 1.4
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(Fig.1.4D). This implies that either sNUCB1 exists as a trimer of dimers
(3 x 100 kDa) or is asymmetric in its shape. Since AUC and MALS
analysis convincingly ruled out any association of sNUCB1 dimers into
higher order structures, we proceeded to derive structural information on
sNUCB1 through Dynamic Light Scattering (DLS). DLS analysis of Ca2+free sNUCB1 yields a hydrodynamic radius (Rh) of 6.2 nm and a frictional
coefficient (f/fo) of 2.03 (Fig.1.4E). The frictional coefficient of globular
proteins usually lies in the range of 1.1 - 1.25 (40). A value of 2.03 for
sNUCB1 indicates an asymmetric shape for the dimer, deviating
considerably from a sphere. Interestingly, Ca2+-free sNUCB1(W333Ter)
has a Rh of 3.3 nm and a f/fo of 1.59 showing that the deletion of CT
domain reduces the radius of hydration by almost 50% (Fig. 1.4F). This
suggests that while the N-terminus of sNUCB1 is relatively more compact
and globular, the CT domain of the protein is elongated, contributing to
the observed asymmetry in the shape of sNUCB1.

1.2.4 sNUCB1 selectively interacts with GDP-bound WT Gα i1 in the
absence of Ca2+
NUCB1 is a Ca2+-binding protein that has been shown to interact with Gi
and Gs classes of α-subunits (16). Physiologically, Gα subunits can
individually exist both in the “inactive” or GDP-bound state and the
“active” or GTP-bound state. To investigate the interaction of sNUCB1
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with WT Gαi1, sNUCB1 was incubated with WT Gαi1•GDP (Fig. 1.5, top
left) and WT Gαi1•GTPγS (Fig. 1.5, top right), respectively, and the
complex formation was analyzed by SEC using a Superdex200 10/30 HR
column. As shown in the top panels of Fig. 1.5, the Coomassie stained
gels of the fractionated peaks show elution of the complex containing both
sNUCB1 and Gαi1 with excess Gαi1 fractionating at higher elution
volume. The amount of Gαi1 eluting with sNUCB1 was significantly
higher when Gαi1 was present in the GDP-bound state rather than in the
GTPγS-bound state. Thus Ca2+-free sNUCB1 preferentially interacts with
Gαi1 in the GDP-bound form. Interestingly, the interaction with Gαi1 in
both the GDP- and GTPγS-bound states is absent when sNUCB1 is bound
to Ca2+ as shown in the lower panels of Fig. 1.5. The two protein subunits
elute out as individual components as the complex is disrupted in the
presence of Ca2+. The inhibition of the complex formation between
sNUCB1 and Gαi1 in the presence of Ca2+ can be explained by the
structural rearrangement of EF hands upon Ca2+-binding. Yeast twohybrid analysis for interaction of Gα with deletion mutants of NUCB1 as
bait proposed the EF hand intervening acidic region of NUCB1 to be
involved in G protein binding (16). The conformational change induced
upon Ca2+-binding can possibly result in the masking of the acidic region
sandwiched between the two EF hands, thereby making it inaccessible for
G protein binding.
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The thermodynamics of Ca2+-free sNUCB1 complex formation with
Gαi1•GDP was investigated using ITC. The exothermic nature of the
reaction shows a thermodynamically favorable binding event between the
two protein subunits with ΔHo = -1.45 ± 0.17 kcal mol-1 and ΔSo = 16.9
cal mol-1 K-1. The data were best fit to a “one-set of binding sites” model
with dimeric sNUCB1 and monomeric G protein as the interacting
partners. The fit provides a Kd value of 18.3 ± 1.45 µM suggesting that
sNUCB1 interacts relatively weakly with GDP-bound Gαi1 (Fig.1.6A).
The association between Ca2+-free sNUCB1 and Gαi1•GDP was also
monitored using light scattering. Protein samples with increasing
concentrations of sNUCB1-Gαi1•GDP complex were injected onto a
Superdex200 10/30 HR column and MALS was done on the complex
elution peak. The analysis shows that binding of Gαi1•GDP to sNUCB1
initiates only after dimerization of Ca2+-free sNUCB1. At lower
concentrations, dimerization of sNUCB1 from molecular mass of 50 kDa
to 100 kDa was traced. Once the dimer was formed, binding of one
Gαi1•GDP subunit to sNUCB1 was evident from increase in molecular
mass to 140 kDa (Fig.1.6B). The trace observed for sNUCB1-Gαi1•GDP
complex formation can be understood from the experimental Kd values.
The Kd for sNUCB1 dimerization is much smaller than Kd for binding to
Gαi1•GDP, resulting in sNUCB1 dimerization prior to Gαi1•GDP binding.
However sNUCB1-Gαi1•GDP association curve does not rule out the
ability of sNUCB1 monomer to interact with Gαi1•GDP.
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Figure 1.5. sNUCB1 forms a stable complex with Gα i1•GDP only in
the absence of Ca2+.

We used size-exclusion chromatography to

determine the nature of the interaction between sNUCB1 and Gαi1 in
solution under several conditions. sNUCB1 and Gαi1•GDP were incubated
together in the absence (upper left), or presence (lower left) of Ca2+ and
the mixture was subjected to size-exclusion chromatography using a
Superdex200 10/30 HR column. Peak fractions were analyzed by SDSPAGE with Coomassie-brilliant blue staining as shown in the insets. In
the absence of Ca2+, sNUCB1 and Gαi1•GDP formed a complex as judged
by (i) the slight shift (from approximately 11.2 ml to 10.6 ml) and
enhancement of the peak containing only sNUCB1 in the presence of
Ca2+, and both sNUCB1 and Gαi1, in the absence of Ca2+, and (ii) the
depletion, in the absence of Ca2+, of the peak eluting at about 14.6 ml,
which contained only Gαi1. The same experiment was repeated with
sNUCB1 and Gαi1•GTPγS in the absence (upper right), or presence (lower
right) of Ca2+. Although the same general trend and Ca2+ dependency
were observed, the apparent ability of Gαi1•GTPγS to form a stable
complex with sNUCB1 was markedly diminished compared to that of
Gαi1•GDP.

41

Figure 1.5
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MALS experiments were also conducted with the monomeric truncation
mutant sNUCB1(W333Ter). A plot of the weight-average molecular mass
obtained from light scattering plotted vs the protein concentration shows
that monomeric Ca2+-free sNUCB1(W333Ter) forms a 1:1 complex with
Gαi1•GDP. The fit yields a Kd value of 1.99 ± 0.26 µM showing that the
interaction of sNUCB1 with WT Gαi1•GDP becomes stronger on deletion
of the CT region of sNUCB1 (Fig.1.6C). This suggests that the CT region
of sNUCB1 possibly acts as a regulatory domain modulating the
interaction of sNUCB1 with G protein α-subunit. Alternatively, the
structural rearrangement associated with dimerization can also result in the
reduced

affinity

of

sNUCB1

for

Gαi1

in

comparison

with

sNUCB1(W333Ter).

1.2.5 sNUCB1 affects nucleotide-exchange by WT Gα i1GDP
GPCRs activate heterotrimeric G proteins by catalyzing the exchange of
GTP for GDP on Gα subunits. The receptor facilitates the nucleotide
exchange by using the CT-linked α5 helix of Gα subunits. The α5 helix
region is postulated to be a molecular micro domain on Gα that
allosterically couples the activation signal from the receptor to the
catalytic pocket of G proteins (30, 31, 41, 42). Farquhar and coworkers
have
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Figure 1.6. Interaction of sNUCB1 and Gα i1•GDP. (A) We used ITC
to measure the binding of Ca2+-free sNUCB1 to Gαi1•GDP. The heat
released per injection of aliquots of a solution of Gαi1•GDP (200 µM) into
a buffered solution of Ca2+-free sNUCB1 (50 µM) was recorded and the
area under the curve was integrated. The heat of dilution for the addition
of Gαi1•GDP to buffer alone was subtracted. A non-linear least squares fit
of the calculated values using the “one-set of sites” model for dimeric
sNUCB1 resulted in a satisfactory fit with a dissociation constant of 18.3
± 1.45 µM as shown in the inset. We used multi-angle light scattering
(MALS) to measure the formation of a complex between (B) sNUCB1 and
Gαi1•GDP or (C) the truncation mutant sNUCB1(W333Ter) and
Gαi1•GDP. MALS data were collected on protein complex peaks eluting
from Superdex200 10/30 HR size exclusion chromatography connected to
a high performance liquid chromatography system equipped with an
autosampler.

Samples with increasing protein concentrations were

successively injected onto the column, and the eluate was monitored using
a photo-diode UV/Vis detector, a differential refractometer, and a static
multi-angle laser light scattering detector. The weight-average molecular
mass of the complex was determined as a function of increasing protein
concentration. The magenta curve in (B) inset and the red curve in (C)
indicate non-linear least-square fits for a complex formation model of
weight average molecular mass values determined for the apex of each
eluting peak at various concentrations. The error bars indicate extent of
variation in molecular mass determination originating from the lightscattering measurement. The data for sNUCB1-Gαi1•GDP complex
formation shows that association between the protein subunits occurs only
after dimerization of sNUCB1 (blue curve). The data suggest that one
Gαi1 subunit binds to a dimer of sNUCB1 and a monomer of
sNUCB1(W333Ter), respectively, and that the binding site for Gαi1 lies in
the sNUCB1(W333Ter) sequence.
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shown that NUCB1 possibly interacts with the CT α5 helix region of Gαi3
(29). Thus, we measured the nucleotide exchange on Gα in the presence
of Ca2+-free sNUCB1. The concentrations of both sNUCB1 and Gαi1 were
kept above the determined Kd for sNUCB1-Gαi1 complex formation.
Steady-state and time-based fluorescence experiments were performed by
monitoring the enhancement in Trp fluorescence, which is coupled to
activation of Gαi1. Any potential contribution from the Trp residues of
sNUCB1 was eliminated by mutating both W232 and W333 to Ala,
thereby generating sNUCB1(W232A/W333A) (Fig.1.1). Both AlF4¯
uptake (Fig.1.7A) and GTPγS binding (Fig.1.7B) to Gαi1•GDP showed an
increase in Trp fluorescence as Gαi1 molecules were activated with time.
However,

Fig.1.7A

and

sNUCB1(W232A/W333A)

B

show

decreases

that

binding

the

observed

to

Ca2+-free

fluorescence

enhancement observed for Trp residues coupled to activation of Gαi1. This
suggests that Ca2+-free sNUCB1(W232A/W333A) possibly affects the
nucleotide exchange by inhibiting the activation process. Furthermore, the
G protein activation was also monitored using a fluorescent nucleotide
analogue, BODIPY FL-GTPγS. The fluorescence of BODIPY FL-GTPγS
in solution is self-quenched by the guanine ring of GTPγS. However,
binding of the fluorescent nucleotide in the catalytic pocket of Gαi1
relieves the self-quenching leading to the enhancement in the observed
fluorescence of the bound fluorophore (43). As shown in Fig1.7C,
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Figure 1.7. sNUCB1 affects nucleotide-exchange by WT Gα i1. (A) We
employed a time-based intrinsic Trp fluorescence assay to measure the
rate of spontaneous nucleotide exchange by Gαi1•GDP in the presence of
increasing concentrations of sNUCB1. The fluorescence emission of
Trp211, which is situated on the Switch II region of Gαi1 increases
dramatically on binding of AlF4¯ to Gαi1•GDP. To eliminate the influence
of intrinsic Trp fluorescence from sNUCB1 on the measured activation
rates, we used site-directed mutagenesis to engineer a Trp free version of
sNUCB1, sNUCB1(W2323A/W333A). Gαi1•GDP alone (20 µM, black
trace) was allowed to equilibrate while Trp fluorescence emission was
recorded at 340 nm. Thereafter, AlF4¯ (20 mM) was injected at 180
seconds and the fluorescence time course was monitored.

The same

experiment was repeated in the presence of increasing concentrations of
sNUCB1(W232A/W333A). The rate of Gαi1•GDP activation by AlF4¯ is
considerably decreased upon preincubation with equimolar (red) or excess
(green)

sNUCB1(W2323A/W333A).

As

a

control,

sNUCB1(W232A/W333A) alone shows no enhancement in Trp
fluorescence upon addition of AlF4¯ (blue). (B) In an analogous
experiment, we monitored the enhancement in fluorescence emission of
Trp211 upon exchange of GDP for GTPγS, a non-hydrolyzable analogue
of GTP. The results show that the rate and extent of GTPγS-mediated
activation

is

less

when

Gαi1•GDP

is

bound

to

Ca2+-free

sNUCB1(W232A/W333A). (C) In addition to measuring intrinsic Trp
fluorescence, we also monitored nucleotide exchange by using the
fluorescent analogue of GTPγS, BODIPY FL-GTPγS. BODIPY FLGTPγS was added to a buffered solution of 20 µM Gαi1•GDP alone or
Gαi1•GDP precomplexed with increasing concentrations of sNUCB1. The
binding of BODIPY FL-GTPγS to the catalytic pocket leads to
enhancement of BODIPY fluorescence since self-quenching by guanine
ring in solution is relieved. The observed time-based fluorescence
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enhancement of BODIPY fluorophore on binding to Gαi1 decreased as
increasing concentrations of Ca2+-free sNUCB1 were used. The data show
that Ca2+-free sNUCB1 decreases the rate and extent of BODIPY FLGTPγS mediated activation of Gαi1•GDP. In a FRET based experiment
(D) Gαi1•GDP activation was monitored through exchange of bound GDP
for fluorescent mant-GTPγS nucleotide. Upon uptake of mant-GTPγS by
Gαi1, Trp211 moves into the catalytic pocket and forms a productive
FRET pair which can transfer energy to the nucleotide analogue mantGTPγS. FRET from Trp211 of Gαi1 to bound mant-GTPγS was measured
at different times after addition of mant-GTPγS. The same experiment was
carried out in the presence of sNUCB1(W2323A/W333A). The addition
of sNUCB1(W2323A/W333A) caused a decrease in the rate of FRET
increase, indicating that uptake of mant-GTPγS by Gαi1 was inhibited.
Maximum FRET intensity at 425 nm with increasing time was plotted. A
fit to each data set clearly shows attenuation of FRET intensity for Gαi1
complexed to Ca2+-free sNUCB1(W232A/W333A) in comparison to Gαi1
alone, suggesting that Ca2+-free sNUCB1(W232A/W333A) inhibits
nucleotide exchange.
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incubation of increasing concentrations of Ca2+-free sNUCB1 with
Gαi1•GDP leads to decrease in the fluorescence enhancement of BODIPY
fluorophore suggesting that Ca2+-free sNUCB1 affects nucleotideexchange by inhibiting it.

To monitor simultaneously the activation associated conformational
change in Gαi1 and the uptake of nucleotide, a mant-GTPγS based FRET
assay was also performed. The binding of mant-GTPγS in the catalytic
pocket of Gαi1 brings it in close vicinity of Trp211 on the switch II region
of Gαi1. Hence, FRET can be observed between the Trp and mant
fluorophores upon Gαi1 activation (44). As shown in Fig.1.7D, the FRET
intensity for Gαi1 alone at each time point is significantly higher in
comparison to the FRET intensity for Gαi1 associated with Ca2+-free
sNUCB1(W232A/W333A). A plot of the λ max at 425 nm with time shows
that the FRET signal is significantly inhibited in the presence of
sNUCB1(W232A/W333A)

(Fig.1.7D).

These

experiments

suggest

towards a possible inhibitory effect of Ca2+-free sNUCB1 towards
nucleotide-exchange.
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Figure 1.8. NUCB1(381-419) does not bind to WT Gα i1GDP. (A) A
CT 39 mer sequence of NUCB1 (residues 381-419) consist of the GluGln-Arg (397-399) triad preceded by an upstream Gln390. (B) The
sequence alignment of NUCB1(381-419) with various GoLoco motif
peptides shows the presence of the conserved Gln and the Asp/Glu-GlnArg motif in the sequence. The stars indicate the positions of the
conserved residues amongst different sequences. (C) We further used ITC
to measure the binding of NUCB1(381-419) to WT Gαi1•GDP.
NUCB1(381-419) (600 µM) was injected into a buffered solution of WT
Gαi1•GDP (40 µM) in the reaction cell and the heat released per injection
was recorded. The heat of dilution for the addition of Gαi1•GDP to buffer
alone was subtracted. The isotherm shows complete absence of any
binding event indicating that NUCB1(381-419) does not interact with WT
Gαi1•GDP.
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1.2.6 The CT sNUCB1 peptide NUCB1(381-419) does not bind to WT
Gα i1GDP
The GDI activity of several G protein interacting partners is attributed to
the presence of a GoLoco motif region, which directly binds to WT
Gαi1GDP and inhibits nucleotide exchange. The GoLoco motif region is
a 36-39 mer long structured fragment that consists of a conserved Gln
residue followed by the presence of a conserved downstream Asp/GluGln-Arg triad wherein the Arg residue directly projects into the catalytic
pocket and interacts with the bound GDP and stabilizes it (54). As shown
in Fig.1.8A, the CT region of NUCB1 (residues 381-419) consists of a Gln
at position 390 followed by a downstream Glu-Gln-Arg motif. A sequence
alignment of NUCB1(381-419) with GoLoco motif sequences from
various GDIs for Gαi1 shows that NUCB1(381-419) consists of the
conserved Gln followed by the triad (Fig.1.8B). Hence in order to evaluate
the binding of the NUCB1(381-419) to WT Gαi1•GDP, we performed ITC
experiment by incubating 40 µ M WT Gαi1•GDP in the reaction cell and
using 600 µM of NUCB1(381-419) as the injectant. The isotherm shows
that NUCB1(381-419) does not bind to WT Gαi1•GDP (Fig. 1.8C). Hence
the isolated CT NUCB1 peptide fragment NUCB1(381-419) does not bind
to WT Gαi1GDP which indicates that the peptide alone cannot act as a
GDI for G protein activation.
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1.2.7 sNUCB1 is a Guanine-Nucleotide Dissociation Inhibitor (GDI) of
Gα i1
WT Gαi1•GDP subunit can readily self-exchange GDP for GTP albeit with
poor efficiency. Our earlier results show that Ca2+-free sNUCB1 can affect
nucleotide exchange by WT Gαi1•GDP. However for Ca2+-free sNUCB1
to be a GDI of nucleotide-exchange, it must cause a decrease in the
number of sites for binding of GTP / GTPγS. In order to investigate the
GDI activity, we incubated 20 µM WT Gαi1•GDP alone or in the presence
of 100 µM Ca2+-free sNUCB1 with 100 µM BODIPY FL-GTPγS present
in the reaction mixture at 25 oC. Samples were withdrawn at various time
points and amount of bound BODIPY FL-GTPγS was estimated by
measuring the absorbance at 504 nm. The data shows that Ca2+-free
sNUCB1 significantly inhibits the nucleotide-exchange by WT Gαi1•GDP
by decreasing the number of binding sites available for BODIPY FLGTPγS (Fig.1.9A). In order to further substantiate the observed GDI
acitivity of Ca2+-free sNUCB1, we monitored the exchange of radioligand
GTPγ35S by WT Gαi1•GDP in the presence and absence of Ca2+-free
sNUCB1 / sNUCB1(W333Ter). The results show that both Ca2+-free
sNUCB1 or sNUCB1(W333Ter) possess similar GDI activity (~ 58 %
inhibition) suggesting that the C-terminus is not necessary for the activity
(Fig.1.9B). As a positive control we also used a C-terminal peptide from
RGS14 protein namely RGS14(496-531) which has been shown to possess
GDI activity due to the presence of a canonical GoLoco motif.
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Figure 1.9. sNUCB1 acts as a GDI of Gα i1. (A) We determined the
number of available nucleotide binding sites on Gαi1 in the absence or
presence of Ca2+-free sNUCB1 by monitoring the absorbance of Gαi1bound BODIPY FL-GTPγS at 504 nm. Gαi1•GDP alone (20 µM, blue) or
in complex with Ca2+-free sNUCB1 (100 µM, orange) was allowed to
undergo nucleotide exchange with 100 µM BODIPY FL-GTPγS in the
reaction mixture. Samples were withdrawn at different time points and
unbound BODIPY FL-GTPγS was removed using a micro-spin desalting
column. The amount of bound BODIPY FL-GTPγS was measured using
the UV/VIS absorbance spectroscopy at each time point. A relative
decrease in the number of nucleotide binding sites on Gαi1 was observed
on association with sNUCB1. This shows that Ca2+-free sNUCB1 binds to
Gαi1 in its GDP-bound form and inhibits nucleotide exchange. We further
investigated the (B) guanine-nucleotide inhibitory activity of Ca2+-free
sNUCB1 using the radioligand based assay. 20 µ M WT Gαi1•GDP was
incubated alone (blue) or with 100 µ M Ca2+-free sNUCB1 (green) /
sNUCB1(W333Ter) (red) in the presence of GTPγ35S and samples were
withdrawn at various time points to estimate the amount of radioligand
bound upon nucleotide exchange. As a positive control, 100 µM of a CT
GoLoco motif peptide from RGS14 namely RGS14(496-531) with
established GDI activity was used as a positive control (magenta). The
data shows that both Ca2+-free sNUCB1 or Ca2+-free sNUCB1(W333Ter)
considerably inhibit nucleotide exchange with similar potency. The GDI
peptide RGS14(496-531) shows complete inhibition of nucleotide
exchange. Each experiment was repeated atleast 3 times and the data was
plotted as mean ± S.E.M. amongst the independent measurements.
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Figure 1.9
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1.3 DISCUSSION
NUCB1 is a ubiquitously expressed multi-domain Ca2+-binding protein
whose physiological role(s) is not well understood. Our results provide the
first direct evidence that NUCB1 is a Ca2+-regulated GDI of Gαi1. SEC
experiments showed that Ca2+-free sNUCB1 interacts primarily with the
GDP-bound state of Gαi1, and that no interaction occurs when sNUCB1 is
bound to Ca2+ (Fig.1.5,1.6). The role of Ca2+-binding as a regulatory
switch for sNUCB1 association with Gαi1 can be explained structurally
through the involvement of the acidic region of sNUCB1. The acidic
region has been previously shown to be a G protein interaction site (29).
Earlier, yeast two-hybrid experiments had suggested that the CT-linked α5
helix of G protein interacts with NUCB1 (29). Interestingly, the α5 helix
is conformationally identical in both the Gαi1•GDP and Gαi1•GTPγS
structures. However, as Gα undergoes transition from the inactive to the
active state, the structurally dynamic switch regions (switch I to IV) of Gα
subunits change conformation (45). Thus, the preferential binding of Ca2+free sNUCB1 to Gαi1•GDP, which can modulate G protein activation,
points toward a possible participation of switch regions in this interaction.

The domain diagram of NUCB1 shows the presence of a CT leucine
zipper domain that can facilitate dimerization (Fig.1.1). Our sedimentation
equilibrium experiments using AUC alongwith MALS analysis show that
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NUCB1 is a dimer in solution. Furthermore, analysis of the dimer of
sNUCB1 using dynamic light scattering revealed that it is considerably
asymmetric in its shape with a long axis of 12.4 nm (Fig1.4E,F). This
elongated shape may facilitate simultaneous interaction of sNUCB1 with
both the α5 helix and the switch regions of Gαi1•GDP. Interestingly,
deletion of the leucine zipper domain along with the CT region of
sNUCB1 increased the binding affinity of monomeric sNUCB1(W333Ter)
for Gαi1•GDP and decreased the Rh to 3.3 nm (Fig.1.6C). This suggests
that the deleted CT of sNUCB1 may play a regulatory role in sNUCB1Gαi1•GDP interaction.

NUCB1 is a major Ca2+-binding protein of Golgi. In 1998, Lin et al. used
labeling studies to show that NUCB1 is concentrated on the membranes of
the stacked Golgi cisternae and associated vesicles on the cis side (16).
NUCB1 assists in Ca2+ uptake, storage and release from the Golgi
apparatus (46). Optimal Golgi Ca2+ levels are required for anterograde
(ER to Golgi), retrograde (Golgi to ER) and intra-Golgi transport (47).
Thus, NUCB1 along with Cab45 (48), the only other known Ca2+-binding
Golgi resident protein, may be involved in maintaining the essential Ca2+
levels and gradient from cis to trans Golgi. The Ca2+ concentration in the
cis-Golgi is around 0.3 mM under unstimulated conditions (47). Thus, the
NUCB1 pool in Golgi should largely be Ca2+ bound given the Kd values
for Ca2+-binding. However, at cytosolic Ca2+ concentrations (100-125 nM)
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(49), NUCB1 should essentially be in a Ca2+-free state, suggesting that
this Ca2+-free cytosolic pool of NUCB1 can interact with cytosolic Gαi1.
NUCB1, like heterotrimeric G proteins, exists in both the cytosolic and
membrane fractions (17). Co-immunoprecipitation and FRET analysis
have convincingly shown that NUCB1 interacts with Gαi and co-localizes
on Golgi lumen (50). Our MALS analysis alongwith the results from ITC
experiments establish the interaction of one Gαi1•GDP subunit with a
dimer of Ca2+-free sNUCB1.

Earlier work by Siderovski and coworkers has unraveled several
interacting partners of Gαi1•GDP namely, RGS12, RGS14, AGS3,
GPSM2, PCP-2 and G18, all of which possess GDI activity (9, 14, 51-53).
The GDI activity was attributed to the presence of a single or tandem
repeats of a 19-amino-acid long conserved GoLoco motif region present in
each of these proteins. The crystal structure of Gαi1•GDP complexed to
RGS14 derived GoLoco peptide showed that the conserved CT of the 19amino-acid GoLoco motif makes contacts with both the switch I region
and the bound nucleotide. Each GoLoco motif ends in a conserved triad of
Asp/Glu-Gln-Arg. On binding to Gα, the Arg side chain extends into the
catalytic pocket to interact directly with the bound GDP and stabilize it. In
addition, the highly conserved Asp/Glu and Gln residues are absolutely
essential for binding to G protein α-subunit as they are involved in both
intra- and inter-molecular H-bonding interactions (54). A sequence
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alignment of CT residues 381-419 of NUCB1 with GoLoco motif regions
of several GDIs of Gαi subunits reveals that NUCB1 also possesses the
highly conserved triad of Glu-Gln-Arg preceded by a conserved upstream
Gln (Fig.1.8B). The other residues in the aligned sequence of NUCB1
show relatively poor conservation across the GoLoco motif. Nevertheless,
the presence of the most conserved regions suggests that mechanistically
NUCB1 might act as a GDI by stabilizing the GDP-bound state of Gαi1 in
a manner analogous to GoLoco region of RGS14.

Nucleotide-exchange assays with GTPγS and its fluorescent analogues
showed that Ca2+-free sNUCB1 interacts with WT Gαi1•GDP and can
possibly affect the nucleotide exchange (Fig.1.7). The results show an
inhibition in fluorescence intensity of Trp residues of Gαi1 on addition of
Ca2+-free sNUCB1 / sNUCB1(W232A/W333A) indicating that Ca2+-free
sNUCB1 inhibits conformational changes in WT Gαi1•GDP associated
with nucleotide exchange. In order to directly show that Ca2+-free
sNUCB1 is a GDI, we used BODIPY FL-GTPγS and radioligand
(GTPγ35S) binding assays to measure the number binding sites available
on WT Gαi1•GDP (Fig.1.9). Our results show that Ca2+-free sNUCB1
significantly inhibits nucleotide exchange by Gαi1•GDP. Interestingly,
even the truncation mutant sNUCB1(W333Ter) possesses the ability to
inhibit nucleotide exchange suggesting that the C-terminal domain of
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sNUCB1 is not essential for its GDI activity. Hence unlike other GDIs
with GoLoco motifs, the GDI activity of NUCB1 is not due to the
presence of a conserved CT Glu-Gln-Arg triad characteristic of a GoLoco
motif.

As shown by the sequence alignment, the core GoLoco motifs between
different GDIs are highly conserved, whereas the residues C-terminus to it
are quite divergent. Evidently, longer GoLoco peptides with additional CT
residues display significantly higher affinity towards Gαi than the minimal
19-amino-acid peptides. The GoLoco motif peptides derived from RGS
proteins have nanomolar binding affinity for Gαi•GDP in comparison to
micromolar binding affinities observed for GPSM2, PCP-2 or G18 derived
GoLoco motif peptides. The binding affinities for full length GDIs like
RGS14, GPSM2 and others with GoLoco motif regions towards Gαi•GDP
is unknown. Unlike these, our in vitro assays estimate that the binding
affinity of full-length ~100 kDa sNUCB1 dimer to Gαi1 is 18.3 µM
(Fig.1.6A). The crystal structure of RGS14 GoLoco motif region bound to
Gαi1 showed numerous stabilizing interactions between the residues CT to
the GoLoco motif and Gαi1•GDP. The activation studies with chimeric Gα
subunits showed that both the CT region of the GoLoco motif and the
helical domain of Gα determine binding of the GoLoco motif towards a
particular class of Gα subunits (54). Yeast two-hybrid analysis by Lin et
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al. showed that NUCB1 preferentially interacts with Gαi1 and Gαi3 with
higher affinity than with Gαi2 and Gαs (16). Future studies of NUCB1
interaction with different classes of Gα subunits are planned to reveal the
selectivity of its GDI activity. Our G protein interaction and nucleotide
exchange studies with the truncation mutant sNUCB1(W333Ter)
(Fig.1.6C, 1.9B) suggest that unlike known GDIs, sNUCB1 interacts with
Gαi1•GDP in a novel manner. A co-crystal structure of the minimum
subunit of NUCB1 bound to Gαi1•GDP that has GDI activity would be
immensely helpful in understanding the precise molecular details of this
interaction and may provide understanding of the Ca2+-dependence of this
interaction.

G proteins are widely expressed in different tissue types and are involved
in various signal transduction pathways interacting with a number of
binding partners. The interaction of NUCB1 with Gαi1 has been previous
established but no GEF or GDI activity was observed because the
experimental concentrations used were below the Kd value of association.
Our results show that the interaction of Gαi1 with sNUCB1 is regulated by
Ca2+-binding. We have evaluated this interaction in terms of cytosolic
Ca2+ concentrations where NUCB1 should exist in a Ca2+-free state
capable of binding to Gαi1. Based on the available evidence, we propose a
model for the role of a cytosolic pool of NUCB1 in regulating G protein
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signaling. According to the model, G protein heterotrimer (Gαβγ) upon
activation by GPCRs, dissociates into Gα and Gβγ subunits to initiate
downstream signaling cascades. RGS proteins acting as GAPs, rapidly
accelerate the hydrolysis of GTP to GDP, thereby bringing the α-subunit
back to the GDP-bound state. Thereafter, the GDP-bound state of Gαi1 can
be stabilized by the Ca2+-free cytosolic pool of NUCB1 to inhibit basal
nucleotide exchange. The GDI activity of NUCB1 would inhibit the selfactivation of Gαi1 subunit and in turn augment the Gβγ-dependent
signaling cascade. Subsequently, NUCB1 would be displaced by Gβγ at
the plasma membrane to promote formation of the heterotrimer, thereby
initiating another cycle of receptor mediated G protein signal transduction.
Future cell-based assays should provide information about the
physiological importance of this interaction and how it affects the ligand
mediated signal transduction cascade which involves activation of
heterotrimeric G proteins.

In summary, our results show that sNUCB1 is a physiological dimer,
which interacts with the GDP-bound Gαi1. This association inhibits the
nucleotide exchange by Gαi1, thus demonstrating the GDI activity of
NUCB1. Ca2+-binding to sNUCB1 regulates NUCB1-Gαi1•GDP complex
formation and possibly modulates this interaction in different cellular
compartments. NUCB1 is a novel Ca2+-binding GDI with a role in
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trafficking and Ca2+ buffering. In addition, NUCB1 also has a nuclear
localization signal sequence within the DNA binding region. Recently, its
role in affecting the biogenesis of amyloid precursor protein was reported
(16). Such a potential for diverse functionality makes the comprehensive
understanding of the physiological role of NUCB1 difficult. Based on our
current knowledge, NUCB1 seems to be neither a RGS nor an AGS
protein. Future experiments will unravel the functional relevance of the
interaction of NUCB1 with other Gα subunits. Understanding the role of
NUCB1 in the context of different Gα subunits will highlight the signaling
pathways modulated by NUCB1. Our discovery of the Ca2+-regulated GDI
activity of NUCB1 adds a new level of understanding to the role of
NUCB1 and to the complexity of G protein-mediated signal regulation.
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CHAPTER 2
Nucleobindin 1 and its Engineered Mutant Disaggregate human Islet
Amyloid Polypeptide fibrils and Inhibit its Aggregation by forming Deadend Prefibrillar Species

2.0 INTRODUCTION
Amyloid deposition is an underlying pathophysiological hallmark of a
number of severe biological disorders like Alzheimer’s Disease,
Creutzfeldt-Jacob disease, Parkinson’s disease, Huntington’s disease and
Type 2 diabetes (T2D) (55, 56). Amyloid deposits are insoluble fibrous
aggregates with a β-pleated sheet structure, formed by aggregation of
natively unfolded or misfolded / partially denatured proteins or peptides.
In T2D, aggregation of human islet amyloid polypeptide (hIAPP) results
in islet amyloid deposits, which has been proposed as an aetiological
factor contributing to the observed pathology in T2D (57, 58). T2D is a
metabolic disorder that stems from disruption of glucose homeostasis
caused by reduced insulin secretion from pancreatic islets and enhanced
insulin resistance of peripheral tissues. In addition, extensive islet amyloid
deposits have been observed extracellularly and adjacent to islet
capillaries in 70-90% of T2D patients (59-61). These amyloid deposits are
composed of unstructured and highly hydrophobic 37-amino-acid long
polypeptide called human Islet Amyloid Polypeptide (hIAPP) or Amylin

64

(62, 63). Once formed, these amyloid deposits are highly toxic and cause
β-cell death. This irreversible loss of β-cell results in insulin depletion and
aggravates T2D. Physiologically, hIAPP is present in both normal and
diabetic individuals but is somehow kept from aggregating into toxic
deposits in non-diabetic populations. The physiological checkpoints /
factors that keep this most amyloidogenic sequence from aggregating into
insoluble and toxic amyloid deposits are poorly understood. Thus arises a
need for investigation of factors that can inhibit the aggregation process
and preferably disaggregate the pre-formed fibrils to facilitate their
clearance from the system.

hIAPP is a glucomodulatory polypeptide co-secreted with insulin from
pancreatic β-cells in response to glucose uptake. The gene for IAPP is
located on the short arm of chromosome 12 and transcribes a 89-aminoacid long precursor protein. This larger precursor is sequentially processed
by proconvertases PC1/3 and PC2 to generate the mature 37-amino-acid
long polypeptide, which has a free N-terminus and an amidated Cterminus with a disulfide bond between Cys2 and Cys7 (58) (Fig.2.1). The
mature form of hIAPP is a natively unstructured neuroendocrine hormone
that regulates food intake and fat storage (64). It suppresses glucagon
secretion and inhibits the secretion of gastric acid, bile and pancreatic
enzymes (65). These functions of hIAPP allow for both exogenous and
endogenous modulation of the rate of glucose appearance in the blood.
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Thus, hIAPP together with insulin constitutes an essential glucoregulatory
cascade (66). The aggregation of hIAPP into amyloid deposits, however,
disrupts this underlying cascade and promotes β-cell death resulting in the
loss of β-cell mass (67).

hIAPP is a very hydrophobic peptide with a significantly high propensity
to rapidly aggregate in aqueous solution at low micromolar concentrations.
Physiologically, the concentration of hIAPP in the secretory granules can
vary from 100 µM to 4 mM. However, even at such high concentrations,
hIAPP does not aggregate under normal environment of secretory granules
(65). Several studies have shown that the physiological molar ratio of
IAPP to insulin, proinsulin and C-peptide protects against IAPP
aggregation (68, 69). Additionally, transgenic mice under normal
metabolic conditions did not develop any amyloid deposits (70). Thus
synthesis and secretion of IAPP alone is not sufficient for islet
amyloidosis. Rather, defects in either IAPP biosynthesis, folding,
trafficking or processing have been postulated as possible mechanisms
facilitating the initiation of amyloid formation (57, 58, 71-73)
Furthermore, the role of several chaperones and proteases has come to
light explaining how the physiological defense mechanisms prevent these
naturally occurring amyloidogenic proteins from aggregating in healthy
individuals. In particular, heat shock proteins Hsp70 and sHsp20 have
been shown to inhibit amyloidogenesis of Aβ which contributes to the
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pathophysiology of Alzheimer’s disease (74, 75). Additionally, the
extracellular chaperone Clusterin has been shown to inhibit the
aggregation of prion protein, Aβ and Apolipoprotein C-II (76, 77) into
amyloid fibrils. Along with the chaperones, Insulin Degrading Enzyme
(IDE), a Zn2+-dependent metallo-endoprotease, has been shown to
proteolytically cleave monomeric hIAPP and may play an important role
in regulating the physiological concentration and eventual clearance of the
peptide (78, 79). In addition, a number of novel approaches towards
preventing both in vivo and in vitro amyloid formation by IAPP have been
undertaken. Administration of drugs that increase insulin sensitivity in
transgenic mouse model of hIAPP overexpression and thereby decrease βcell demand to produce more IAPP have shown to reduce amyloid
formation (80). Several peptide fragments and derivatives of hIAPP have
been identified that inhibit fibril formation in vitro by targeting the
amyloidogenic region (residues 8-20 and 20-29) of hIAPP (81-84).
However we still lack a deeper understanding of the physiological factors
that inhibit aggregation of hIAPP into amyloid fibrils and help keep it in a
soluble form. In this study, we present the anti-amyloidogenic properties
of a ubiquitously expressed mammalian protein Nucleobindin 1 (NUCB1)
or commonly known as Calnuc in inhibiting the progression of hIAPP
aggregation into amyloid fibrils and more importantly, in disaggregating
the formed fibrils.

67

NUCB1 is a 55 kDa protein, which was first reported as a growth and
differentiation factor associated with lupus syndrome (19) (Fig.2.1). Since
then NUCB1 has been postulated to be involved in several important
cellular functions like matrix modulation and maintaining Ca2+homeostasis in Golgi (46). NUCB1 has also been shown to interact with
heterotrimeric G protein α-subunits leading to possible intervention in the
regulation of downstream signaling events (16, 29, 50). However, the
selective pathways associated with the functionality of NUCB1, which
require its strong conservation across the animal kingdom, still remain
elusive. Since its discovery, NUCB1 has been reported to be widely
expressed in cells and tissues and is conserved from flies to humans (85).
This suggests that NUCB1 is an essential Ca2+-binding protein present in
the eukaryotic proteome. It is primarily a Golgi-resident protein found in
both cytosolic and membrane fractions (16). NUCB1 shows high
homology with the ER resident protein Calreticulin and displays
properties suggesting its role in both Ca2+-storage and homeostasis in
Golgi.

Recent in vitro studies have suggested that overexpression of NUCB1
down-regulates the mRNA production of Amyloid precursor protein
(APP) and inhibits its biogenesis. It was further shown that the expression
level of NUCB1 is decreased by 50% in the brains of Alzheimer’s disease
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Figure 2.1. Modular structure of human NUCB1 and the engineered
NUCB1 variants. The domain diagram of NUCB1 is depicted
schematically with its N-terminal signal sequence (grey square), putative
DNA binding domain (green square), two EF hand loops (magenta
rectangles), acidic region (blue oval) and leucine zipper domain (yellow
hexagon). The amino acid residues at domain borders are numbered. We
engineered a construct for expression in E. coli of a soluble form of
NUCB1 that included an N-terminal hexa-His tag and a PreScission
protease recognition sequence with an intervening spacer sequence as
shown for eNUCB1. Endoprotease cleavage yields a soluble form of
NUCB1 that begins with the amino acid sequence GPHMAS and
continues with the remainder of the native sequence beginning at Gly32.
We refer to this expressed protein construct as soluble NUCB1 or
sNUCB1. Thereafter we used the sNUCB1 template to make point
mutations in each EF hand as indicated by the arrows to generate
sNUCB1(tetramutant) which lacks the ability to bind to Ca2+.Finally, we
also generated a variant of sNUCB1 whereby the Ser44 was substituted by
a Cys residue to generate sNUCB1(S44C), which was used for labeling
studies. We also generated a CT peptide fragment of sNUCB1 namely
NUCB1(381-419) which consists of residues 381-419. Thereafter the
complete sequences for the mature human Islet Amyloid PolyPeptide
(hIAPP) and its non-aggregating synthetic analog namely Pramlintide are
listed. Both peptides have a free N-terminus and an amidated C-terminus.
The highlighted residues (red) in the sequence of Pramlintide show
prolines, which are absent in hIAPP.
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Figure 2.1
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patients (28). Thus in order to test for potent anti-amyloidogenic property
and to understand the possible mechanism of action, we investigated the
ability of NUCB1 towards inhibiting fibril formation by the highly
amyloidogenic hIAPP .

In the present study we show that soluble form of NUCB1, sNUCB1
(Fig.2.1), inhibits hIAPP fibril formation at sub-stoichiometric amounts
and also effectively disaggregates preformed fibrils in a Ca2+-dependent
manner. Interestingly, the anti-amyloidogenic functional ability of
sNUCB1 is completely absent when bound to Ca2+. In order to circumvent
this, we designed a mutant of sNUCB1 namely sNUCB1(tetramutant),
which similar to sNUCB1 can effectively inhibit hIAPP fibril formation
and disaggregate hIAPP fibrils even in the presence of excess Ca2+.
Interestingly, Ca2+-free sNUCB1 can bind to Zn2+ and ATP but does not
possess protease activity towards hIAPP nor can it protect firefly
Luciferase against heat denaturation. We further show that mechanistically
Ca2+-free sNUCB1 binds to and stabilizes a prefibrillar species of hIAPP
by “capping” the ends to inhibit their further association to form fibrils.
Interestingly, these Ca2+-free sNUCB1 bound prefibrilar species form
dead-end products incapable of seeding the aggregation reaction of hIAPP.
Finally we also isolated a small peptide fragment from the C-terminal
(CT) region of NUCB1 namely NUCB1(381-419) (Fig.2.1), which similar
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to sNUCB1, inhibits hIAPP fibril formation and can also facilitate
disaggregation of amyloid fibrils.
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2.1 MATERIALS AND METHODS
2.1.1 REAGENTS
Thioflavin-T was purchased from Fisher Scientific and Uranyl Acetate
was purchased from SPI-ChemTM. For TEM, 300 mesh carbon coated Cu
grids were purchased from EMS diasum (Hatfield, PA). Nano-Au
Maleimide was purchased from Invitrogen Molecular Probes (Cat #
20345). Rabbit polyclonal hIAPP prediluted antibody (Cat # GTX15128)
was purchased from Genetex Inc. (Irvine, CA) and Rabbit polyclonal
NUCB1 antibody (Cat # P102230_T100) was purchased from Aviva
Systems Biology (San Diego, CA).

NUCB1(381-419) was purchased

from Keck facility at Yale University. All reagents and chemicals used
were of the highest available purity.

2.1.2 Heterologous expression and purification of sNUCB1 and its
variants
The cDNA clone for human NUCB1 was obtained from ATCC and the
DNA fragment for the soluble form of NUCB1 or sNUCB1,
corresponding to residues 31-461 of the human NUCB1 protein without
the N-terminal signal sequence (residues 1-31) was cloned into a
pET28a(+) expression vector (Amersham Biosciences) to generate a Nterminal His6-tagged construct. The construct for sNUCB1 served as a
template to generate the His6-tagged mutants of sNUCB1 namely
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sNUCB1(tetramutant) and sNUCB1(S44C). For sNUCB1(tetramuant) the
coding sequence changes leading to generation of D253K, E264A, D305K
and E316A mutations were introduced by site-directed mutagenesis using
the Quick Change system (Stratagene, La Jolla, CA) whereas a coding
sequence for Ser44 was mutated to Cys to generate sNUCB1(S44C) . The
vectors were then used to transform BL21 (DE3) cells to express a Nterminal His6-tag protein containing a PreScission protease site following
the His6-tag. Both proteins were expressed in BL21 (DE3) cells grown in
the presence of 50 µg / ml kanamycin. Cells were grown at 37 oC to A600nm
of ~ 0.7 and then induced with 500 µ M isopropylthio-β-D-galactoside
(IPTG) (US Biological). Post induction the culture was grown overnight at
17 oC and subsequently harvested. The resulting pellets were re-suspended
in a buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM βmercaptoethanol, bovine lung aprotinin (20 mg/ml), 2 mM phenylmethane
sulfonyl fluoride (PMSF) and complete EDTA-free protease inhibitor
cocktail tablets (Roche). Thereafter the cells were lysed and the expressed
His6-tag protein was purified from crude extract by using affinity
chromatography using Ni-NTA column pre-equilibrated with buffer A (50
mM Tris, pH 8.0, 150 mM NaCl, 50 mM β-mercaptoethanol). The bound
His6-tag protein was eluted from the column by using buffer A
supplemented with 500 mM imidazole. The His6-tag was cleaved by
PreScissionTM protease, which was subsequently removed. In order to
remove Ca2+ from sNUCB1 or its variant, the proteins were extensively
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dialyzed against buffer A supplemented with 5 mM EGTA and 1 mM
EDTA, which were also eventually removed through dialysis. Finally, size
exclusion chromatography (SEC) was done using Superdex200 26/60 HR
column equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM NaCl, 1
mM DTT) to obtain homogenously pure protein. The typical yield for
sNUCB1 and its variant was ~ 5 mg / L. The purity of the proteins was
assessed by Coomassie brilliant blue staining after the proteins were
separated through SDS-PAGE. The purity of both the proteins was greater
than 95%.

2.1.3 Solid phase peptide synthesis and purification of hIAPP
Wild type human IAPP (hIAPP) was synthesized and purified by Ruchi
Gupta at Stony Brook University, NY in the lab of Dr Daniel P Raliegh.

2.1.4 Monitoring hIAPP aggregation kinetics using thioflavin-T
fluorescence
The kinetics of aggregation of hIAPP was monitored in the absence and
presence of Ca2+-free sNUCB1 using thioflavin-T or thio-T fluorescence.
All fluorescence measurements were done on a Jobin Yvon Horiba
fluorescence spectrophotometer using an excitation wavelength of 450 nm
and an emission wavelength of 485 nm. The emission and excitation slits
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were both set to 5 nm and a 1.0 cm cuvette was used. Experiments were
performed by diluting a stock of hIAPP in 20 mM Tris pH 7.5. Each stock
solution was filtered through a 0.45 µm pore size GHP Acrodisc syringe
filter prior to the experiment. The final reaction mixture contained hIAPP
with or without a particular concentration Ca2+-free sNUCB1 along with
32 µM thio-T in the reaction buffer at 25 oC with constant stirring. The
fluorescence intensity observed for binding of thio-T to Ca2+-free
sNUCB1 alone was subtracted from each kinetic curve.

2.1.5 Transmission Electron Microscopy (TEM)
TEM was performed at the Bioimaging facility at Rockefeller University.
Samples were prepared by placing 5 µl of solution onto formvar coated
300 mesh copper grids and counterstained with 2% aqueous uranyl acetate
solution. Samples were viewed with a FEI Tecnai12 BioTwinG2
transmission electron microscope at 80 kV. Digital images were acquired
with an AMT XR-60 CCD Digital Camera System and compiled using
Adobe Photoshop CS2 and Image J.

2.1.6 Size Exclusion Chromatography (SEC)
Size exclusion chromatography (SEC) was done using a Superose 6 10 /
30 GL column attached to an AKTA explorer FPLC. 200 µl of a reaction
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mixture with Ca2+-free sNUCB1 (32 µM) alone in 20 mM Tris pH 7.5 or
Ca2+-free sNUCB1 preincubated with equimolar amount of hIAPP in
reaction buffer were injected onto a buffer equilibrated Superose 6 10 / 30
GL column. The chromatogram corresponding to absorbance at 280 nm
for each reaction was plotted as a function of elution volume.

2.1.7 Dot Blot Assay
Dot blot was done by blotting samples onto an activated polyvinylidene
fluoride (PVDF) membrane and allowed to dry followed by blocking with
5 % milk solution in TBS (20 mM Tris, pH 7.5, 150 mM NaCl) at room
temperature. Subsequently the membrane was incubated with a solution of
rabbit polyclonal primary antibody against hIAPP (1:2 dilution of
prediluted stock) or NUCB1 (1:500 dilution of 1 µg / µl stock) in TBS for
1 h at room temperature followed by three washes with TBS-T (20 mM
Tris pH 7.5, 150 mM NaCl, 0.05 % Tween-20) for 5 min each. After this,
the membranes were incubated with horseradish peroxidase conjugated
anti-rabbit secondary antibody (1:8000 dilution of the stock) in TBS for 30
min at room temperature followed by two washes with TBS-T for 5 min
each and a subsequent wash with TBS for 5 min. The blots were
developed using the supersignal west femto maximum sensitivity substrate
(Thermo Scientific).
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2.1.8 Light Scattering
The light scattering data was collected using a Superose6 10/30 GL SEC
column (GE Healthcare, Piscataway, NJ), connected to High Performance
Liquid Chromatography System (HPLC), Agilent 1200, (Agilent
Technologies, Wilmington, DE) equipped with an autosampler.

The

elution from SEC was monitored by a photodiode array (PDA) UV / VIS
detector

(Agilent

Technologies,

Wilmington,

DE),

differential

refractometer (OPT-Lab rEx Wyatt Corp., Santa Barbara, CA), static and
dynamic, multiangle laser light scattering (LS) detector (HELEOS II with
QELS capability, Wyatt Corp., Santa Barbara, CA). The SEC-UV / LS /
RI system was pre-equilibrated in buffer (20 mM Tris pH 7.5) and 200 µl
of reaction mixture containing either Ca2+-free sNUCB1 alone or
incubated with equimolar amount of hIAPP were injected onto the
column. Two software packages were used for data collection and
analysis: the Chemstation software (Agilent Technologies, Wilmington,
DE) controlled the HPLC operation and data collection from the multiwavelength UV / VIS detector, while the ASTRA software (Wyatt Corp.,
Santa Barbara, CA) collected data from the refractive index (RI) detector,
the light scattering detectors, and recorded the UV trace at 280 nm sent
from the PDA detector. Molecular masses were determined across the
entire elution profile for each observed peak in the intervals of 1 sec from
static LS measurement using ASTRA software as previously described
(33). The approach uses a Rayleigh-Debye-Gans light scattering model

78

(equation 1), which relates the amount of scattered light to the
concentration and molecular mass of solute and second virial coefficient:

K ∗c
1
=
+ 2A2c
R(θ ) M w

(1)

where R(θ) is the intensity of excess scattered light at angle θ, c is the
€
concentration of the solute, Mw is the weight average molecular weight of
the solute, A2 is the second virial coefficient, K* is an optical parameter
2

equal to 4 π 2 n 2

(dn dc)
, where n is the refractive index, dn/dc is the
λ40 N A

refractive index increment for the solute, NA is Avogadro’s number, and

€
λ0 is the wavelength of the scattered light.

Dynamic light scattering (DLS) measurements were made “on line” at an
angle of 100° with a 2 sec collection time across the elution peaks. Time
resolved scatter intensity fluctuations were analyzed using ASTRA
Software (Wyatt Corp., Santa Barbara, CA) which implements the
cumulants method (Koppel, 1972) to determine the time dependence of
diffusive motion also referred to as the intensity correlation function, G(τ),
(35):

G(T) = B{1+ α [exp(−DT q 2 t)]2 }

(2)

where B is the average baseline intensity, α is an instrument-specific
€
correction factor, DT
is the concentration-dependent translational
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diffusion constant of the solute, t is a delay time, and q is the scattering
vector equal to

4 πn
sin θ 2 , where n is the refractive index of the solvent,
λ

λ is the wavelength of the scattered light and θ is the scattering angle.

€ 2 describes the relationship between the time dependency of
Equation
fluctuation in scatter intensity and the translational diffusion coefficient.
The value of DT was used to estimate the apparent hydrodynamic radius of
an equivalent sphere using Stokes-Einstein relationship (equation 3):

Rh =

kT
6πηDT

(3)

where k is the Boltzmann constant, T is the absolute temperature, and η is
€
the temperature corrected viscosity of the solution.

2.1.9 Nano-Au labeling of sNUCB1(S44C)
Heterologously purified Ca2+-free sNUCB1(S44C) was extensively
dialyzed against phosphate buffer saline (PBS) pH 7.5 and concentration
of the dialyzed protein was measured using UV / VIS spectroscopy. A
nano-Au

maleimide

solution

stock

was

prepared

according

to

manufacturer’s protocol (Molecular Probes, Invitrogen) after which 2
nmoles of buffer dialyzed Ca2+-free sNUCB1(S44C) protein was
incubated with 6 nmoles of nano-Au maleimide in PBS supplemented with
500 µ M tris carboboxyethyl phosphine (TCEP) overnight at 4 oC. After
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this the reaction mixture was injected onto a PBS equilibrated
Superdex200 10 / 30 GL column and the elution profiles for absorbance at
280 nm and 420 nm were recorded. The labeled protein elutes at a peak
centred at 12.2 ml with the excess nano-Au eluting at higher elution
volume. The efficiency of labeling was estimated using a Biorad DC assay
kit. A calibration curve using serial dilutions of unlabeled Ca2+-free
sNUCB1(S44C) was prepared to use for estimation of the concentration of
the labeled protein by measuring absorbance at 750 nm. The concentration
of nano-Au label was estimated by measuring absorbance at 420 nm
where nano-Au probe absorbs strongly. A ratio of the protein
concentration to nano-Au concentration gave a value of 1.02, indicating
stoichiometric labeling of Ca2+-free sNUCB1(S44C) with each monomeric
subunit labeled with one nano-Au probe.

2.1.10 Nano-Au labeling of hIAPP
32 µM of hIAPP was incubated in 20 mM Tris pH 7.5 buffer solution at
room temperature. After fibrils were formed, the reaction mixture was
sonicated for 15 sec and sonicated mixture was dialyzed against PBS at 4
o

C. Thereafter 2 nmoles of hIAPP solution were incubated with 6 nmoles

of nano-Au maleimide in PBS supplemented with TCEP overnight at 4 oC.
The excess nano-Au was removed through extensive dialysis. The labeled
solution was then used to “seed” a hIAPP aggregation reaction and the
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incorporation of nano-Au labeled hIAPP fragment into growing fibril was
observed using TEM.

2.1.11 Scanning Transmission Electron Microscopy (STEM) and mass
per unit length measurements
Dark-field micrographs of unstained freeze-dried specimens together with
Tobacco Mosaic Virus (TMV) particles as a mass standard were prepared
according to the standard “wet film” method of the Brookhaven STEM
facility. This involved freeze-drying the sample with TMV on titanium
grids supporting a 2 - to 3 - nm carbon film as described by Wall and
Hainfeld. Grids were scanned at - 150 °C on a custom-built STEM at
40 kV with a probe focused to 0.25 nm with a dwell time of 30 µs / pixel.
Digital dark-field micrographs of freeze-dried specimens were recorded
with 512 × 512 pixels at raster steps of 1.0 or 2.0 nm per pixel and an
average radiation dose of 1 × 102 to 5 × 102 electron / nm2. The images
were analyzed using the PCMass30 software (Brookhaven STEM
resource). The resulting data were normalized to the known mass per unit
length of TMV (131.4 kDa / nm).
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2.1.12 BODIPY FL-Casein based Protease assay
An experimental stock of 1 µg / µl was prepared for BODIPY FL-Casein
(Molecular Probes), Trypsin (Sigma, NJ) and Ca2+-free sNUCB1 in
digestion buffer (10 mM Tris pH 7.8, 100 µM NaN3). Thereafter 10 µg of
BODIPY FL Casein substrate was incubated in digestion buffer at 25 oC
and the fluorescence readout was measured with λex = 505 nm and λem =
513 nm. After 60 sec, 100 µg of Ca2+-free sNUCB1 or 10 µg of Trypsin
was added to the reaction mixture and enhancement in fluorescence was
recorded. In addition, BODIPY FL Casein was also incubated with
Trypsin, or with varying concentrations of sNUCB1(tetramutant) or Ca2+free sNUCB1 and samples were withdrawn after 5 min and 60 min and
subjected to SDS-PAGE analysis followed by coomassie staining.

2.1.13 Liquid chromatography Mass Spectrometry (LC-MS)
HPLC-MS analysis was performed using an Acquity UPLC System
(Waters, Milford, MA) in combination with a QSTAR QqTOF mass
spectrometer (Applied Biosystems). The column used was a 150 mm × 2.1
mm BEH C18 column. The LC was coupled with the mass spectrometer
using a Pico Tip sprayer (New Objective, Woburn, MA) with an inner
diameter of 15 µm. UPLC-MS / MS analysis was carried out at a flow rate
of 100 µ l / min. Samples were loaded directly on the analytical column.
After a washing period of 1 min with 1% B (acetonitrile with 0.01%
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TFA), a linear gradient was from 99% A (water with 0.01% TFA), 1%B to
30% A, 70% B in 10 minutes, respectively. Similar results were also
obtained with nano-HPLC coupled to a LTQ mass spectrometer at 250
nanoliter/minute and a linear gradient was from 99% A (water with 0.01%
TFA), 1%B to 30% A, 70% B in 40 minutes.

2.1.14 Matrix Metallaproteinase (MMP) assay
The Sensolyte® 520 Matrix Metalloproteinase (MMP) substrate kit
(AnaSpec) was used to assay for MMP activity of Ca2+-free sNUCB1.
Sixteen synthetic FRET peptide (5-aminocarboxy fluorescein or 5-FAM
and QXL™520 are used as the fluorophore / quencher pair) substrates
were used as fluorogenic indicators to assay MMP activities. Within the
peptide, QXL™520 quenches the fluorescence readout of 5-FAM whereas
upon MMP mediated proteolytic cleavage of the peptide this internal
quenching is be relieved and the fluorescence emission readout for 5-FAM
can be monitored at Ex / Em wavelengths = 490 / 520 nm. The assay was
done in a 96-well plate format. A serial dilution of the reference standard
was done in the assay buffer to calibrate the optimal concentration of the
substrate needed for the reaction. Thereafter we incubated the optimal
concentration of each FRET peptide substrate with either 15 ng / 50 µl /
well of MMP-1 or with 7.5 or 750 ng / 50µl / well of Ca2+-free sNUCB1
and the fluorescence emission was recorded at 10 min time intervals for 90
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min. In order to eliminate the contribution from the background, the
fluorescence emission for each FRET peptide alone was subtracted from
all monitored reactions.

2.1.15 Luciferase Assay
The Luciferase assay kit was bought from Promega and the Luciferin
(substrate) stock was prepared in the assay buffer according to the
manufacturer’s protocol. Thereafter a serial dilution curve for Luciferase
activity was generated by incubating the substrate with varying
cconcentrations of Luciferase and quatifying the chemiluminiscence
readout 10 min after substrate addition with an EnVision Multimode Plate
Reader (Perkin Elmer). The analysis showed that 0.7 nM concentration of
Luciferase was optimal and was used in all subsequent experiments. For
renaturation assay, native Luciferase was denatured by incubating it at 40
o

C for 10 min. Thereafter, denatured Luciferase (0.7 nM) was

independently incubated with 0.7 nM, 7 nM or 70 nM concentration of
Ca2+-free sNUCB1 in a reaction mixture with substrate present and the
chemiluminiscence recorded after 10 min, 20 min and 30 min. The
chemiluminiscence of the substrate alone was substracted from each
monitored reactions. In addition, we also tested for the ability of Ca2+-free
sNUCB1 towards inhibiting heat denaturation of Luciferase. We
preincubated 0.7 nM Luciferase separately with 0.7 nM and 70 nM
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concentration of Ca2+-free sNUCB1 and heated each reaction mixture at
42

o

C for 10 min. The chemilumiscience from each reaction was

monitored 10 min after addition of substrate post incubation period. Each
experiment was repeated atleast 3 times. The error bars represent mean ±
S.E.M. of independent measurements.
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2.2 RESULTS
2.2.1 Ca2+-free sNUCB1 inhibits hIAPP fibril formation at substoichiometric concentrations
hIAPP is a 37-amino-acid long neuroendocrine hormone that readily
aggregates into characteristic amyloid fibrils with β-sheet morphology.
The aggregation kinetics of hIAPP alone or in the presence of equimolar
or sub-stoichiometric amounts of Ca2+-free sNUCB1 were monitored
using thioflavin-T binding assay (Fig.2.2A). For hIAPP alone, aggregation
starts with a nucleation phase of “seed” formation within 5 min that
extends into a rapidly growing elongation phase between 5 and 20 min.
The growth phase finally plateaus into a stationary phase indicative of
extensive fibril formation. Interestingly, in the presence of equimolar
amount (32 µM) of Ca2+-free sNUCB1, there is significant decrease in the
enhancement of thioflavin-T fluorescence suggesting that Ca2+-free
sNUCB1 inhibits aggregation of hIAPP into amyloid fibrils. The
inhibition persists even at sub-stoichiometric concentrations of 10.7 µM,
6.4 µM and 3.2 µM Ca2+-free sNUCB1 with 32 µM hIAPP in the reaction
mixture (Fig.2.2A). Interestingly, incubation with limiting concentration
of 0.64 µM results in a similar aggregation profile as observed for hIAPP
alone, suggesting that at this concentration Ca2+-free sNUCB1 cannot
inhibit fibril formation. Subsequent TEM analysis of samples withdrawn
from individual reactions show that hIAPP alone (32 µM) aggregates to
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Figure 2.2. Concentration dependent inhibition of hIAPP fibril
formation by Ca2+-free sNUCB1.

(A) We monitored the kinetics of

hIAPP aggregation using enhancement in thioflavin-T fluorescence. The
aggregation of 32 µ M hIAPP alone (blue) shows an initial nucleation
phase which then extends into a rapid growth phase. The aggregation
continues and reaches a plateau indicating the completion of aggregation
with the formation of hIAPP amyloid fibrils. We then incubated hIAPP
with different concentrations of Ca2+-free sNUCB1, ranging from
equimolar (32 µ M) (black) to sub-stoichiometric amounts. The
aggregation profiles show that Ca2+-free sNUCB1 effectively inhibits
hIAPP aggregation when present at equimolar (32 µ M) concentrations.
However, relative enhancement in thio-T fluorescence was observed when
6.4 µM

(green) or 3.2 µ M (orange) Ca2+-free sNUCB1 was used.

Interestingly, incubation with 0.64 µ M (pink) concentration of Ca2+-free
sNUCB1 results in an aggregation profile similar to hIAPP alone. We also
monitored each reaction using TEM. As a control (B) hIAPP (32 µM) and
Ca2+-free sNUCB1 were incubated alone and reaction was monitored by
withdrawing samples at 7 min, 13 min and 60 min. hIAPP alone (32 µM)
aggregates rapidly to form oligomers within 7 min which associate to form
protofibrils and protofilaments within 13 min. These intermediates rapidly
associate to form amyloid fibrils within 60 min. Unlike hIAPP, Ca2+-free
sNUCB1 alone (32 µ M) does not aggregate to form higher order
aggregates. (C) We also used TEM to monitor inhibition of hIAPP
aggregation by varying concentrations of Ca2+-free sNUCB1. The
micrographs show that Ca2+-free sNUCB1 when incubated with hIAPP at
equimolar (32 µ M) or sub-stoichiometric concentration upto 3.2 µM
concentration effectively inhibits hIAPP fibril formation. However at the
limiting concentration of 0.64 µM, fibril formation is uninhibited as seen
by the presence of amyloid fibrils in the 60 min sample. Thus inhibition of
amyloid formation is a dose-dependent process. The scale bar represents
200 nm.
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Figure 2.2

89

form oligomers within 7 min, which continue to grow and form higher
order intermediates protofilaments

and protofibrils as shown for the

sample at 13 min. These protofibrillar intermediates associate and extend
into mature amyloid fibrils within 60 min. In a control experiment, 32 µM
Ca2+-free sNUCB1 alone does not aggregate when incubated at room
temperature

(Fig.2.2B).

Thereafter,

the

reaction

mixtures

with

stoichiometric or lower concentrations of Ca2+-free sNUCB1 preincubated
with hIAPP (32 µM) were analyzed through TEM (Fig.2.2C). The samples
withdrawn at 7 min and 13 min for reaction mixtures with 32 µ M, 10.7
µM, 6.4 µ M and 3.2 µ M concentration of Ca2+-free sNUCB1 show
oligomeric species and the 60 min sample shows the presence of high
order prefibrillar species in the reaction mixture. The formation of
prefibrillar species in each of these reactions explains the observed
increase in the thioflavin-T fluorescence as shown in Fig.2.2A.
Furthermore, the absence of a lag phase in the presence of Ca2+-free
sNUCB1 suggests towards a facilitated rapid association of hIAPP
towards forming prefibrillar species by Ca2+-free sNUCB1. Interestingly,
when 0.64 µM concentration of Ca2+-free sNUCB1 was used, fibrils were
observed in the 60 min sample, showing that at this concentration Ca2+free sNUCB1 does not inhibit fibril formation by 32 µ M hIAPP. Thus
Ca2+-free sNUCB1 inhibits fibril formation by hIAPP in a dose-dependent
manner.
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2.2.2 Ca2+-bound sNUCB1 does not inhibit hIAPP fibril formation
NUCB1 is a multi-domain protein with two Ca2+-binding EF hand
domains (Fig.2.1). Ca2+ readily binds to sNUCB1 and induces
conformational change within the protein subunit (Fig.1.2C,D). As shown
earlier, Ca2+-free sNUCB1 effectively inhibits hIAPP aggregation into
amyloid fibrils (Fig.2.2). In order to investigate the effect of Ca2+-binding
on the functional efficacy of sNUCB1, we monitored inhibition of hIAPP
aggregation by equimolar amounts (32 µM) of sNUCB1 in the absence or
presence of 3 mM Ca2+ in the reaction mixture. The experiment was setup
by first incubating Ca2+-free sNUCB1 in 20 mM Tris pH 7.5
supplemented with or without 3 mM Ca2+. Thereafter stoichiometric
amount (32 µ M) of hIAPP was added to each reaction mixture and
samples were withdrawn at 15 min, 30 min and 60 min time points for
analysis using TEM (Fig.2.3A). As shown, Ca2+-free sNUCB1 effectively
inhibits fibril formation as only characteristic protofibrillar species are
seen even at 60 min time point. In contrast, Ca2+-bound sNUCB1 does not
inhibit fibril formation. TEM images for 15 min sample show presence of
protofibrils and protofilaments, which continue to grow into fibrillar
structures seen in coexistence with protofibrillar intermediates in the 30
min sample. These eventually combine to form mature amyloid fibrils as
shown for 60 min sample (Fig.2.3B). Thus Ca2+-binding nullifies the
functional ability of sNUCB1 to effectively inhibit hIAPP fibril formation.
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Figure 2.3. Ca2+-binding prevents sNUCB1 from inhibiting hIAPP
fibril formation. We monitored aggregation of hIAPP in the presence of
sNUCB1. (A) In the absence of Ca2+, equimolar amount (32 µ M) of
sNUCB1 preincubated with hIAPP effectively inhibits aggregation of
hIAPP into fibrils. The micrographs corresponding to 15 min and 30 min
show the presence of oligomeric and protofibrillar species that do not
progress to form fibrils as shown by the micrograph corresponding to the
60 min sample. (B) However, in the presence of excess Ca2+ (3 mM) in the
reaction mixture, sNUCB1 is unable to inhibit hIAPP aggregation. hIAPP
aggregates to form protofibrils and protofilaments as observed at 15 min
and 30 min respectively which eventually grow into mature fibrils within
60 min. The scale bar on each micrograph represents 200 nm.
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2.2.3 Engineered sNUCB1 Ca2+-insensitive mutant,
sNUCB1(tetramutant), inhibits hIAPP fibril formation in a Ca2+independent manner
sNUCB1 consists of two EF hand domains that bind to Ca2+. The
sequence alignment of the 12-amino-acid long Ca2+-binding EF hand
loops of NUCB1 with known Ca2+-binding proteins highlights the
presence of completely conserved Asp residue at the 1st position followed
by a Glu at the 12th position (marked by asterisk) (Fig2.4A). In order to
disrupt the Ca2+-binding ability of sNUCB1, we mutated the Ca2+coordinating Asp253 and Asp305 in each EF hand domain to a Lys and
Glu264 and Glu316 into Ala to generate a tetramutant namely
sNUCB1(tetramutant) (Fig.2.1). The far-UV CD spectra of homogenously
purified sNUCB1(tetramutant) showed a majorly helical structure
(Fig.2.4B) similar to Ca2+-free sNUCB1 itself (Fig.1.3A). Furthermore,
the folding of sNUCB1(tetramutant) was observed to be non-cooperative
and irreversible with an apparent Tm of 48.7 oC (Fig. 2.4B,inset). In
addition, we performed ITC experiment to test for the ability of
sNUCB1(tetramutant) to bind Ca2+. 5 µ l aliquots of 500 µ M solution of
Ca2+ were injected into a buffered solution of sNUCB1(tetramutant) in the
reaction cell and the heat released per injection was recorded. The
observed isotherm shows no significant heat release due to complete
absence of Ca2+-binding to sNUCB1(tetramutant) (Fig.2.4C). Thereafter,
in order to investigate the functional efficacy of sNUCB1(tetramutant)
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Figure 2.4. sNUCB1(tetramutant) is majorly helical and does not bind
to Ca2+. (A) A sequence alignment of the 12-residue Ca2+-binding loop
within the EF hand domains of NUCB1 with similar regions from several
known Ca2+-binding proteins is shown. The alignment highlights the
presence of highly conserved aspartic acid at the beginning (pink) and
glumatic acid (brown) at the end of the loop sequence. Interestingly,
NUCB1 EF hand 1 loop sequence contains a conserved glycine at the 6th
position (green) whereas it is an Arg (blue) in the EF hand 2 sequence.
The respective aspartic and glutamic acid residues were mutated to
generate sNUCB1(tetramutant). (B) The secondary structure analysis for
sNUCB1(tetramutant) (8 µ M) was done using CD spectroscopy. The
recorded spectrum shows that sNUCB1(tetramutant) is fully folded with a
majorly helical secondary structure highlighted by the characteristic
minima at 208 nm and 222 nm respectively. The inset shows the thermal
unfolding transition for 8 µ M recombinant sNUCB1(tetramutant)
monitored by recording CD signal at 222 nm at a heating rate of 1 oC /
min. The trace is indicative of a multistep non-cooperatively folded
protein with an apparent Tm of 48.7 oC. sNUCB1(tetramutant) was
generated to nullify the Ca2+-binding ability of sNUCB1. Thus, (C) we
used isothermal titration calorimetry (ITC) to measure the Ca2+-binding
affinity of sNUCB1(tetramutant). 5 µl aliquots of 500 µ M CaCl2.6H2O
were injected into the reaction cell containing 50 µ M solution of
sNUCB1(tetramutant) at 25 oC and the heat released per injection was
recorded. The inset shows effectively no release of energy as Ca2+ is
injected into the sample cell containing sNUCB1(tetramutant), indicating
the absence of any binding event.
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Figure 2.4
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towards inhibiting hIAPP fibril formation we incubated equimolar
amounts of hIAPP with sNUCB1(tetramutant) in the absence and presence
of 3 mM Ca2+ in the reaction mixture. Samples were withdrawn at 15 min,
30 min and 60 min time points and analyzed using TEM (Fig.2.5). As
shown, sNUCB1(tetramutant) effectively inhibits hIAPP fibril formation
in the absence of Ca2+ since no fibrillar aggregates are observed for the 60
min

sample

(Fig.2.5A).

Intriguingly,

unlike

sNUCB1,

sNUCB1(tetramutant) also inhibits fibril formation in the presence of
excess Ca2+ in the reaction mixture. TEM images of the samples
withdrawn at various time points show complete absence of amyloid
fibrils (Fig.2.5B). Hence the engineered sNUCB1(tetramutant) effectively
inhibits hIAPP fibrils formation but unlike sNUCB1 is insensitive to the
presence of Ca2+ in the reaction mixture.

2.2.4 sNUCB1 and sNUCB1(tetramutant) disaggregate hIAPP fibrils
hIAPP rapidly aggregates in vitro to form amyloid fibrils. As shown
earlier, sNUCB1 and sNUCB1(tetramutant) effectively inhibit hIAPP
fibril formation (Fig.2.3,2.5). We further investigated the functional ability
of these proteins towards disaggregating preformed fibrils. 32 µM hIAPP
was incubated in 20 mM Tris pH 7.5 buffer for 60 min to form mature
amyloid fibrils. Thereafter, equimolar amounts of Ca2+-free sNUCB1 or
sNUCB1(tetramutant) were added to the reaction mixture and samples
were withdrawn after 15 min, 30 min and 60 min for analysis using TEM.
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Figure 2.5. Ca2+ does not prevent sNUCB1(tetramutant) from
inhibiting hIAPP aggregation. We monitored aggregation of hIAPP in
the presence of sNUCB1(tetramutant). (A) In the absence of Ca2+,
equimolar amount (32 µ M) of sNUCB1(tetramutant) preincubated with
hIAPP effectively inhibit aggregation of hIAPP into fibrils. The
micrographs corresponding to 15 min and 30 min show the presence of
oligomeric and protofibrillar species that do not progress to form fibrils as
shown by the micrograph corresponding to the 60 min sample. (B)
Interestingly, even in the presence of excess Ca2+ (3 mM in the reaction
mixture, sNUCB1(tetramutant) is still effective at inhibiting fibril
formation. The micrographs for the samples withdrawn at 15 min, 30 min
and 60 min time points show complete absence of fibril formation. The
scale bar on each micrograph represents 200 nm.
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The micrographs show that in the absence of Ca2+ both sNUCB1 and
sNUCB1(tetramutant) effectively disaggregate hIAPP fibrils into smaller
molecular species within 15 min. These species do not associate to form
fibrils even at 60 min time point (Fig.2.6A and B). Interestingly, Ca2+binding nullifies the functional ability of sNUCB1 towards disaggregating
hIAPP fibrils. TEM images corresponding to samples withdrawn after
addition of equimolar amount of sNUCB1 to fibrils in the presence of 3
mM Ca2+ show fibrillar species in the micrographs at all monitored time
points. Intriguingly, sNUCB1(tetramutant) is insensitive to the presence of
Ca2+ in the reaction mixture and disaggregates hIAPP fibrils even in the
presence of 3 mM Ca2+. TEM images for 15 min, 30 min and 60 min time
point show that sNUCB1(tetramutant) effectively disaggregates hIAPP
fibrils into smaller molecular species within 15 min which continue to
exist even at 60 min (Fig2.6A and B). Thus Ca2+-binding disrupts the
ability

of

sNUCB1

to

disaggregate

amyloid

fibrils

but

sNUCB1(tetramutant) continues to perform its function even in the
presence of excess Ca2+ in the reaction mixture.
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Figure 2.6. Ca2+ prevents sNUCB1 but not sNUCB1(tetramutant)
from disaggregating hIAPP fibrils. We monitored disaggregation of
hIAPP

fibrils

in

the

presence

of

(A)

sNUCB1

or

(B)

2+

sNUCB1(tetramutant). In the absence of Ca , equimolar amount (32 µM)
of sNUCB1 or sNUCB1(tetramutant) incubated with hIAPP fibrils
effectively disaggregates them into smaller molecular species. The
disaggregation was observed within 15 min of incubation and continues
with effective disaggregation seen in 30 min and 60 min micrographs
corresponding to samples withdrawn from the reaction mixture. However,
when excess Ca2+ (3 mM) is present in the reaction mixture, sNUCB1 is
unable to disaggregate hIAPP fibrils as shown by the presence of
aggregates characteristic of fibrils for all monitored time points. Unlike
sNUCB1, sNUCB1(tetramutant) is still effective at disaggregating hIAPP
fibrils even in the presence of 3 mM Ca2+ in the reaction mixture. The
microgrpahs for the 15 min, 30 min and 60 min show complete absence of
any

fibrillar

aggregates,

indicating

that

potent

activity

of

sNUCB1(tetramutant) persists even in the presence of Ca2+. The scale bar
represents 200 nm.
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2.2.5 Ca2+-free sNUCB1 inhibits hIAPP fibrillization along any stage
of amyloid formation pathway
We monitored the aggregation of 32 µ M hIAPP in 20 mM Tris pH 7.5
using thioflavin-T binding assay (Fig.2.7). The aggregation curve
represented by solid spheres shows the nucleation phase in blue, growth
phase in green and the saturation phase corresponding to formation of
mature amyloid fibrils in yellow. In order to monitor the functional ability
of Ca2+-free sNUCB1 towards inhibiting fibril formation when added at
different states along the hIAPP aggregation pathway, 32 µ M Ca2+-free
sNUCB1 was individually added to hIAPP aggregation reaction in the
nucleation phase at 7 min, middle of growth phase at 13 min and in the
steady-state phase at 40 min (pink spheres). As a control, TEM
micrographs for samples prior to the addition of Ca2+-free sNUCB1 show
presence of oligomers at 7 min, protofibrillar intermediates in 13 min and
mature fibrils in 40 min. Subsequently each of these species was incubated
with equimolar amount (32 µM) of Ca2+-free sNUCB1 and samples were
withdrawn after 60 min for TEM analysis (Fig.2.7). Interestingly, TEM
analysis for each reaction mixture shows complete absence of amyloid
fibrils. This suggests that Ca2+-free sNUCB1 is effective at inhibiting fibril
formation even when added at any intermediate state along the
aggregation pathway. Moreover, as shown earlier, once the fibrils are
formed Ca2+-free sNUCB1 can effectively disaggregate them into smaller
molecular species, which do not aggregate into amyloid fibrils.
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Figure 2.7. Ca2+-free sNUCB1 inhibits hIAPP amyloidogenesis in a
state-independent manner. (A) We monitored hIAPP (32 µM)
aggregation using thioflavin-T (32 µM) with the lag phase in blue, growth
phase in green and stationary phase in yellow. The circles in pink indicate
the corresponding time points at which sNUCB1 was added to the
aggregation reaction. hIAPP (32 µM) aggregation was allowed to proceed
to (A) nucleation phase at 7 min, (B) mid-point of growth phase at 15 min
and (C) initiation of stationary phase at 40 min after which equimolar
amount (32 µM) of Ca2+-free sNUCB1 was added to the reaction mixture.
TEM images were collected immediately before addition of sNUCB1 and
60 min after incubation with Ca2+-free sNUCB1. The micrographs
corresponding to samples withdrawn at 60 min after addition show that
Ca2+-free sNUCB1 both effectively inhibits the progression of seeds into
mature fibrils and also disaggregates amyloid fibrils. The scale bar
represents 200 nm.
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Thus Ca2+-free sNUCB1 possesses the unique ability to inhibit
amyloidogenesis of hIAPP at any stage of fibril formation.

2.2.6 Ca2+-free sNUCB1 inhibits fibril formation by stabilizing hIAPP
prefibrillar species
Our earlier results showed that Ca2+-free sNUCB1 effectively inhibits
hIAPP fibril formation and TEM analysis of samples withdrawn from the
reaction mixture after 60 min show the presence of molecular species
much smaller than the mature fibrils. Hence to characterize these observed
molecular species we incubated 32 µM of Ca2+-free sNUCB1 with 32 µM
hIAPP in 20 mM Tris pH 7.5 buffer at room temperature for 60 min.
Thereafter, we injected 200 µ l of reaction mixture onto a buffer
equilibrated Superose6 10 / 30 GL column and the elution profile
corresponding to absorbance at 280 nm was recorded (Fig.2.8A, blue
curve). Since hIAPP does not have any Trp residues, absorbance at 280
nm must primarily result from contribution of Trp residues of sNUCB1.
Injection of 32 µM solution of Ca2+-free sNUCB1 alone onto the column
generates a peak centered at 12 ml (Fig.2.8A, dotted red curve) (Peak2). In
order to determine the molecular constituents of Peak1 and Peak2, we
fractionated the individual peaks and performed dot blot analysis. The
results show that Ca2+-free sNUCB1 was present in both Peak1 and Peak2
fractions whereas hIAPP was present only in the Peak1 fraction
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Figure 2.8. Biophysical characterization of Ca2+-free sNUCB1 stabilized
hIAPP protofibrillar species. (A) We used size exclusion chromatography
using Superose6 10/30 GL column to elute Ca2+-free sNUCB1 alone (32
µM) (red dotted curve). Thereafter a 60 min sample from a reaction mixture
with equimolar concentration of hIAPP and Ca2+-free sNUCB1 incubated at
t = 0 was injected and the fractions corresponding to the eluting peaks were
collected (blue curve). Ca2+-free sNUCB1 alone elutes in Peak2 centered at
12 ml while the reaction mixture gives an additional peak namely Peak1
eluting at 7.8 ml. We further investigated the molecular constituents within
each peak using dot-blot assay. (B) We blotted 5 µ l of Peak1 and Peak2
fractions on a PVDF membrane and probed each of them with either antisNUCB1 antibody or anti-hIAPP antibody. The upper blot shows that
sNUCB1 is present in both peak fractions whereas the lower blot shows
that hIAPP is present only in Peak1 and not Peak2 fractions. As controls,
hIAPP and sNUCB1 were blotted to show that the antibodies are specific
with no cross-reactivity. Thereafter (C) we used TEM to analyze both
Peak1 and Peak2 fractions. Micrograph corresponding to Peak1 shows the
presence of oligomeric and prefibrillar species whereas Peak2 fraction
shows no higher order structures. As a control, hIAPP fibrils formed within
60 min with hIAPP alone are shown in the inset for micrograph
corresponding to Peak1. (D) We used both multi-angle light scattering
(MALS) (left) and dynamic light scattering (DLS) (right) analysis across
Peak1 and Peak2 respectively. MALS analysis across Peak1 estimates a
molecular mass in the range of 2 - 6 MDa and DLS predicts hydrodynamic
radii in the range of 22 - 42 nm. These numbers point towards an isolated
sNUCB1-bound prefibrillar species of hIAPP. In addition, MALS analysis
of Peak2 predicts a molecular mass in the range of 97 - 99 kDa, which
corresponds to the molecular mass of a dimer of Ca2+-free sNUCB1. DLS
analysis gives an invariant hydrodynamic radius of 6.2 nm, which is
characteristic for Ca2+-free sNUCB1 dimer. Thereafter we utilized STEM to
quantitatively determine a mass / unit length (M / L) distribution of
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prefibrillar species in Peak1 fraction. (E) The analysis shows the presence
of prefibrillar species with M / L ranging from 1 - 7 kDa / Å with species
predominantly ranging from 2 - 5 kDa / Å. The adjacent micrograph shows
a typical large-angle dark-field cryo-STEM image of Peak1 fraction with
tobacco mosaic virus (TMV) helical rod as the calibration control for data
analysis. The scale bar represents 100 nm. Furthermore, the images below
represent examples of prefibrillar species observed in STEM wherein the
width of each box represents 200 nm. (F) We further investigated the
stability of the Peak1 fraction by incubating it at room temperature for 7
days with constant stirring. Thereafter, we injected the reaction mixture
onto a buffer pre-equilibrated Superose6 10/30 GL column and the elution
profile at 280 nm was recorded. The trace shows that Peak1 is reproduced
suggesting that Ca2+-free sNUCB1 bound hIAPP prefibrillar species is
highly stable and does not proceed to form fibrillar aggregates as shown by
the TEM of the eluting Peak1 fraction.
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(Fig.2.8B). As a control, Ca2+-free sNUCB1 and hIAPP alone were blotted
onto the membrane to test for the cross-reactivity of each antibody. Both
Peak1 and Peak2 fractions were further subjected to TEM analysis. The
corresponding micrograph shows the presence of only prefibrillar species
in Peak1 fraction whereas Peak2 fraction shows a typical image
corresponding to Ca2+-free sNUCB1 without any aggregates (Fig.2.8C).

In order to characterize the species constituting the Peak1 and Peak2
fractions, we performed multi-angle light scattering (MALS) and dynamic
light scattering (DLS) analysis to estimate the average molecular mass and
the hydrodynamic radii of the eluting species. MALS analysis across
Peak1 estimates a molecular mass in the range of 2 - 6 MDa for the eluting
species with the hydrodynamic radii of 22 - 42 nm obtained from the DLS
analysis across Peak1 (Fig.2.8D). These numbers suggest that Ca2+-free
sNUCB1 binds to and stabilizes a high molecular mass prefibrillar hIAPP
aggregate. Similar analysis across Peak2 fraction gave a 97 - 99 kDa
molecular mass species with a hydrodynamic radii of 6.2 nm (Fig.2.8D),
characteristic for a dimer of Ca2+-free sNUCB1 alone (Fig.1.4). We
further performed scanning transmission electron microscopy (STEM)
analysis on Peak1 fraction to estimate the mass per unit length (M / L) for
the observed prefibrillar species. Dark field images were collected for
Peak1 fraction with Tobacco Mosaic Virus (TMV) as an internal standard
and PCMass30 software was used for image analysis. The M / L data was
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pooled and is presented in histograms. A typical dark field micrograph is
shown with several prototypical examples with mass densities
corresponding to the prefibrillar species shown below it. The data shows
that Peak1 fraction comprises of molecular species with M / L ranging
from 1 - 7 kDa / Å with predominant species varying from 2 - 5 kDa / Å
(Fig.2.8E). Earlier, similar analysis by Goldsbury et al. on 100 nm long
hIAPP fibril segments reported a M / L in the range of 2 - 5 kDa / Å with a
median at 3 kDa / Å (86). This suggests that sNUCB1 stabilized
prefibrillar species is comparable in mass density to the reported
protofibrils. However, these 40-80 nm long prefibrillar species are
stabilized by bound sNUCB1. Thus the M / L contributed by hIAPP alone
to the prefibrillar species would be less when compared to protofibrils
alone. We thus refer to this species as prefibrillar. We further investigated
the stability of these Ca2+-free sNUCB1 bound prefibrillar species by
incubating Peak1 fraction at room temperature to facilitate their
association into mature fibrils. The reaction mixture was constantly stirred
for 7 days after which it was injected onto a buffer equilibrated Superose6
10 / 30 GL column. Interestingly, we were able to reproducibly generate
the Peak1 as earlier. TEM analysis of the sample before and after elution
from the column shows the characteristic prefibrillar species as observed
before for Peak1 (Fig.2.8F). This shows that Ca2+-free sNUCB1 bound
prefibrillar species is highly stable and does not associate further to form
fibrils. These biophysical experiments prove that Ca2+-free sNUCB1
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inhibits hIAPP fibril formation by stabilizing a high molecular mass
prefibrillar species of hIAPP.

As a control, we performed ITC experiments with Pramlintide (Fig2.1), a
non-aggregating analog of hIAPP. We injected Pramlintide into a reaction
cell with buffered solution of Ca2+-free sNUCB1 and heat released per
injection was recorded. The result shows that Pramlintide does not interact
with Ca2+-free sNUCB1 (Fig.2.9A). In addition, we also performed SEC
experiments similar to as shown in Fig.2.8A. We incubated 32 µM of
pramlintide with equimolar amount of Ca2+-free sNUCB1 for 3 h after
which the reaction mixture was injected onto a buffer equilibrated
Superose6 10 / 30 GL column. Unlike earlier, we did not observe an
elution profile with Peak1 suggesting that Ca2+-free sNUCB1 interacts
only with an aggregated form of hIAPP and probably not the monomeric
form (Fig.2.9B).

2.2.7 sNUCB1 does not possess protease activity and cannot cleave
hIAPP
The above-proposed mechanism of inhibition of hIAPP fibril formation
does not rule out the possibility of a proteolytic activity of sNUCB1. An
alternate hypothesis might be that sNUCB1 proteolytically cleaves hIAPP
into smaller fragments, which can still aggregate to form protofibrils
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Figure 2.9. Pramlintide does not bind to Ca2+-free sNUCB1. (A) We used
isothermal titration calorimetry (ITC) to measure the binding affinity of the nonaggregating analog of hIAPP namely Pramlintide to Ca2+-free sNUCB1. 5 µl
aliquots of 600 µ M Pramlintide solution were injected into the reaction cell
containing 40 µM solution of Ca2+-free sNUCB1 at 25 oC and the heat released
per injection was recorded. The inset shows effectively no release of energy as
Pramlintide is injected into the reaction cell containing Ca2+-free sNUCB1,
indicating the lack of any binding event. In addition, (B) we incubated
Pramlintide with equimolar amount (32 µM) of Ca2+-free sNUCB1 for 5 h. 200 µl
of the reaction was injected onto a buffer equilibrated Superose6 10 / 30 GL
column and the chromatogram corresponding to sample absorbance at 280 nm
was recorded. The plot shows the presence of only a single peak centered at the
characteristic volume (~12 ml) for elution of Ca2+-free sNUCB1 alone. The
absence of a lower elution volume peak suggests that Pramlintide does not
aggregate into higher order structures due to which Ca2+-free sNUCB1 does not
bind to it.
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Figure 2.10. Ca2+-free sNUCB1 / sNUCB1(tetramuant) do not possess
protease activity. (A) We incubated 10 µ g of BODIPY FL-Casein
substrate in digestion buffer (10 mM Tris pH 7.8, 100 µ M NaN3) for 5
min at 25 oC followed by time-based fluorescence emission measurement
with λex = 505 nm and λem = 513 nm. After 60 sec, 100 µg of Ca2+-free
sNUCB1 (green) or 10 µg of Trypsin (orange) was added to the reaction
mixture and enhancement in fluorescence was recorded. As shown,
addition of Trypsin causes significant enhancement in the observed
fluorescence intensity whereas even 10-fold excess of Ca2+-free sNUCB1
did not result in any notable enhancement in fluorescence intensity. This
suggests that Ca2+-free sNUCB1 possibly does not proteolytically cleave
BODIPY FL-Casein. In addition, (B) protease digestion assays were setup
with 20 µ g of either Trypsin or sNUCB1(tetramuant) incubated with 20
µg BODIPY FL-Casein substrate and samples were withdrawn at different
subsequent time points for SDS-PAGE analysis. The Coomassie stained
gel shows that Trypsin rapidly cleaves the substrate into smaller molecular
fragments whereas sNUCB1(tetramutant) is unable to cleave the substrate
even after 60 min of incubation. Similarly, (C) 30 µg BODIPY FL-Casein
substrate was incubated with 3 µ g or 30 µ g of Ca2+-free sNUCB1 and
samples were withdrawn after 5 min and 60 min for SDS-PAGE analysis.
As earlier, the Coomassie stained gel image shows that similar to
sNUCB1(tetramutant), Ca2+-free sNUCB1 also does not possess any
proteolytic activity. In addition, (D) the proteolytic activity of Ca2+-free
sNUCB1 towards hIAPP was also investigated using LC-MS. We
incubated equimolar amount (32 µ M) of Ca2+-free sNUCB1 with hIAPP
and sample was withdrawn after 2 h for analysis using LC-MS. The mass
spectrum shows characteristic peak pattern for sNUCB1 (pink) and a
single peak for hIAPP (blue). The spectrum shows a complete absence of
any smaller fragments of hIAPP confirming that Ca2+-free sNUCB1 does
not protealytically cleave hIAPP.
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similar to the observed sNUCB1-bound prefibrillar species. We thereby
investigated for any proteolytic activity of Ca2+-free sNUCB1 by first
using a fluorescence based protease assay with BODIPY FL-Casein as the
substrate. In principle, if Ca2+-free sNUCB1 proteolytically cleaves
Casein, the intrinsic quenching of the BODIPY fluorophore label on
Casein would be relieved, resulting in enhanced fluorescence readout. As
shown in figure 2.10A, addition of stoichiometric amount of Trypsin, a
serine-protease, to a buffered solution of BODIPY FL-Casein substrate
causes a significant enhancement in the fluorescence intensity. In contrast,
addition of even 10-fold molar excess of Ca2+-free sNUCB1 does not
result in any notable enhancement in the fluorescence intensity of labeled
Casein. SDS-PAGE analysis of the samples withdrawn from the reaction
mixtures with equimolar or excess Ca2+-free sNUCB1 incubated with
BODIPY FL-Casein substrate show that unlike Trypsin (Fig.2.10B),
neither

sNUCB1(tetramuant)

(Fig.2.10B)

nor

Ca2+-free

sNUCB1

(Fig.2.10C) cleave BODIPY FL-Casein. Reaction mixtures containing
Trypsin show generation of lower molecular mass fragments due to
proteolytic cleavage of BODIPY FL-Casein which is not observed upon
incubation with either sNUCB1(tetramuant) or Ca2+-free sNUCB1.
However, to directly rule out the proteolysis of hIAPP monomer by Ca2+free sNUCB1 as a contributing factor towards inhibition of fibril
formation, we incubated Ca2+-free sNUCB1 with equimolar concentration
(32 µM) of hIAPP for 45 min and subjected the reaction mixture to liquid
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chromatography-mass spectrometry (LC-MS). As shown in figure 2.10D,
the mass spectrum shows the peaks characteristic for sNUCB1 (pink
spectrum) and a peptide peak for hIAPP alone (purple peak). This suggests
that inhibition of hIAPP aggregation by Ca2+-free sNUCB1 does not
involve proteolysis of hIAPP as no other cleavage products for hIAPP
were observed. Thus sNUCB1 inhibits hIAPP fibril formation by capping
the ends of a high molecular mass soluble prefibrillar species of hIAPP
and thereby inhibiting their further association into mature amyloid fibrils.

NUCB1 is a ubiquitously expressed protein, which is found both
intracellularly and extracellularly. The above results show that NUCB1 is
not an intracellular endopeptidase but since NUCB1 possesses a Nterminal (NT) signal sequence and is found extracellularly, we could not
rule out the possibility of it being an extracellular protease like a matrix
metalloproteinase (MMP). MMPs are extracellular endopeptidases whose
ability to proteolytically cleave their substrates is dependent on their
ability to bind to Zn2+. Hence in order to test for matrix metalloproteinase
activity of sNUCB1, we first measured the Zn2+-binding ability of Ca2+free sNUCB1 using ITC. 5 µ l aliquots of 400 µ M ZnCl2 solution were
injected into a buffered solution of 50 µ M Ca2+-free sNUCB1 in the
reaction cell and heat released per injection was recorded. The data fit to a
“one-set-of-site” model show binding of a monomer of sNUCB1 to one
Zn2+-cation (N = 0.99 ± 0.08) with a Kd value of 22 ± 1.89 µM
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Figure 2.11. Ca2+-free sNUCB1 binds to Zn2+ but is not a Matrix
Metalloproteinase. (A) We used isothermal titration calorimetry (ITC) to
measure the Zn2+-binding affinity of sNUCB1. 5 µl aliquots of 400 µM
ZnCl2 were injected into the reaction cell containing 50 µ M solution of
Ca2+-free sNUCB1 at 25 oC and the heat released per injection was
recorded. The inset shows a fit of the data using “one-set of sites” model
using the concentration for Ca2+-free sNUCB1 monomer as the interacting
subunit. The calculated dissociation constant for Zn2-binding to Ca2+-free
sNUCB1 was 22µM ± 1.96 µM with a stoichiometry of N = 0.99 ± 0.07
suggesting that each subunit of a dimer of Ca2+-free sNUCB1 binds to one
Zn2+-cation. Thereafter we used FRET based assay to investigate the
MMP activity of Zn2+-bound sNUCB1. Sixteen synthetic FRET peptide
substrates were incubated with either (B) 15 ng MMP-1, (C) 7.5 ng Zn2+bound sNUCB1 or (D) 750 ng Zn2+-bound sNUCB1 and the fluorescence
readout was recorded at 10 min intervals for 90 min at room temperature
(λex = 490 nm, λ em = 520 nm). The results show that (B) incubation of the
peptide substrates with MMP-1 results in significant enhancement in the
fluorescence readout for a number of substrates due to their proteolytic
cleavage. However incubation with both (C) 7.5 ng and (D) 750 ng Zn2+bound sNUCB1 did not cause any enhancement. The fluorescence
emission recorded for the substrate alone was subtracted from each
monitored time point. The results show that unlike MMP-1, Zn2+-bound
sNUCB1 does not possess any MMP activity.
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(Fig.2.11A). Thereafter, in order to check for matrix metalloproteinase
activity of Zn2+-bound sNUCB1 we performed a MMP test assay using
sixteen synthetic FRET peptides wherein 5-FAM (5-aminocarboxy
fluorescein) and QXL™520 are used as the fluorophore / quencher pair.
Within the peptide, QXL™520 quenches the fluorescence readout of 5FAM whereas upon MMP mediated proteolytic cleavage of the peptide
this internal quenching is relieved and the fluorescence emission readout
for 5-FAM can be monitored at Ex / Em wavelengths = 490 / 520 nm. As
a control we incubated 15 ng of MMP-1 in 50 µl of reaction volume with
optimal concentration of each substrate at room temperature and the
fluorescence emission readout was recorded for 90 min at 10 min time
intervals. As shown in Figure 2.11B, MMP-1 has strong proteolytic
activity towards Substrate 14 and relatively weaker activity towards
Substrates 3, 4, 11 and 12. The fluorescence emission readout for the
peptide substrates alone was substracted at each monitored time point.
Thereafter the MMP activity of Zn2+-bound sNUCB1 was monitored in an
identical experimental setup. We incubated either 7.5 ng or 750 ng of
Zn2+-bound sNUCB1 with the peptide substrates and the fluorescence
emission readout was recorded. The results show that unlike MMP-1,
Ca2+-free sNUCB1 does not cleave any of the peptide substrates
(Fig.2.11C,D). This is in agreement with earlier observations that Ca2+free sNUCB1 does possess protease activity. Thus Ca2+-free sNUCB1 can
bind to Zn2+ but is not a MMP.
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2.2.8 Ca2+-free sNUCB1 binds to ATP with low affinity but neither
reverts nor inhibits Luciferase heat denaturation
NUCB1 is a multi-domain protein with an extended CT domain (Fig2.1,
1.4). Our results so far do not rule out the possibility that sNUCB1 can
have chaperone like activity wherein it can utilize energy from ATP
hydrolysis to perform its function. Therefore, we investigated the ATPbinding ability of Ca2+-free sNUCB1 using ITC. 5 µl aliquots of 600 µM
solution of ATP were injected into a buffered solution of 40 µM Ca2+-free
sNUCB1 in the reaction cell and the heat released per injection was
recorded. The plotted data was fit to a “one-set-of-sites” model wherein
the concentration of dimeric Ca2+-free sNUCB1 was used to obtain the fit.
The results show that a dimer of Ca2+-free sNUCB1 binds to one (N= 1.26
± 0.12) ATP molecule with a Kd value of 18.3 ± 0.86 µM (Fig.2.12A). In
addition, Figure 2.12B shows that Ca2+-free sNUCB1 does not bind to
ADP. Thereafter, the ATP-binding to Ca2+-free sNUCB1 was extended to
test for its ability to refold denatured proteins using firefly Luciferase
based chemiluminiscence assay (Fig.2.12C). Recombinant Luciferase was
heat denatured at 42 oC for 10 min. The denatured Luciferase was then
incubated in ATP containing buffer either alone or with Ca2+-free
sNUCB1 and the chemiluminiscence of luciferin was recorded at different
time intervals. The green bar in Fig.2.12C shows chemiluminiscence of
heat denatured Luciferase at t = 0 in comparison to recombinant
Luciferase chemiluminiscence (yellow bar). The significant decrease in
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Figure 2.12. Ca2+-free sNUCB1 binds to ATP but cannot refold
denatured Luciferase or protect it against heat denaturation. We used
isothermal titration calorimetry (ITC) to measure the (A) ATP-binding or
(B) ADP-binding affinity of Ca2+-free sNUCB1. 40 µM

Ca2+-free

sNUCB1 was titrated with 600 µM ATP / ADP solution at 25 oC and the
heat released per injection was recorded and integrated. The isotherms
show that Ca2+-free sNUCB1 binds only to ATP and does not bind ADP.
A non-linear least squares fit of the calculated values using the “one-set of
sites” model by using the concentration for Ca2+-free sNUCB1 dimer
resulted in an excellent fit as shown in the inset. The calculated
dissociation constant for ATP-binding to Ca2+-free sNUCB1 was 18.4 ±
0.86 µM with a stoichiometry of N = 1.26 ± 0.12 suggesting that each
dimer of Ca2+-free sNUCB1 binds to one ATP molecule. Thereafter we
used a Luciferase activity assay to test for the ability of Ca2+-free sNUCB1
to affect the (C) refolding or (D) heat denaturation of Luciferase. (C) We
incubated 0.7 nM of native (yellow) or heat denatured (green) firefly
Luciferase with the substrate and the chemiluminiscence was recorded.
Thereafter 0.7 nM of heat denatured Luciferase was incubated with 0.7
nM (blue), 7 nM (orange) or 70 nM (red) of Ca2+-free sNUCB1 in a
reaction mixture with the substrate and the chemiluminiscence was
recorded after 10 min, 20 min and 30 min. The results show that Ca2+-free
sNUCB1 does not influence refolding of denatured Luciferase.
Subsequently, (D) we investigated the ability of Ca2+-free sNUCB1 to
affect Luciferase heat denaturation. In the control experiment, similar
chemiluminiscence was recorded for reaction with 0.7 nM Luciferase
alone (yellow) or Luciferase incubated with 70 nM Ca2+-free sNUCB1
(grey). Subsequently, Luciferase alone (brown) or with Ca2+-free sNUCB1
(pink) was incubated at 42 oC for 10 min and the chemiluminiscence was
monitored. The results show significant and similar decrease in the
recorded chemiluminiscence suggesting that Ca2+-free sNUCB1 does not
protect Luciferase against heat denaturation.
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the recorded chemiluminiscence confirms the heat denaturation of
Luciferase. Thereafter we incubated heat denatured Luciferase with 0.7
nM (blue bar), 7 nM (orange bar) or 70 nM (red bar) Ca2+-free sNUCB1 in
the presence of luciferin and ATP and the chemilumiscence was recorded
at 10 min, 20 min and 30 min time points. The absence of any relative
enhancement in the recorded chemiluminiscence with time suggests that
Ca2+-free sNUCB1 cannot refold heat denatured Luciferase.

In an additional experiment, we also investigated the ability of Ca2+-free
sNUCB1 to inhibit heat denaturation of Luciferase (Fig.2.13D). As a
control, we incubated 0.7 nM of Luciferase alone (yellow bar) or in the
presence of 70 nM Ca2+-free sNUCB1 (grey bar) with the substrate and
recorded the chemiluminiscence output. The results show that Ca2+-free
sNUCB1 alone does not affect the enzymatic activity of Luciferase.
Thereafter, we incubated 0.7 nM Luciferase alone (pink bar) or with 70
nM Ca2+-free sNUCB1 (brown) at 42 oC for 10 min after which substrate
was added to each solution and the chemiluminiscence recorded. As
shown, incubation of Luciferase alone or with Ca2+-free sNUCB1 results
in similar reduction in the recorded chemiluminiscence suggesting that
Ca2+-free sNUCB1 does not inhibit Luciferase against heat denaturation.
Hence although Ca2+-free sNUCB1 does not affect the catalytic activity of
Luciferase, it cannot protect it against heat denaturation.
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2.2.9 Ca2+-free sNUCB1 inhibits fibril formation by “capping” the
ends of prefibrillar intermediates
NUCB1 is a 461-amino-acid long polypeptide, which lacks cysteine
residues in its primary sequence. This provides an opportunity to sitespecifically introduce cysteine residues that can be used for labeling the
homogenously purified protein subunit. We generated a mutant of
sNUCB1 namely sNUCB1(S44C) wherein a Ser44 residue was mutated to
a Cys (Fig2.1). Ca2+-free sNUCB1(S44C) similar to sNUCB1, is stable in
solution and does not aggregate. TEM analysis of a solution of 32 µM of
Ca2+-free sNUCB1(S44C) incubated alone does not show any aggregation
(Fig.2.13A). Thereafter we investigated inhibition of hIAPP fibril
formation by incubating Ca2+-free sNUCB1(S44C) with equimolar
concentration (32 µ M) of hIAPP in 20 mM Tris pH 7.5 buffer solution.
TEM analysis of sample withdrawn after 60 min shows complete absence
of fibrillar aggregates, which suggests that Ca2+-free sNUCB1(S44C) can
inhibit hIAPP fibril formation (Fig.2.13A).

In order to chemically label Ca2+-free sNUCB1(S44C), we incubated the
protein overnight at 4 oC with molar excess of nano-Au maleimide to
covalently conjugate nano-Au to the cysteine residue. Thereafter the
labeled subunit was separated from excess nano-Au in the reaction
mixture by injecting the reaction mixture onto a Superose6 10 / 30 GL
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Figure 2.13. Nano-Au labeled sNUCB1(S44C) “caps” hIAPP
prefibrillar species. We designed a single-point mutant of sNUCB1
namely sNUCB1(S44C) whereby a Ser44 was mutated to a Cys in the
primary sequence of sNUCB1. (A) Ca2+-free sNUCB1(S44C) alone does
not aggregate and upon incubation with equimolar concentration (32 µM)
of hIAPP effectively inhibits fibril formation as seen by the complete
absence of fibrillar species from a 60 min sample of the reaction mixture
(Scale bar : 200 nm). We then utilized the presence of Cys44 in
sNUCB1(S44C) to nano-Au label the protein. (B) Nano-Au labeled
sNUCB1(S44C) was purified through SEC using Superose6 10/30 GL
column. The elution chromatogram shows the co-elution of a
characteristic 280 nm peak for the protein (black) and the 420 nm peak for
nano-Au (red). The inset shows a schematic of the typical conjugation
reaction that happens to covalently link the nano-Au to an unlabeled
macromolecule through a Cys residue. Thereafter, (C) we prepared a
calibration curve (blue) from a serial dilution series of unlabeled
sNUCB1(S44C) to estimate the concentration of the nano-Au labeled
protein in the eluting peak for the labeled protein. As shown, the
concentration for the labeled protein is 751.9 µg / µl which is equivalent
to 14.7 µ M. The concentration of nano-Au in the labeled protein sample
(15.08 µ M) was estimated from the UV-Vis absorption of the sample at
λ420nm , a wavelength at which only the nano-Au probe absorbs energy.
The labeling efficiency from the ratio of the concetration of the labeled
protein to the concentration of nano-Au which gives a value of 1.02,
showing

that

we

have

stoichiometric

labeling

of

Ca2+-free

sNUCB1(S44C). (D) TEM analysis of the labeled sample shows the
presence of two typical nano-Au densities next to each other
corresponding to a dimer of a labeled Ca2+-free sNUCB1(S44C). In
addition (E) we used the labeled protein to investigate the inhibition of
hIAPP

aggregation

into

fibrils.

Nano-Au

labeled

Ca2+-free

sNUCB1(S44C) was incubated with equimolar (32 µM) amount of hIAPP
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for 60 min after which samples were withdrawn from the reaction mixture.
TEM analysis of the negatively stained samples show high molecular mass
prefibrillar species with labeled ends. This suggests that sNUCB1(S44C)
“caps” the ends of the prefibrillar species and possibly inhibits further
aggregation into fibrils by preventing end-to-end association of prefibrillar
species into mature fibrils. The scale bar represents 100 nm.
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column equilibrated with phosphate buffer saline (PBS) pH 7.5. The
recorded chromatograms show co-elution of 280 nm peak corresponding
to elution of the protein and a 420 nm peak corresponding to nano-Au
(Fig.2.13B). Since nano-Au label absorbs at 280 nm, we used BioRad DC
assay to estimate the protein concentration by measuring absorbance at
750 nm. The concentration of nano-Au was calculated by measuring
absorbance at 420 nm. Using these we calculated a labeling efficiency of
1.02, which suggests that each Ca2+-free sNUCB1(S44C) subunit has a
nano-Au label attached to it (Fig.2.13C). TEM analysis of the collected
peak fraction shows density for two nano-Au molecules next to each other
consistent with the labeling of each protein subunit in a sNUCB1(S44C)
dimer (Fig.2.13D). Thereafter we incubated equimolar amount (32 µM) of
nano-Au labeled sNUCB1(S44C) with hIAPP to investigate inhibition of
aggregation. TEM analysis of sample withdrawn at 60 min shows the
presence of prefibrillar species with characteristic nano-Au density present
at

their

ends

(Fig.2.13E).

This

suggests

that

mechanistically

sNUCB1(S44C) inhibits hIAPP fibril formation by stably interacting with
and capping the ends of high molecular mass prefibrillar species. The
capping probably inhibits further association to form mature fibrils. This
provides evidence for a possible mechanism of action by which sNUCB1
inhibits hIAPP fibril formation.
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2.2.10 Ca2+-free sNUCB1 inhibits hIAPP fibrillization by promoting
formation of Dead-End Prefibrillar (DEP) species
hIAPP is a 37-amino-acid long peptide with two N-terminal cysteine
residues which can be used for labeling the peptide (Fig.2.1). We
incubated 32 µ M of hIAPP in a buffer solution to allow for fibril
formation. Once fibrils were formed, we sonicated the fibrils for 15 s to
generate smaller molecular mass protofibrillar fragments, which were used
for nano-Au labeling. The labeled protofibrils were then used to “seed” a
hIAPP aggregation reaction for fibril formation. As shown, the labeled
protofibrils can get incorporated into a growing fibril with the presence of
the characteristic nano-Au density distributed along the length of the fibril
(Fig.2.14A). As above, we incubated 32 µM Ca2+-free sNUCB1 with 32
µM hIAPP and monitored the reaction for 2 h. Thereafter, we injected 200
µl of the reaction volume onto a Superose6 10 / 30 GL column resulting in
an elution profile with characteristic Peak1 and Peak2 as earlier
(Fig.2.8A). We then collected the Peak1 fraction (Fig.2.14B) and used it
for nano-Au labeling of hIAPP. TEM analysis of samples withdrawn from
the labeling reaction shows the presence of multiple nano-Au labels per
prefibrillar species (Fig.2.14C). We then used the labeled protofibrils as
“seed” in a hIAPP fibrillization reaction. TEM analysis of samples
withdrawn from the aggregation reaction shows the presence of extensive
fibrils which do not possess nano-Au label possibly due to inability of the
sNUCB1 stabilized nano-Au labeled prefibrillar species to get
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Figure 2.14. Ca2+-free sNUCB1 stabilized hIAPP prefibrillar species
are not incorporated into growing fibrils. (A) We incubated hIAPP
monomers at room temperature to form fibrils, which were then sonicated
to generate protofibrils, and oligomers. These were then labeled with
nano-Au and used to seed the fibril assembly reaction upon incubation
with soluble hIAPP. TEM analysis of the fibril formation reaction shows
incorporation of the nano-Au labeled protofibrils into the fibrils. (B)
Equimolar concentration (32 µ M) of Ca2+-free sNUCB1 was incubated
with hIAPP for 60 min and the reaction mixture was subsequently injected
onto a Superose6 10/30 GL column. The chromatogram shows Peak1
consisting of Ca2+-free sNUCB1 stabilized hIAPP prefibrillar species and
Peak2

corresponding

to

unbound

Ca2+-free

sNUCB1.

(C)

We

subsequently collected the Peak1 fraction and labeled the Cys of hIAPP
with nano-Au. TEM analysis of the reaction shows Ca2+-free sNUCB1
stabilized nano-Au labeled protofibrils. (D) We then used these Ca2+-free
sNUCB1 stabilized labeled protofibrils as seed in hIAPP aggregation
reaction. TEM analysis of a 60 min reaction sample shows presence of
mature hIAPP fibrils without the incorporation of nano-Au labeled
protofibrils. The scale bar represents 200 nm. Thereafter, we used both
post sonication hIAPP fragments and Peak1 fraction as seeds in
independent hIAPP aggregation reactions monitored using thio-T binding
assay. (E) The results show hIAPP aggregation (black, inset) gets
accelerated in the presence of both 20 µ l (blue) or 50 µ l (red) seed as
observed by a decreased lag phase of the process. Interestingly, even when
50 µ l (orange), 100 µ l (purple) or 200 µ l (green) of Peak1 fraction was
added to hIAPP aggregation reaction, no effect was observed on the lag
phase of the process. This shows that sNUCB1 stabilized high molecular
mass prefibrillar aggregate of hIAPP cannot get incorporated into a
growing fiber and hence does not seed the aggregation reaction.
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incorporated into a growing fibril (Fig2.14D). This suggests that Ca2+-free
sNUCB1 stabilizes an intermediate that is a Dead End Prefibrillar (DEP)
species and cannot be incorporated into a growing hIAPP amyloid fibril.
In addition, we also monitored the effect of SEC purified prefibrillar
species in Peak1 fraction on hIAPP aggregation by recording the
enhancement in thioflavin-T fluorescence (Fig.2.14E). In principle, if a
species can act as a seed for aggregation reaction it should shorten the lag
phase of the process since nucleation is the rate limiting step in amyloid
formation. The plot shows that incubation of hIAPP with increasing
amounts of Peak1 fraction has little to no affect on the lag phase of the
process. This suggests that in agreement with the above results, the
prefibrillar species cannot “seed” a fibrillization reaction. As a control,
incubation of hIAPP with seeds generated from sonication of hIAPP fibrils
shorten the lag phase of the aggregation process (Fig.2.14E,inset).

2.2.11 A CT peptide fragment of NUCB1 namely NUCB1(381-419)
effectively inhibits hIAPP fibril formation and also disaggregates
amyloid fibrils
Our earlier results showed that Ca2+-free sNUCB1 effectively inhibits
hIAPP fibril formation and also disaggregates preformed amyloid fibrils.
However we are interested in isolating a smaller fragment of Ca2+-free
sNUCB1 that exhibits similar activity. The CT of Ca2+-free sNUCB1 is
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Figure 2.15. NUCB1(381-419) inhibits hIAPP aggregation and
disaggregates hIAPP amyloid fibrils. NUCB1(381-419) is a CT peptide
fragment from sNUCB1. (A) We investigated the secondary structure of
NUCB1(381-419) using CD spectroscopy. The spectra recorded for a 50
µM solution of NUCB1(381-419) shows that the peptide is essentially
unstructured. Thereafter we incubated 32 µM (B) hIAPP for 1 h or (C)
NUCB1(381-419) for 5 h alone in 50 mM Tris pH 8.0 at room temperature
after which samples were withdrawn and monitored using TEM. The
corresponding micrographs show that (B) hIAPP alone forms typical
amyloid fibrils within 1 h whereas (C) NUCB1(381-419) does not
aggregate to form higher molecular mass structrues. (D) We then
incubated equimolar amount (32 µM) of hIAPP with NUCB1(381-419) in
the buffer at room temperature and sample was withdrawn after 2 h for
TEM analysis. The corresponding micrographs show that NUCB1(381419) inhibits hIAPP amyloid formation by stabilizing high molecular mass
intermediates. Furthermore, we added (E) equimolar amount of
NUCB1(381-419) to hIAPP fibrils. TEM analysis of sample withdrawn
after 1 h of incubation shows that NUCB1(381-419) effectively
disaggregates hIAPP fibrils into smaller molecular fragments. The scale
bar represents 200 nm.
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majorly unstructured and has an unusual PolyQ (residues 401-407) stretch
(Fig.2.1) that may have important functional implications. Hence we
designed a peptide fragment namely NUCB1(381-419) from the CT of
sNUCB1 to test for its ability to inhibit or disaggregate hIAPP fibrils. As
shown in Figure 2.15B, hIAPP alone (32 µ M) forms characteristic
amyloid fibrils within 1 h. Interestingly, 32µM of NUCB1(381-419) even
though unstructured (Fig.2.15A), does not aggregate even after 5 h as
shown by the complete absence of higher order amyloid structures in the
micrograph (Fig.2.15C). Thereafter we incubated equimolar amounts (32
µM) of hIAPP with NUCB1(381-419) at room temperature and sample
was withdrawn after 2 h for TEM analysis. The corresponding
micrographs show that NUCB1(381-419) effectively inhibits hIAPP fibril
formation by stabilizing high molecular mass protofibril like species
(Fig.2.15D). Additionally, we also investigated the ability of NUCB1(381419) to disaggregate hIAPP fibrils. We incubated equimolar amount (32
µM) of NUCB1(381-419) with hIAPP amyloid fibrils at room temperature
and sample was withdrawn after 1 h for TEM analysis. The recorded
micrographs show presence of smaller molecular mass fragments and
complete absence of any amyloid fibrils suggesting that NUCB1(381-419)
can disaggregate hIAPP amyloid fibrils (Fig.2.15E). Hence NUCB1(381419) similar to Ca2+-free sNUCB1 has the functional ability to inhibit
hIAPP fibril formation and also disaggregate amyloid fibrils.
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2.3 DISCUSSION
IAPP is a neuroendocrine peptide hormone expressed in pancreatic islets
of all mammals and can aggregate to form amyloid deposits depending on
species-specific amino acid sequence. Amongst all naturally occurring
hormones, hIAPP has the most hydrophobic and highly amyloidogenic
sequence. It thus provides a useful model system to test for molecules with
potent inhibitory acitivity against fibril formation. In the present study we
report the anti-amyloidogenic property of Ca2+-free sNUCB1 towards
inhibiting hIAPP fibril formation and disaggregate the preformed amyloid
fibrils. In addition, our results show that sNUCB1 assisted inhibition of
hIAPP fibril formation is dose-dependent and observed even at substoichiometric concentrations. Thus inhibition of hIAPP aggregation by
sNUCB1 presents a crucial and interesting finding, possibly one of the
several mechanisms at work in keeping these naturally occurring
amyloidogenic peptides from aggregating into insoluble amyloid fibrils.
Importantly, Ca2+-free sNUCB1 can inhibit fibril formation even when
added either during nucleation or growth phase of amyloidogenesis. Thus
if aggregation of hIAPP has been initiated, Ca2+-free sNUCB1 can prevent
the growth of existing amyloidogenic intermediates into fibrils.
Functionally, this ability is very unique and significant as it may not only
assist in clearing the existing amyloid aggregates but also prevent further
sequestration of functional monomers into amyloid deposits. It has been
reported that IAPP monomers released during β-cell secretion can be

134

rapidly seeded at the nucleation site and assembled into fibrils (87).
Several drug-based approaches to reduce IAPP secretion in animal models
by increasing insulin sensitivity caused a marked reduction and retardation
in islet amyloid formation. However, the cytotoxic effects of small IAPP
amyloid aggregates were still observed. This suggests that therapeutic
approaches to preventing β-cell loss not only require clearance of mature
islet amyloid deposits but inhibition of formation of early aggregates as
well (80). In this regard, the functional ability of NUCB1 to target both
amyloid fibrils and intermediates may provide a therapeutically relevant
approach to circumvent islet amyloidosis.

Physiologically, both hIAPP and insulin are secreted as precursor propeptides whose proteolytic processing by proconvertases generates the
mature hormone (58) The disproportionate release of proinsulin relative to
mature insulin is well documented in T2D (88-92). Functionally, it has
been shown that only insulin and not proinsulin can inhibit fibril formation
(68, 93). Thus incomplete processing of Insulin may promote Islet
amyloid formation. In addition, recently it was shown that Insulin only
impedes but does not completely inhibit IAPP fibril formation (94). Thus
additional factors may be necessary towards keeping IAPP in a nonaggregated and soluble form at millimolar concentrations in the secretory
granules (95). Moreover, incomplete processing of proIAPP has also been
postulated as a possible cause for facilitating amyloid formation.
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Immunostaining assays have shown that proIAPP ubiquitinated at Nterminus to be a component of intracellular fibrils (96). These intracellular
fibrils are located in pre-Golgi part of the secretory pathway to be directed
for lysosomal degradation (97). Lysosomal enzymes are however less
efficient in clearing these aggregates whose accumulation results in
cellular disintegration and apoptosis (68, 98). This release of hIAPP from
intracellular compartments can stimulate IAPP aggregation. Thus
inhibition of intracellular aggregation and clearance of fibrillar aggregates
are both essential in preventing loss of β-cell mass. Physiologically,
NUCB1 is present in both Golgi and ER (23, 26). RT-PCR of total RNA
from rat insulinoma (RIN-m5F) cells and western blot analysis of RINm5F cell lysate revealed presence of both NUCB1 mRNA and protein.
Thus anti-amyloidogenic activity of NUCB1 could be crucial in
preventing intracellular aggregation and clearing fibrillar aggregates of
hIAPP in conjunction with the cellular chaperone machinery. We have
shown that Ca2+-binding regulates the anti-amyloidogenic ability of
sNUCB1. Both disruption of Ca2+-homeostasis in the cells and generation
of reactive oxygen species have been shown to significantly contribute to
the cytotoxicity associated with hIAPP (99). Higher concentrations of Ca2+
have been shown to promote aggregation of hIAPP (68). Under these
conditions, our engineered Ca2+-insensitive mutant sNUCB1(tetramutant)
can effectively inhibit hIAPP fibrillization and also dissociate the
preformed

amyloid

fibrils.

The
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Ca2+-insensitive

mutant

sNUCB1(tetramutant) provides a handle for overriding the functional
dependence of sNUCB1 on Ca2+ without any loss of anti-amyloidogenic
ability.

NUCB1 is a novel Ca2+-binding protein whose precise physiological
role(s) is still poorly understood. Since it shows potential for antiamyloidogenic properties and can bind to ATP even though with weak
affinity, we also investigated the ability of sNUCB1 to refold or inhibit
denaturation of natively folded proteins. Using firefly Luciferase as a
model system we showed that even though Ca2+-free sNUCB1 does bind
to ATP, it alone cannot help refolding of denatured Luciferase or protect it
against heat denaturation. This suggests that Ca2+-free sNUCB1 unlike
several chaperones like Hsp70 lacks the ability to refold denatured or
aggregated proteins (74, 75). However there is a possibility that similar to
Hsp70 it may also require certain other cofactors to robustly perform its
function (100). Future work pertaining to understanding the in vivo
functional role of NUCB1 would be immensely helpful towards
establishing it.

Our biochemical results show that both Ca2+-free sNUCB1 and
sNUCB1(tetramutant) possess anti-amyloidogenic properties but neither
exhibited any proteolytic activity. Using BODIPY FL-Casein as a
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substrate to test for proteolytic activity showed that unlike Trypsin, both
Ca2+-free sNUCB1 and sNUCB1(tetramutant) lack the functional ability to
cleave it. In addition, LC-MS analysis directly showed that Ca2+-free
sNUCB1 does not proteolytically cleave hIAPP as evident from the
complete absence of any smaller molecular fragments of hIAPP detected
through LC-MS. Interestingly, our control experiments with the nonaggregating analog of hIAPP namely Pramlintide also showed that Ca2+free sNUCB1 does not bind to it. It hints towards a preferential interaction
of Ca2+-free sNUCB1 only with intermediate oligomeric species of hIAPP
and not with monomeric hIAPP. Functionally, the ability of Ca2+-free
sNUCB1 to bind to Zn2+ alongwith the observation that NUCB1 has a
signal sequence and is found extracellularly raises a possibility that
NUCB1 may act as a MMP. However our studies using fluorescently
modified natural substrates of MMPs showed that unlike MMP-1, Ca2+free sNUCB1 does not proteolytically cleave them. Hence unlike the
native Zn2+-dependent metalloproteases like IDE and Neprilysin, which
facilitate clearance of amyloidogenic peptides like IAPP and Aβ by
cleaving them (79) (Neprilysin), NUCB1 does not possess any proteolytic
activity

against

Amylin.

Thus

the

observed

anti-amyloidogenic

functionality of Ca2+-free sNUCB1 is not due to its protease activity.

The biophysical characterization of Ca2+-free sNUCB1 stabilized
prefibrillar species using light scattering analysis shows that Ca2+-free
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sNUCB1 interacts with hIAPP to form a 2 - 6 MDa complex, which can
be isolated by SEC. In addition, Ca2+-free sNUCB1 stabilized soluble
species of hIAPP range from 40 - 80 nm in length with a predominant
mass density of 2 - 5 kDa / Å. Mechanistically, the stabilization of the
prefibrillar species is achieved by “capping” its ends as shown by our
inhibition experiments followed by TEM analysis using nano-Au labeled
Ca2+-free sNUCB1(S44C). Interestingly, these capped prefibrillar species
neither aggregate when incubated for over a week nor seed the
aggregation of hIAPP monomers to form amyloid fibrils. This presents a
unique mechanism of action for activity of an amyloidogenesis inhibitor,
in preventing the aggregation of hIAPP. In addition, the ability of
sNUCB1 to disaggregate would further assist in clearing the pre-formed
amyloid fibrils. Physiologically, Insulin degrading enzyme (IDE) can
proteolytically cleave hIAPP, which provides a cellular mechanism to
clear excess peptide from the system. However, IDE can only degrade
monomeric hIAPP and is ineffective when hIAPP aggregates into higher
order structures (79). We have shown that Ca2+-free sNUCB1 does not
possess any proteolytic activity but is effective at inhibiting amyloid
formation. Alternatively, several heat shock proteins (Hsps), small heat
shock proteins (sHsps) and chaperones have been reported to inhibit
aggregation of several amyloidogenic peptides. Both Hsp70 and
extracellular chaperone Clusterin bind to prefibrillar species and prevent
the formation of amyloid fibrils (76, 77). The results shown in the present
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study however do not rule out the role of NUCB1 as a chaperone. It is
possible that similar to sHsps, NUCB1 stabilizes the prefibrillar species
and delivers them to Hsps for clearance from the system. These
hypotheses will be addressed in our future studies.

Ca2+-free sNUCB1 is a ~ 100 kDa protein which can limit its potency and
usefulness towards usage as a therapeutic agent. Hence in search of a
smaller molecular fragment of NUCB1 which retains the functional ability
and efficacy to inhibit hIAPP fibril formation and preferably also
dissociates amyloid fibrils, we isolated a 39-amino-acid long polypeptide
namely NUCB1(381-419) from CT domain of NUCB1. Intriguingly,
similar to Ca2+-free sNUCB1, the peptide inhibits hIAPP fibril formation
as well as effectively dissociates amyloid fibrils at sub-stoichiometric
concentrations. In addition to this functional ability, NUCB1(381-419)
also provides a tool to override the inherent Ca2+-dependence on the
functional efficacy of sNUCB1. It provides a molecular handle, which in
its present or an altered form can be useful in designing agents for
inhibiting amyloidogenesis of hIAPP. The extension of these in vitro
results in relevant animal models will be useful in testing their in vivo
efficacy. Future work pertaining to continuation of these results to other
amyloidogenic proteins / peptides like Aβ and Tau as relevant to
pathology of AD would be particularly interesting in understanding if the
observed ability is specific or generic.
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T2D is commonly associated with insulin resistance and reduced insulin
secretion causing increase in plasma glucose levels. Thus most drugs
administered to diabetic patients either stimulate β-cells to release more
insulin or act as insulin sensitizers to promote skeletal muscle glucose
uptake (80). However loss of β-cell mass is tightly correlated with IAPP
cytotoxicity and islet amyloid formation (101). Transgenic mice over
expressing hIAPP in their islet cells show amyloid deposits, β-cell
depletion and develop non-insulin dependent diabetes mellitus (102, 103).
The depletion of β-cells contributes to insulin resistance and decreased
effectiveness of the administered drugs with time. This underlines the
significance of strategies aimed at decreasing or preventing islet amyloid
formation. The ability of Ca2+-free sNUCB1 to inhibit fibrillization of
hIAPP at any stage of aggregation is therefore therapeutically relevant. It
would be interesting to test for sNUCB1’s functional efficacy towards
inhibiting the formation of amyloid plaques and disaggregating islet
amyloids in relevant mouse models of diabetes. As shown here, the
mechanism employed by sNUCB1 is unique and offers insights into
designing strategies for inhibiting amyloidogenesis. However, the need for
inhibition of aggregation and disaggregation of fibrillar deposits would
require a molecule, which can effectively work under conditions of Ca2+
flux. The designed sNUCB1(tetramutant) or the isolated CT peptide
fragment namely NUCB1(381-419) are Ca2+-insensitive and may
efficiently execute the anti-amyloidogenic activity in the presence of high
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concentrations

of

Ca2+.

Interestingly,

the

truncation

mutant

sNUCB1(W333Ter) (Fig.1.1) neither inhibits not disaggregates hIAPP
amyloid fibrils (data not shown). This can be explained by the possible
role of the CT region comprising of residues 381-419 in sNUCB1 that is
absent in the heterologously expressed sNUCB1(W333Ter).

In vivo, the presence of amyloid fibrils leads to generation of reactive
oxygen species. The particular susceptibility of β-cells to these species
results from the physiologically low levels of antioxidant enzymes such as
superoxide dismutase and catalase (104, 105). Hence the antiamyloidogenic properties of NUCB1 along with other contributing factors
might be part of physiological machinery that protects the highly
susceptible pancreatic β-cells from amyloid mediated toxicity. In
conclusion, our data provides evidence that NUCB1 has novel antiamyloidogenic functional ability and provides opportunity to understand
the possible defense mechanisms against islet amyloidosis as relevant to
T2D. If apoptosis and β-cell depletion due to islet amyloid formation
contribute to the observed loss of β-cell function, then the antiamyloidogenic

activity

of

sNUCB1,

its

engineered

mutant

sNUCB1(tetramutant) or the isolated CT peptide fragment NUCB1(381419) can be crucial in designing therapeutics towards targeting islet
amyloidosis.
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CHAPTER 3
Nucleobindin 1 and its Engineered Mutant Inhibit Aβ42 Aggregation and
Disaggregate Aβ42 Fibrils into Non-toxic Species

3.0 INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized
by the presence of extracellular β -amyloid (Aβ) fibril deposits with
subsequent intra-neuronal accumulation of hyperphosphorylated tau into
neurofibrillary tangles (NFTs), both of which trigger neuronal dystrophy
(106). Evidently, a role of extracellular Aβ fibrillar deposits on
intracellular tau hyperphosphorylation has been postulated (101, 107). In
tissue culture experiments with hippocampal neurons from transgenic
mice, it was shown that tau is essential to β-amyloid induced neurotoxicity
(108). AD is a synaptic failure disease in which aggregation of Aβ, both
intracellularly and extracellularly, causes neuritic and synaptic pathology
through reduction in synaptic plasticity and associated proteins (109-111).
Aβ is a 38 - 43 residue (~ 4 kDa) proteolytic fragment generated by the
sequential cleavage of single-span transmembrane Amyloid Precursor
Protein (APP) by membrane aspartyl proteases namely β- and γ-secretases
respectively (112-119). Cell biological studies have shown that Aβ
generation occurs majorly in trans-Golgi network (TGN) with much less
in endoplasmic reticulum (ER). However, ER seems to be more selective
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towards

generation

of

more

amyloidogenic

Aβ42

than

Aβ40.

Mechanistically, Aβ40 has been shown to be the predominantly secreted
form of Aβ peptide (120, 121). In a recent study, Cirrito et al. showed that
synaptic activity increases the cell-surface levels of APP by stimulating its
anterogade transport to synapses and plasma membrane. APP is then
internalized from cell surface into endosomes where it is proteolytically
cleaved to generate Aβ for release into the brain interstitial fluid (122).
Functionally, Aβ42 monomers have also been shown to protect mature
neurons from excitotoxicity and support the survival of developing
neurons under trophic conditions (123). However, when Aβ monomers
oligomerize into amyloidogenic intracellular aggregates, they cause
neuritic

dystrophy.

Numerous

studies

have

reported

behavioral,

physiological, oxidative and plaque mediated abnormalities in transgenic
mouse models of AD much before the appearance of Aβ amyloid deposits
(124-129). These observations point towards the pathogenic activity of
intracellular Aβ aggregation in promoting cytotoxicity. Thereafter, the
subsequent release of these aggregates into the extracellular space,
possibly due to neuronal apoptosis or membrane disruption, impairs
processes involved in learning and memory. Thus both intracellular and
extracellular Aβ deposits contribute to cognitive impairment but early
events involving intracellular amyloidogenesis initiate synaptic pathology
as observed in AD (130, 131). Hence, preventing intraneuronal Aβ
aggregation in addition to eliminating extracellular amyloid deposits might
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be therapeutically relevant for the treatment and control of AD. Therefore
the leading target of emerging AD therapies is the suppression of Aβ by
reduced generation or enhanced degradation.

Several decades of research in understanding AD has put forth different
Aβ lowering strategies for potential drug development. These include
suppression of Aβ generation by employing β - or γ-secretase inhibitors,
preventing Aβ aggregation and immunization based approaches (132-134).
Several small molecule inhibitors have been explored and tested that
prevent Aβ fibril formation and seem to partially reverse the cognitive
impairment (101). Naturally occurring Zn2+-dependent endopeptidases
namely Insulin Degrading Enzyme (IDE) and Neprilysin (NEP) decrease
amyloid load in the brain by proteolytically cleaving Aβ (79, 135-139).
Recently, several heat shock proteins (Hsp’s) and small heat shock
proteins (sHsp’s) have also been shown to effectively inhibit aggregation
of amyloidogenic peptides. Interestingly, several members of sHsp’s like
αB-crystallin, Hsp27, Hsp20 and HspB8 completely inhibit Aβ40
amyloidogensis by binding to and stabilizing prefibrillar species (74, 75).
In addition, extracellular chaperone clusterin has been shown to inhibit the
fibril formation by prion protein, Aβ and apolipoprotein CII. Along with
Hsp70, clusterin has been shown to bind to prefibrillar species and prevent
the formation of amyloid fibrils. The stabilization of these prefibrillar
species, however, resulted in enhanced toxicity in a cell culture based
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assay (76, 77). Importantly, a direct role of apolipoprotein E (apoE) and
its isoforms in differentially promoting clearance of Aβ from extracellular
space has also been established (140, 141).

In a recent study Lin et al. showed that overexpression of a novel Ca2+binding protein Nucleobindin 1 or NUCB1 in an in vitro setup reduces
APP mRNA level and regulates APP biosynthesis. This consequently
causes a reduction in the proteolytic metabolites of APP including Aβ.
Intriguingly, the expression level of NUCB1 was also reported to decrease
by 50% in the brains of AD patients (28). NUCB1 is a 55 kDa multidomain protein that was first reported as a growth and differentiation
factor associated with lupus syndrome in mice (18). Since its discovery,
NUCB1 has been reported to be widely expressed in cells and tissues and
is conserved from flies to humans (85). NUCB1 is primarily a Golgiresident protein also found in both cytosolic and membrane fractions
(142). NUCB1 has been shown to function as a matrix modulator and may
act as a Ca2+-buffer in Golgi (16, 46). In both sporadic and familial AD,
Ca2+-dysregulation has been known to play a critical role. Abnormal Ca2+homeostasis has been observed in the dendritic spines adjacent to the
amyloid plaques (143). Since NUCB1 interacts with APP in a Ca2+dependent manner and has been shown to regulate Aβ generation (28), we
proceeded to test the effect of NUCB1 on the amyloidogenesis of
synthetic Aβ42. In the present study, we use the heterologously expressed
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and purified sNUCB1, a soluble form of NUCB1 without the signal
sequence (residues 1-31) (Fig.3.1) and show that sNUCB1 in its Ca2+-free
form completely inhibits Aβ fibril formation as well as effectively
disaggregates pre-formed amyloid fibrils. We further engineered a Ca2+independent mutant of sNUCB1, namely sNUCB1(tetramutant), which
continues to inhibit Aβ42 amyloidogenesis and disaggregates preformed
Aβ42 fibrils even in the presence of Ca2+. In addition, in a tissue-culture
based assay, the species generated upon Aβ42 fibril disaggregation by
sNUCB1 or sNUCB1(tetramutant) were non-toxic. Finally, this antiamyloidogenic property of sNUCB1 was also tested against aggregation of
tau K19(C322S), a heterologously expressed construct corresponding to
the microtubule binding domain of human tau (htau) with only 3 repeat
domains (Fig.3.1) (144). Our results show that similar to Aβ, Ca2+-free
sNUCB1 inhibits fibrillarization of tau K19(C322S).
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Figure 3.1. Domain architecture of human NUCB1 and engineered
NUCB1 variants, human tau and tauK19. The modular nature of the
NUCB1 protein structure is depicted schematically with its N-terminal
signal sequence (grey square), putative DNA binding domain (green
square), two EF hand loops (magenta rectangles), acidic region (blue oval)
and leucine zipper domain (yellow hexagon). The amino acid residues at
domain borders are numbered. We engineered a construct for expression
in E. coli of a soluble form of NUCB1 that included an N-terminal hexaHis tag and a PreScission protease recognition sequence with an
intervening spacer sequence as shown. Endoprotease cleavage yields a
soluble form of NUCB1 that begins with the amino acid sequence
GPHMAS and continues with the remainder of the native sequence
beginning at Gly32.

We refer to this expressed protein construct as

soluble NUCB1 or sNUCB1 throughout the text. Furthermore we used the
sNUCB1 template to make point mutations in each EF hand as indicated
by the arrows to generate sNUCB1(tetramutant) which lacks the ability to
bind to calcium. Thereafter the domain diagram of the longest form of
human Tau protein shows three alternatively spliced exons (exon 1, 2 and
3) along with proline rich domains P1 and P2. The CT proximal
microtubule-binding repeat domains are labeled R1-R4 followed by a low
homology repeat domain namely R’. The domain diagram of tauK19
consists of repeat domains R1, R3 and R4 followed by three residues KIE
(370-372) from the R’ domain at its CT end.
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3.1 MATERIALS AND METHODS
3.1.1 REAGENTS
Thioflavin-T was purchased from Fisher Scientific and Uranyl Acetate
was purchased from SPI-ChemTM. For TEM, 300 mesh carbon coated Cu
grids were purchased from EMS diasum (Hatfield, PA). Nano-Au
Maleimide was purchased from Molecular Probes. Aβ42 peptide was
purchased from the Keck peptide synthesis facility at Yale university,
New Haven CT. Heterologously expressed, purified and lyophilized
tauK19(C322S) was a generous gift from Dr David Eliezer (Weill,
Cornell). All reagents and chemicals used were of the highest available
purity.

3.1.2 Heterologous expression and purification of sNUCB1 and its
variants
The cDNA clone for human NUCB1 was obtained from ATCC and the
DNA fragment for the soluble form of NUCB1 or sNUCB1,
corresponding to residues 31-461 of the human NUCB1 protein without
the N-terminal signal sequence (residues 1-31) was cloned into a
pET28a(+) expression vector (Amersham Biosciences) to generate a Nterminal His6-tagged construct. The construct for sNUCB1 served as a
template to generate the His6-tagged mutant of sNUCB1 namely
sNUCB1(tetramutant. For sNUCB1(tetramuant) the coding sequence
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changes leading to generation of D253K, E264A, D305K and E316A
mutations were introduced by site-directed mutagenesis using the Quick
Change system (Stratagene, La Jolla, CA). The vectors were then used to
transform BL21 (DE3) cells to express a N-terminal His6-tag protein
containing a PreScission protease site following the His6-tag. Both
proteins were expressed in BL21 (DE3) cells grown in the presence of 50
µg / ml kanamycin. Cells were grown at 37 oC to A600nm of ~ 0.7 and then
induced with 500 µ M isopropylthio-β-D-galactoside (IPTG) (US
Biological). Post induction the culture was grown overnight at 17 oC and
subsequently harvested. The resulting pellets were re-suspended in a
buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 50 mM βmercaptoethanol, bovine lung aprotinin (20 mg/ml), 2 mM phenylmethane
sulfonyl fluoride (PMSF) and complete EDTA-free protease inhibitor
cocktail tablets (Roche). Thereafter the cells were lysed and the expressed
His6-tag protein was purified from crude extract by using affinity
chromatography using Ni-NTA column pre-equilibrated with buffer A (50
mM Tris, pH 8.0, 150 mM NaCl, 50 mM β-mercaptoethanol). The bound
His6-tag protein was eluted from the column by using buffer A
supplemented with 500 mM imidazole. The His6-tag was cleaved by
PreScissionTM protease, which was subsequently removed. In order to
remove Ca2+ from sNUCB1 or its variant, the proteins were extensively
dialyzed against buffer A supplemented with 5 mM EGTA and 1 mM
EDTA, which were also eventually removed through dialysis. Finally, size
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exclusion chromatography (SEC) was done using Superdex 200 26 / 60
HR column equilibrated with buffer S (50 mM Tris, pH 8.0, 150 mM
NaCl, 1 mM DTT) to obtain homogenously pure protein. The typical yield
for sNUCB1 and its variant was ~ 5 mg / L. The purity of the proteins was
assessed by Coomassie brilliant blue staining after the proteins were
separated through SDS-PAGE. The purity of both the proteins was greater
than 95%.

3.1.3 Aβ42 fibril formation protocol
In order to produce homogeneous Aβ fibrils, purified and lyophilized
Aβ42 peptide (0.6 mg) was added to DDI water (0.2 ml) in a
polypropylene eppendorf tube and allowed to stand for 2 min. Thereafter
the sample was vortexed for 10 s, and an equal volume of 200 mM Tris
pH 7.4 was added, followed by another round of vortexing for 10 s. The
sample was then filtered through a 10 kDa cutoff filter by spinning it at
17,200 g in a benchtop microcentrifuge for 3.5 min. Subsequently, the
flowthrough was collected and the peptide concentration was determined
by absorbance at 280 nm. This solution was used within 5-10 min to set up
the fibrillization reaction to obtain mature, elongated and well resolved
Aβ42 fibrils within 24 h.
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3.1.4 tau K19(C322S) neurofibrillary tangle (NFT) formation protocol
Lyophilized tau K19(C322S) was reconsistuted in a buffer solution (100
mM NaH2PO4 pH 7.4, 150 mM NaCl) at a concentration of 50 µM. The
reaction mixture was constantly stirred at room temperature and samples
were withdrawn at successive time points and analyzed using TEM to
confirm formation of NFTs. The analysis shows that tau K19(C322S)
forms NFTs within 27 h as shown in the corresponding micrographs.

3.1.5 Transmission Electron Microscopy (TEM)
TEM was performed at the Bioimaging facility at Rockefeller University.
Samples were prepared by placing 5 µl of solution onto formvar coated
300 mesh copper grids and counterstained with 2% aqueous uranyl acetate
solution. Samples were viewed with a FEI Tecnai12 BioTwinG2
transmission electron microscope at 80 kV. Digital images were acquired
with an AMT XR-60 CCD Digital Camera System and compiled using
Adobe Photoshop CS2 and Image J.

3.1.6 MTT Assay
In this assay, 7000 to 9000 undifferentiated PC12 cells in 100 µ l were
plated in each well of a 96-well plate. Thereafter, cells were grown for an
additional 12-16 h at 37 oC in an incubator with 5 % CO2 supply. To test

153

for toxicity, samples were added to the cells at a concentration of 10 µM /
well followed by incubation for 4 h. Thereafter, 10 µl of the MTT (3-(4,5Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium

bromide)

stock

solution (Sigma-Aldrich, Cat # CGD1) was added to the cells followed by
incubation for an additional 4 h. Finally, the media was withdrawn and
200 µ l of DMSO was added to each well to dissolve the reduced MTT
(formazan)

crystals

giving

a

characteristic

purple

color.

Spectrophotometric measurement of the absorbance at 570 nm was done
for each well and cell viability was calculated with respect to vehicle alone
as the control.
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3.2.1 Ca2+-free sNUCB1 inhibits Aβ42 fibril formation and
disaggregates Aβ42 fibrils
Aβ42 is the most amyloidogenic isoform generated from APP proteolytic
cleavage and is the predominant species present in amyloid deposits in
AD. APP mutants associated with early-onset AD show increased
production of Aβ42 (145). Interestingly, preplaque increases in soluble
Aβ42 but not Aβ40 are also observed in patients with Down’s Syndrome
(146). Biochemically, Aβ42 forms fibrils at pH 7.4 much more rapidly
than Aβ40. In addition, Aβ42 fibrils are comparatively more stable and
resistant to sodium dodecyl sulphate treatment (147, 148). Hence, Aβ42
was chosen to test the inhibitory activity of sNUCB1 in preventing fibril
formation. Initially, in vitro aggregation of Aβ42 alone (32 µ M) was
monitored using TEM analysis of samples withdrawn at time zero, 5 h,
12h and 24 h respectively (Fig.3.2A). The corresponding micrographs
show presence of oligomers and protofibrils for the 5h and 12 h sample
respectively which eventually grow into long, unbranched and wellresolved fibrils within 24 h (Fig.3.2A). Thereafter, we incubated
equimolar (32 µM) amount of Ca2+-free sNUCB1 with Aβ42 and samples
were withdrawn at time zero, 5 h 12 h and 24 h as above. TEM analysis of
samples withdrawn at various time points show presence of high
molecular mass species which do not progress to form fibrils even at 24 h
(Fig.3.2B). Interestingly, samples withdrawn even after 24 h of incubation
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Figure 3.2. Ca2+-free sNUCB1 inhibits Aβ42 fibril formation and
disaggregates Aβ42 fibrils. Aβ42 alone slowly aggregates in vitro to
form amyloid fibrils. (A) We monitored aggregation of 32 µM solution of
Aβ42 with time using TEM. Samples withdrawn at time zero contain low
molecular weight species. Thereafter as the aggregation of Aβ42 proceeds,
the 5 h sample shows the presence of both oligomers and protofibrils.
These continue to form and associate into fibrils as seen in the 12 h sample
containing fibrils along with protofibrils and oligomers. The aggregation
in complete at 24 h with the formation of characteristic amyloid fibrils.
Thereafter, (B) we monitored inhibition of Aβ42 fibril formation in the
presence of equimolar amount of Ca2+-free sNUCB1 (32 µ M) added at
time zero. TEM images collected after 5 h, 12 h and 24 h of incubation
show no trace of fibril formation. Finally, (C) disaggregation of Aβ42
fibrils by Ca2+-free sNUCB1 was monitored with time using TEM. Aβ42
aggregates to form fibrils within 24 h, which were then incubated with
equimolar amount (32 µM) of Ca2+-free sNUCB1. Samples withdrawn at
60 min time point show that sNUCB1 effectively dissociates Aβ42 fibrils
into smaller molecular mass fragments, which continue to exist even at 5 h
or 24 h time point without reassociation to form fibrils. The scale bar
represents 200 nm.
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continued to show inhibition of fibril formation. This shows that Ca2+-free
sNUCB1 effectively inhibits Aβ42 fibril formation. Subsequently, to
explore the effect of Ca2+-free sNUCB1 towards disaggregating preformed
Aβ42 fibrils, we added equimolar amount (32µM) of Ca2+-free sNUCB1
to Aβ42 fibrils in a reaction mixture. TEM analysis shows that Ca2+-free
sNUCB1 can effectively dissociate Aβ42 fibrils within 60 min and the
disaggregated species continue to exist without progressing to form fibrils
even at 24 h time point (Fig. 3.2C). Thus functionally, Ca2+-free sNUCB1
inhibits Aβ42 aggregation and also effectively disaggregates the
preformed fibrils.

3.2.2 Ca2+ disrupts inhibition and disaggregation of Aβ42 fibrils by
sNUCB1
NUCB1 is a multi-domain protein with two characteristic Ca2+-binding EF
hand motifs (Fig.3.1). Ca2+-binding to sNUCB1 has been shown to induce
structural rearrangement in the protein (Fig.1.2). Hence, the effect of Ca2+binding on the anti-amyloidogenic properties of sNUCB1 was
investigated. As earlier, Aβ42 was incubated with equimolar amount (32
µM) of sNUCB1 in the presence of 1 mM Ca2+ in the reaction mixture.
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Figure 3.3. Ca2+ prevents the ability of sNUCB1 to inhibit aggregation
and dissociate Aβ42 fibrils. (A) 32 µM

Ca2+-free sNUCB1 was

incubated with 1 mM Ca2+ in the reaction mixture at 25 oC with the
subsequent addition of equimolar amount of Aβ42. Samples were
withdrawn at the indicated time points and analyzed using TEM. As
shown, Ca2+-bound sNUCB1 does not inhibit aggregation of Aβ42 as
fibrils are present in the 12 h sample, which continue to grow extensively
as seen in the 24 h sample. In addition, the ability of Ca2+-bound sNUCB1
towards (B) disaggregating Aβ42 fibrils was monitored using TEM.
Equimolar amount of Ca2+-bound sNUCB1 (32 µ M) was added to Aβ42
fibrils and samples were withdrawn at the indicated time points. As
shown, fibrils are still present in the reaction mixture after 60 mins of
incubation showing that Ca2+-bound sNUCB1 cannot dissociate Aβ42
fibrils. The scale bar represents 200 nm.
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Unlike with Ca2+-free sNUCB1, the TEM analysis of samples withdrawn
from the reaction mixture at various time points show initiation of fibril
formation within 12 h with extensive Aβ42 fibrils present at 24 h
(Fig.3.3A), which is similar to the time frame of fibril formation by Aβ42
alone (Fig.3.2A). This shows that binding of Ca2+ to sNUCB1 disrupts its
functional ability towards inhibiting Aβ42 fibril formation and points
towards Ca2+-free sNUCB1 as being the only functionally adept form in
preventing Aβ42 amyloidogenesis. In addition, disaggregation of
preformed Aβ42 fibrils by equimolar (32 µM)

sNUCB1 was also

examined in the presence of 1 mM Ca2+ in the reaction mixture. TEM
analysis clearly shows that unlike Ca2+-free sNUCB1, Ca2+-bound
sNUCB1 cannot dissociate Aβ42 fibrils as observed by the presence of
fibrils in samples withdrawn after 5 min, 30 min and 60 min of incubation.
Thus Ca2+-binding nullifies the anti-amyloidogenic properties of sNUCB1.

3.2.3 sNUCB1(tetramutant) is insensitive to Ca2+ but functionally
similar to sNUCB1
Our earlier results showed that heterologously expressed and purified
sNUCB1(tetramutant) is correctly folded and unlike sNUCB1, lacks the
ability to bind to Ca2+. Hence in order to test the anti-amyloidogenic
properties of sNUCB1(tetramutant)

towards Aβ42 in the presence of

excess Ca2+, we incubated equimolar amount (32 µM) of Aβ42 with
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Figure

3.4.

Ca2+-insensitive

anti-amyloidogenic

activity

of

sNUCB1(tetramutant). sNUCB1(tetramutant) does not bind to Ca2+ and
was tested for its ability to affect Aβ42 amyloid formation. We incubated
Aβ42 with equimolar concentration of sNUCB1(tetramutant) (32 µM),
both in the (A) absence and (B) presence of 1 mM Ca2+. TEM analysis of
samples withdrawn from each reaction mixture at T = 0 h, 5 h, 12 h and 24
h time points show complete inhibition of fibril formation. Subsequently,
the ability of sNUCB1(tetramutant) to disaggregate fibrils was
investigated. Thereafter, we incubated stoichiometric amount of
sNUCB1(tetramutant) (32 µM) with fibrils in a reaction mixture, both in
the (C) absence or (D) presence of 1 mM Ca2+. As a control, micrographs
with Aβ42 fibrils before addition of sNUCB1(tetramutant) are shown on
the left. TEM images corresponding to samples withdrawn after 30 min
and

60

min

of

sNUCB1(tetramutant)

addition

show

that

sNUCB1(tetramutant) can efficiently dissociate the preformed fibrils of
Aβ42. The scale bar represents 200 nm.
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sNUCB1(tetramutant) in a reaction mixture in the absence and presence of
1 mM Ca2+. Samples were withdrawn at the indicated time points and
effect of sNUCB1(tetramutant) on aggregation was analyzed using TEM.
The corresponding micrographs show that similar to sNUCB1,
sNUCB1(tetramutant) also effectively inhibits aggregation of Aβ42 to
form amyloid fibrils (Fig.3.4A). However more importantly, even in the
presence of excess Ca2+ in the reaction mixture, sNUCB1(tetramutant)
continues to be functionally active and inhibits Aβ42 fibril formation as
shown by the complete absence of any fibrillar aggregates in the
micrograph corresponding to 24 h sample (Fig.3.4B). Thereafter we
investigated the functional ability of sNUCB1(tetramutant) towards
disaggregating Aβ42 fibrils and the effect of Ca2+ on it. Aβ42 alone (32
µM) aggregates within 24 h to form fibrils. We then added equimolar
amount (32 µ M) of sNUCB1(tetramutant) to it in the absence and
presence of 1 mM Ca2+ in the reaction mixture (Fig.3.4C,D). Samples
from each reaction were withdrawn after 30 min and 60 min for analysis
using

TEM.

The

corresponding

micrographs

show

that

sNUCB1(tetramutant) effectively disaggregates Aβ42 fibrils both in the
absence (Fig.3.4C) and presence of Ca2+ (Fig.3.4D). Hence unlike
sNUCB1, the functional ability of sNUCB1(tetramutant) is unaffected by
Ca2+ and it retains its anti-amyloidogenic properties towards Aβ42 even in
the presence of high concentrations of Ca2+ in the reaction mixture.
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3.2.4 sNUCB1 / sNUCB1(tetramutant) mediated Aβ42 fibril
dissociation generates non-toxic species
Aβ42 aggregation leads to fibril formation through association of
oligomers and protofibrils. Tissue culture based MTT assay can provide
quantitative calorimetric estimate of the toxicity of intermediate species
along with the fibrillar aggregates (149). As shown earlier, Ca2+-free
sNUCB1 inhibits Aβ42 fibril formation and effectively disaggregates
preformed Aβ42 fibrils. However, TEM analysis cannot rule out the
presence of oligomeric species stabilized by sNUCB1 in the reaction
mixture. Several studies have shown that along with fibrils, oligomeric
species are also cytotoxic (150, 151). Hence, to test the potential toxicity
of the species generated after Aβ42 fibril dissociation by Ca2+-free
sNUCB1 or sNUCB1(tetramutant), MTT assays were conducted with
undifferentiated PC12 cells. As a control, administration of either
sNUCB1 or sNUCB1(tetramutant) to the cells showed that they are
completely non-toxic to the cells. Thereafter in the first set of experiments,
samples from Aβ42 aggregation reaction alone were withdrawn at time
zero, 5 h and 24 hours and administered to cells at a final concentration of
10 µM to assay for cytotoxicity by monitoring reduction of MTT. For time
zero sample, neuronal cells showed 80% viability. As aggregation
continues, monomers assemble into oligomers within 5 h for which the
cell viability decreased to 60%. Eventually, administration of sample
containing Aβ42 fibrils at 24 h further reduced the cell viability to 40%
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Figure 3.5. Inhibition of cytotoxicity of Aβ42 fibrils by sNUCB1 and
sNUCB1(tetramutant). We measured the cell viability of PC12 cells
using the standard MTT reduction assay. The delivery vehicle alone was
administered to the cells as the control. Both sNUCB1 and
sNUCB1(tetramutant) individually resulted in 90% to 95% final cell
viability, showing that each of the protein subunits by themselves are nontoxic. Thereafter, we administered samples withdrawn from a Aβ42
aggregation reaction at 0 h, 5 h and 24 h to PC12 cells such that the final
concentration for each is 10 µM. Cell viability measurements using MTT
reduction estimate that T = 0 h sample decreases the cell viability to 80%.
The subsequent addition of samples consisting of essentially oligomers (T
= 5h) and fibrils (T = 24h) continue to decrease cell viability to 55% and
39% respectively. We then incubated the Aβ42 fibrils at T = 24 h with
equimolar (32 µ M) amounts of sNUCB1 or sNUCB1(tetramutant) and
samples were withdrawn after 5 min, 15 min, 30 min and 60 min
respectively. Each sample was then administered to PC12 cells in culture
at a final concentration of 10 µ M and cell viability was estimated using
MTT reduction. The results show ~ 90 % cell viability for samples
withdrawn from reaction mixture containing sNUCB1 were administered
whereas cell viability of ~ 95 % was observed for sNUCB1(tetramuant)
containing samples. Each experiment was repeated atleast 3 times and the
data was plotted as the mean ± S.E.M.
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(Fig.3.5). In the next set of experiments, Aβ42 fibrils were incubated with
equimolar amount of Ca2+-free sNUCB1 or sNUCB1(tetramutant) and
samples were withdrawn at 5 min, 15 min, 30 min and 60 min time points
for administration to PC12 cells at a final concentration of 10 µM.
Intriguingly, MTT reduction dependent cell viability measurements
estimated ~ 90 % viability for 5 min sample from the disaggregation
reaction with either sNUCB1 or sNUCB1(tetramutant) and greater than 95
% viability for later time points showing that disaggregated species are
essentially non-toxic to PC12 cells (Fig.3.5). Thus, MTT assay shows that
both sNUCB1 and sNUCB1(tetramutant) disaggregate cytotoxic Aβ42
fibrillar aggregates into non-toxic species.

3.2.5 Ca2+-free sNUCB1 inhibits tau K19(C322S) NeuroFibrillary
Tangle (NFT) formation
Human tau is a multi-domain protein with 31-32 residue long repeat
regions (R1-R4) at the CT constituting the microtubule-association
domain (Fig.3.1). Tau K19 represents a synthetic and truncated form of
tau, which can aggregate in vitro to form NFTs. A growing role of tau in
AD pathology has recently been reported. Hence in order to investigate the
functional ability of Ca2+-free sNUCB1 towards inhibiting aggregation of
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Figure 3.6. Ca2+-free sNUCB1 inhibits tau K19(C322S) neurofibrillary
tangle (NFT) formation. Tau K19(C322S) slowly aggregates in vitro to
form NFTs. (A) We monitored aggregation of 50 µM tau K19(C322S) in
solution with time using TEM. Samples withdrawn from a constantly
stirred solution at room temprature after 27 h show presence of NFTs of
tau K19(C322S). In order to monitor the effect of Ca2+-free sNUCB1 on
aggregation of tau K19(C322S) to form NFTs, (B) we incubated
equimolar amount (50 µ M) of tau K19(C322S) with Ca2+-free sNUCB1
for 27 h. Samples were withdrawn after 27 h and analyzed using TEM.
The micrographs show complete absence of any NFTs. This suggests that
Ca2+-free sNUCB1 can effectively inhibit NFT formation by tau
K19(C322S). The scale bar represents 200 nm.

168

tauK19 towards forming NFTs, we used the mutant tau K19(C322S),
which lacks the ability to form intermolecular disulphide bonds. We
incubated 50 µ M tau K19(C322S) alone or with equimolar amount of
Ca2+-free sNUCB1 in 100 mM NaH2PO4 pH 7.4, 150 mM NaCl for 27 h at
room temperature with constant stirring. TEM analysis of samples
withdrawn from the reaction mixtures show that tau K19(C322S) alone
aggregates within 27 h to form NFTs (Fig. 3.6A). However, incubation of
tau K19(C322S) with Ca2+-free sNUCB1 completely inhibits NFT
formation as seen by the complete absence of any fibrillar aggregates in
the corresponding micrographs for the 27 h sample (Fig.3.6B). Hence,
Ca2+-free sNUCB1 effectively inhibits in vitro formation of NFTs by tau
K19(322S).
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3.3 DISCUSSION
Amyloid hypothesis has been the central dogma of AD research. Both Aβ
oligomers and fibrillar aggregates have been shown to exert neurotoxic
effects (150, 152). For decades, generation of Aβ was thought to be a nonessential product resulting from the erroneous cleavage of APP by γsecretase. However, recent work has revealed the neuroprotective role of
monomeric Aβ and has highlighted the involvement of APP in synaptic
transmission (110, 123). Thus neuritic dystrophy observed in AD can
result from both the loss of function of Aβ and the neurotoxic effects of
Aβ aggregates. In addition, a secondary role of tau hyperphosphorylation
and its aggregation into NFTs dependent on Aβ fibril formation has also
been postulated and shown to exacerbate cytotoxicity (153). Hence,
preventing the aggregation of Aβ is the primary therapeutic target with
significant interest in understanding and controlling intracellular tau
aggregation. Our results show that the soluble form of NUCB1 can both
inhibit Aβ42 aggregation and effectively disaggregate the pre-formed
fibrils in a Ca2+-dependent manner. In addition, Ca2+-free sNUCB1 also
inhibits aggregation of a truncated form of tau namely tauK19(C322S)
into NFTs and thus might inhibit aggregation of hyperphosphorylated
intracellular pool of full-length tau as relevant to AD pathology. Thus this
dual anti-amyloidogenic functionality of sNUCB1 presents an ideal target
that may be therapeutically relevant and useful. Clinically, the symptoms
of cognitive impairment in an AD patient appear years after initiation of
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Aβ aggregation, tau hyperphosphorylation, synaptic loss and neurite
dystrophy (154). Thus prevention of neurodegeneration requires the
clearance of deposited Aβ aggregates and inhibition of any further Aβ
aggregation to restore physiological Aβ function. In accordance with this
observation, our data shows that Ca2+-free sNUCB1 possesses the ability
to both inhibit fibril formation and disaggregate them into non-toxic
species.

AD research in the past decade has unraveled the neurotoxicity effects of
Aβ oligomers and fibrils. However, the events that initiate Aβ aggregation
are still not clearly understood. In 2006, Yankner and coworkers showed
that Ca2+ enhanced the aggregation of early protofibrillar species and
increased their association to form fibrils. They proposed a potential role
of Ca2+ in Aβ aggregation and toxicity in the AD brains (155). It is known
that Ca2+-homeostasis plays a central role in many aspects of brain
physiology including growth, plasticity, learning and memory as well as
cell death and degeneration. Ca2+ ions are essential during signal
transmission from one neuron to another and Ca2+-dysregulation has been
repeatedly observed in AD research (156, 157). Aβ is believed to cause
Ca2+-dysregulation either by interacting with cell surface receptors
coupled with Ca2+-flux or by forming leaky membrane pores (56).
NUCB1 is a Ca2+-binding protein, which maintains Ca2+-homeostasis and
Ca2+-storage in Golgi (16, 46). NUCB1 is ubiquitously expressed, found
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in ER and resides in Golgi for more than 12 hours (23). APP is
synthesized in ER, transported through the Golgi apparatus into the TGN.
Immunofluorescence assays have shown that Aβ42 generated from APP is
present in ER under steady state conditions and is also localized in TGN
(158). Co-localization of NUCB1 and APP has been reported in both
cultured cells and mouse brains (28). Thus the role of NUCB1 in
maintaining Ca2+-homeostasis and its interaction with APP and Aβ
suggests towards a possible involvement of NUCB1 in AD pathology.

An alternative hypothesis to initiation of Aβ aggregation could be the
disruption of cellular machinery involving Hsps, sHsps, cellular proteases
and trafficking molecules that normally prevent the aggregation and
accumulation of Aβ. Both extracellular and intracellular chaperones have
been shown to co-localize with Aβ deposits in senile plaques and inhibit
Aβ aggregation and are involved in its clearance across the blood-brain
barrier (74, 159). In addition, Zn2+-dependent metalloprotease Neprilysin
targets Aβ diffuse deposits and neuritic plaques for their catalytic
degradation (137). Synaptic activity has been shown to decrease
intracellular Aβ levels. Upon APP cleavage, Aβ40 is generated which is
secreted while intraneuronal Aβ42 is subjected to Neprilysin mediated
degredation (110). Overexpression of IDE decreases the extracellular
levels of both Aβ40 and Aβ42 monomers. The current prevailing evidence
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also suggests a differential role of apolipoprotein E (apoE) isoforms in
mediating clearance of Aβ from the extracellular space. Importantly, the
apoE4 isoform, which is associated with increased risk for AD, has been
shown to exhibit an impaired ability to promote Aβ proteolysis and thus
clearance from the extracellular space compared to apoE2 and apoE3
(140, 141). Furthermore, Low-density lipoprotein receptor-related protein
1 or LRP1, was shown to bind Aβ or to its chaperone complex with β2
Microglobulin or apoE4 and deliver the complex to lysosomes for
degradation (160). A soluble form of LRP1 sequesters 70-90 % of plasma
Aβ peptides and its levels and capacity to bind Aβ are reduced in AD
brains (161). In a recent study, Brodeur et al. showed that NUCB1
strongly binds to LRP, assists in its endosomal sorting and consequently
prevents its lysosomal degradation (27). Functionally, NUCB1 has also
been shown to affect the biogenesis of APP, which in turn attenuates Aβ
production (28). Thus physiologically, NUCB1 can possibly regulate Aβ
production, assist in its clearance through reduced degradation of LRP and
inhibit the deposition of Aβ aggregates. Future work investigating the
physiological role of NUCB1 should provide evidence in favor or against
these hypotheses.

Our results show that NUCB1 inhibits Aβ42 fibril formation only in its
Ca2+-free form. This is consistent with the reported interaction of NUCB1
with APP only in the absence of Ca2+. Physiologically, neuronal Ca2+
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levels vary from 100 nM intracellular to 1 mM extracellular concentration.
Given the Kd values of Ca2+-binding to sNUCB1 of 6.3 µM and 73.5 µM
respectively (Fig1.3), NUCB1 should primarily exist in a Ca2+-free form
intraneuronally and Ca2+-bound in the extracellular environment. This
implies that NUCB1 can interact with Aβ42 intraneuronally but
extracellular Ca2+ levels may inhibit this interaction. However, our
engineered Ca2+-insensitive mutant, sNUCB1(tetramutant) should be
functional both intra- and extracellularly. The role of intraneuronal and
extracellular Aβ in facilitating tau hyperphosphorylation, mitochondrial
and proteosomal disruption, dysregulation of Ca2+ homeostasis, synaptic
failure and cognitive dysfunction has placed it at the forefront of AD
research. Additionally, it has been shown that Aβ42 when generated is
poorly secreted and has a high tendency to aggregate under physiological
conditions. Thus the discovery of the functional role of NUCB1 in
inhibiting Aβ42 aggregation and disaggregating its fibrils into non-toxic
species becomes increasingly important. Furthermore, the ability of Ca2+free sNUCB1 towards inhibiting tau K19(C322S) aggregation to form
NFTs suggests that NUCB1 might have some role in regulating the
aggregation of full-length tau upon hyperphosphorylation. Future work
investigating this observation both in an in vitro and in vivo model would
be useful towards understanding and establishing the physiological role of
NUCB1. In addition, the observed reduction of NUCB1 levels in the
brains of AD patients along with the disruption of Ca2+-homeostasis could
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individually or together cause progression of the diseased state in AD
patients. sNUCB1(tetramutant) circumvents the Ca2+-dependence of the
anti-amyloidogenic properties of NUCB1 and should be functional under
disrupted Ca2+-homeostasic conditions. This can be a useful molecular
handle and future studies with both sNUCB1 and sNUCB1(tetramutant) in
relevant mouse models of AD should provide important insights into their
functional capabilities. Hence understanding of the role of NUCB1 in AD
pathology can be useful in designing novel and effective therapeutics.
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Heptahelical G-protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors couple to heterotrimeric G proteins to relay
extracellular signals to intracellular signaling networks, but the molecular
mechanism underlying guanosine 5′-diphosphate (GDP) release by the G
protein α-subunit is not well understood. Amino acid substitutions in the
conserved α5 helix of Gi, which extends from the C-terminal region to the
nucleotide-binding pocket, cause dramatic increases in basal (receptorindependent) GDP release rates. For example, mutant Gαi1-T329A shows
an 18-fold increase in basal GDP release rate and, when expressed in
culture, it causes a significant decrease in forskolin-stimulated cAMP
accumulation. The crystal structure of Gαi1-T329A·GDP shows substantial
conformational rearrangement of the switch I region and additional
striking alterations of side chains lining the catalytic pocket that disrupt
the Mg+2 coordination sphere and dislodge bound Mg+2. We propose a
“sequential release” mechanism whereby a transient conformational
change in the α5 helix alters switch I to induce GDP release. Interestingly,
this mechanistic model for heterotrimeric G protein activation is similar to
that suggested for the activation of the plant small G protein Rop4 by
RopGEF8.
© 2009 Elsevier Ltd. All rights reserved.

Edited by I. Wilson

Keywords: G-protein-coupled receptors (GPCRs); heterotrimeric G-proteins;
α5 helix; X-ray crystallography; activation mechanism

Introduction
Heterotrimeric guanine nucleotide-binding regulatory proteins, G proteins (Gαβγ),1,2 relay signals from
heptahelical transmembrane G-protein-coupled
receptors (GPCRs) to downstream effector mole-

*Corresponding author. E-mail address:
sakmar@mail.rockefeller.edu.
Abbreviations used: G protein, heterotrimeric guanine
nucleotide-binding protein; GPCR, G-protein-coupled
receptor; GDP, guanosine diphosphate; GTP, guanosine
5'-triphosphate; CT, C-terminus; Gt, transducin; EPR,
electron paramagnetic resonance; WT, wild type; FRET,
fluorescence resonance energy transfer; FK, forskolin;
GTPase, guanosine triphosphatase; AC, adenylyl cyclase;
SEAP, secreted alkaline phosphatase; ITC, isothermal
titration calorimetry; GEF, guanine nucleotide exchange
factor; FCS, fetal calf serum.

cules.3,4 GPCRs activate G proteins by inducing the
release of guanosine 5′-diphosphate (GDP) from the
Gα subunit in the active receptor (R⁎)–G protein
complex.5–7 Guanosine 5′-triphosphate (GTP) uptake
by Gα leads to the dissociation of the heterotrimer
into the Gα and Gβγ subunits, making them
available to interact with various downstream
effectors. The interface between the cytoplasmic
structure of an active GPCR and its bound G protein
might be as far as 30 Å away from the bound GDP.8,9
The agonist ligand-binding site on the receptor, as
judged by the crystal structures of inverse-agonistbound rhodopsin10 and adrenergic receptors,11,12 are
approximately an additional 40 Å away from the
inner surface of the bilayer. How does ligand binding
to a GPCR induce GDP release from Gα at a distance
of ∼70 Å?
Although the crystal structures of several G protein subunit isoforms, 13–18 complexes 19–22 and
mutants with altered exchange rates 23,24 have
been solved, we still lack a mechanistic understanding of how active GPCRs stimulate nucleotide
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exchange by the Gα subunit. Nevertheless, these
structural studies have identified state-dependent
conformational differences within the Gα subunit
and suggest allosteric coupling of well-defined switch
regions to the activation process.15 The exchange of
GDP for GTP induces ordering in the switch regions,
making the GTP-bound state conformationally more
rigid.
During activation, R⁎ engages the C-terminus
(CT) of G protein α-subunit. Earlier mutagenesis
work with transducin (Gt) showed that activation
signal is transferred to the catalytic pocket via the α5
helix that connects the CT to the nucleotide-binding
β6–α5 loop.25 Additionally, site-directed mutagenesis of α5 helix residues of Gt showed drastic
alterations in the basal rates of nucleotide exchange.26,27 Previous electron paramagnetic resonance (EPR) studies with site-directed spin-labeled
G protein α-subunits proposed a rigid-body movement of the α5 helix upon binding of receptor during
activation.28–30 Furthermore, the crystal structure of
Q333C–I56C Gαi1, a mimic of EPR-measured
receptor-associated conformation, suggests a shift
of α5 helix toward the bound nucleotide.31 The
recent structure of ligand-free opsin in complex
with a peptide analogue of the CT tail of the αsubunit of Gt shows, as shown earlier by NMR,32
that the Gt peptide binds at an angle of ∼ 40° to the
hypothetical plane of the bilayer and makes
contacts with several conserved amino acid residues on the receptor transmembrane border
regions, notably R135. The structure also suggests
how the G protein heterotrimer might dock to R⁎.33
However, the lack of a crystal structure of an active
GPCR in complex with the full-length G protein αsubunit or heterotrimer limits our understanding of
the exact molecular determinants of receptormediated G protein activation.
We present here the molecular details of a probable
intermediate state along the G protein activation
pathway. We carried out Ala-scanning mutagenesis
to make a panel of site-specific mutants of the α5
helix of Gαi1 and identified a number of mutants
with orders-of-magnitude increases in basal exchange rates of guanine nucleotides in the absence
of receptor. The mutant Gαi1-T329A, for example,
showed a nearly 20-fold increase in receptor-independent basal nucleotide-exchange rate. In cellbased assays, Gαi1-T329A significantly attenuated
forskolin (FK)-induced cAMP accumulation and
lowered basal cellular cAMP levels. We then solved
high-resolution crystal structures of Gαi1-T329A in
both GDP- and guanosine GTPγS-bound states and
compared the structures with other available G
protein structures. The T329A mutation caused
significant alterations in the structure of the switch
I region and affected the complex Mg2+ coordination
sphere in the nucleotide-binding site. Based on the
new structures, we propose a “sequential release”
mechanism for receptor-induced nucleotide exchange where specific structural changes mediated
by the α5 helix destabilize bound Mg2+, which exits
the active site to facilitate GDP release.
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Results
Fluorescence measurement of nucleotide
binding
We first constructed a set of single point mutants
of Gαi1 in which residues T329, V332 and F336 on
the α5 helix and residue Q52 on the α1 helix were
replaced with Ala (Fig. 1). A double-mutant
construct with both Q52 and T329 residues replaced
with alanine was also engineered. All single and
double mutants were expressed as recombinant
proteins in Escherichia coli and purified to homogeneity. The intrinsic fluorescence of W211, which is
present in the switch II region of Gαi1, increases
upon GTP binding due to its movement from a
solvent-exposed environment to a hydrophobic
pocket in the nucleotide-binding pocket14 and has
been used to measure the kinetics of GTP uptake
reaction.34 The rate of basal nucleotide exchange for
each mutant was measured by monitoring its
fluorescence in the presence of GTPγS (a nonhydrolyzable analogue of GTP) (Fig. 2a). Pseudo-firstorder rate constants for GTPγS uptake by wild-type
(WT) Gαi1 and the single and double Gαi1 mutants
were calculated.
The nucleotide-exchange reaction was also monitored using the fluorescence nucleotide analogue,
mant [2′,3′-O-(N-methyl-anthraniloyl)]-GTPγS
(Fig. S1). As Gα takes up mant-GTPγS, W211
moves into its characteristic hydrophobic pocket in
the nucleotide-binding site. Since the excitation
spectrum of mant-GTPγS overlaps with the emission spectrum of Trp, fluorescence resonance energy
transfer (FRET) is observed upon mant-GTPγS
binding to Gαi1. Higher rates of FRET increase
were observed for the Gαi1 mutants compared with
that of the WT Gαi1, thereby corroborating the
results of the GTPγS uptake assay. In general, we
observed multifold increases in basal nucleotideexchange rates in the mutants compared with that in
WT Gαi1. In particular, Gαi1-T329A displayed an 18fold increase in its rate of GTPγS uptake compared
with that of WT Gαi1 and appeared to be stable in
solution over extended time periods (data not
shown). Therefore, we chose the Gαi1-T329A mutant
for additional detailed studies.
Physiological role of Gαi1-T329A
To investigate the potential physiological relevance
of the T329A mutation, we expressed the human
Gαi1-T329A mutant in mammalian HEK 293 cells. In
control experiments, HEK cells were transfected with
WT Gαi1 or a constitutively active, guanosine triphosphatase (GTPase)-deficient mutant, Gαi1-Q204L.35
We next measured FK-stimulated intracellular cAMP
levels in the transfected cells. FK directly activates
adenylyl cyclase (AC) and is commonly used as an
adjunct in assays designed to evaluate the ability of
Gs and Gi to activate or inhibit, respectively, cellular
AC activity. GTP-bound, active WT Gαi1 acts to
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Fig. 1. The structure of Gαi1 showing sites of amino acid substitution on the α5 helix. (a) The structure of the GDPbound form of WT Gαi1 consists of the GTPase domain (green) and the helical domain (salmon) with the nucleotide
shown as a ball-and-stick model (yellow) sandwiched between them. The α5 helix (blue) connects the receptor interacting
C-terminal tail with the GDP-interacting β6–α5 loop (orange). (b) The structure in (a) has been rotated clockwise by 70°
along the vertical axis. The α5 helix, lying in a trough formed by the α1 helix and β1–β6 strands, is ∼ 50% solvent-exposed
and oriented in an N- to C-terminal order coming out of the plane of paper. (c) A zoom into the α5 helix region shows the
sites of mutations on the α5 helix (F336, V332, T329) and the neighboring α1 helix (Q52A). As shown, T329 and Q52
residues could be involved in a possible H-bonding interaction via their side-chain groups that are placed 3.3 Å apart.
Each of the residues was mutated to alanine for generation of single- and double-point mutants. The bound nucleotide
close to the CT of the α1 helix is shown as a ball-and-stick model (yellow).

inhibit AC, resulting in a decreased concentration of
intracellular cAMP.36,37 We tested the ability of the
Gαi1-T329A mutant to affect FK-stimulated cellular
cAMP levels, using a highly sensitive gene reporter
assay that relies on secreted alkaline phosphatase
(SEAP) to report intracellular cAMP concentration.38,39 Compared with WT, expression of the

constitutively active Gαi1-Q204L mutant caused a
dramatic decrease in FK-stimulated cAMP levels
(Fig. 2b and c). This effect is presumed to be a direct
result of increased inhibition of AC by the Gαi1Q204L mutant. Interestingly, the Gαi1-T329A mutant
mimics the effect of the Q204L mutant in its ability to
inhibit FK-stimulated cAMP production. Also, unlike
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residue Q204, T329 is not in close proximity to the
bound nucleotide and hence cannot directly influence the stability of the bound nucleotide even
though the T329A-Gαi1 mutant mimics a constitutively active state. This suggests that the mutation
somehow allosterically modulates the fast rates of
nucleotide exchange on the Gαi1 subunit.
Crystal structure of Gαi1-T329A in the
GDP- or GTPγS-bound form
To probe the molecular determinants and structural basis for the increased rates of nucleotide exchange
observed in the mutant Gαi1 proteins, we determined
the crystal structures of Gαi1-T329A in both the GDP-
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and the GTPγS-bound forms (Table 1). The intended
mutation of Thr to Ala in the protein was confirmed
by the crystal structure, where electron density at
position 329 corresponded to Ala (Fig. S2A). The
structure of the GDP-bound form of Gαi1-T329A was
refined to 2.5-Å resolution using the structure of
Gαi1·GDP·Mg2+ [Protein Data Bank (PDB) code
1BOF] as a template for molecular replacement. In
the final model, the region corresponding to amino
acids M1–L5, Q204–C217 and V233–E239 is missing
due to lack of electron density for these residues.
Similarly, the structure of the GTPγS·Mg2+-bound
form of Gαi1-T329A was refined to a resolution of
2.3 Å, using the structure of Gαi1-G42V·GTPγS·Mg2+
(PDB code 1AS0) as a template. In the final model, the
region corresponding to amino acids M1–R32 and
K349–F354 is missing due to lack of electron density
for these residues. The GDP- and GTPγS-bound
structures for T329A-Gαi1 were solved in space
groups identical to those of the WT Gαi1 structures.
We systematically compared and contrasted the
structures of the WT and mutant Gαi1 proteins.
Although the switch II (residues 199–219) and
switch III (residues 231–242) regions of Gαi1T329A·GDP are essentially disordered as in the
WT Gαi1·GDP, both of these switch regions are
nicely ordered and resolved in the active GTPγSbound states of both proteins.15 Interestingly, a
well-defined electron density for switch I (residues
177–187) shows that it has moved away from the
nucleotide in Gαi1-T329A·GDP compared with
switch I in WT Gαi1 (Fig. 3). Overall the root-meansquare deviation (r.m.s.d.) between WT Gαi1·GDP
and Gαi1-T329A·GDP was 0.79 Å, whereas it was
only 0.29 Å for their GTPγS-bound structures.
Hence, overall the GTPγS-bound-state structures
WT Gαi1 and Gαi1-T329A are essentially identical
Fig. 2. Fluorescence assay of nucleotide uptake rates
and forskolin (FK)-induced SEAP assay. (a) Nucleotide
exchange was monitored by measuring the enhancement
in intrinsic Trp fluorescence as a function of time after
addition of GTPγS. Traces show the activation of the WT
Gαi1 (black) and T329A mutant (red) and rates of exchange for all proteins studied are given in the table (inset).
Uncatalyzed t1/2 values are presented as the mean ± SEM
of at least three independent experiments. As observed,
substitutions of residues on the α5 helix (T329, V332, F336)
or residues in close proximity to the α5 helix (Q52) increase
the basal rate of exchange, indicating a possible involvement of the α5 helix during the receptor-catalyzed
nucleotide-exchange process. (b) Gαi1 mutants, T329A
and Q204L, show increased inhibition of FK-induced
cAMP-dependent SEAP activity. Mock (black), WT (red),
T329A (green), Q204L (blue) and pCRE-SEAP cotransfected cells were incubated for 6 h in the presence of FK
ranging from 0 to 12.5 μM prior to SEAP activity
measurement. Inset: expression levels were similar based
on immunoblot analysis. (c) Increased inhibition of basal as
well as FK-stimulated SEAP activity is observed in cells
transfected with Q204L and T329A Gαi1 mutants. SEAP
activity is expressed as a percentage of the activity
obtained with 12.5 μM FK stimulation in mock-transfected
cells. Data are mean + SEM from three independent experiments done in triplicate.
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Table 1. Crystallographic data and refinement statistics

Data processinga
Space group
Unit cell dimensions
a, b, c (Å)
α, β, γ (degrees)
Crystal dimensions (mm)
Total no. of reflections
Unique reflections
No. of molecules
per asymmetric unit
Rmerge on Ib
Mean I/σIc
Completeness (%)
Multiplicity
Model for MR (PDB)
Refinement statistics
Resolution (Å)
Reflections in file
Reflections used
Rwork (%)d
Rfree (5% of data)
No. of atoms
Protein
Ions
Mg2+
SO2−
4
Ligand (GDP/GTPγS)
Water
B-factor
Average
Ligand
r.m.s.d.'s
Bond lengths (Å)
Bond angles (°)
Chiral angles (°)

T329A Gαi1
(GDP)

T329A Gαi1
(GTPγS)

I4

P3221

121.76, 121.76,
68.71
90, 90, 90
0.2 × 0.5 × 0.7
118,368
16,157
1

79.29, 79.29,
105.6
90, 90, 120
0.1 × 0.2 × 0.3
92,656
17,460
1

6.0 (27.5)
8.4 (2.6)
100 (100)
7.3 (7.5)
1BOF

8.3 (22.6)
6.7 (3.3)
100(100)
5.3 (5.5)
1AS0

59.8–2.5
16,157
15,346
18.1
22.6

68.4–2.3
17,447
16,564
18.5
25.2

2690

2627

0
1
1
46

1
1
1
49

40.0
27.0

30.0
12.0

0.02
1.79
0.11

0.02
1.82
0.11

a
Numbers in parentheses indicate statistics for the highestresolution shell.
b
Rmerge = ∑hkl∑i│I(hkl)i − 〈I(hkl)〉│/∑hkl∑i〈I(hkl)i〉.
c
I/∑I, signal-to-noise ratio, where I is the integrated intensity of
a measured reflection and σI is the estimated error in measurement.
d
∑│FP − FP(calc)│/∑FP, where FP and FP(calc) are the observed
and calculated structure factor amplitudes. Rfree is calculated
similarly using test set reflections never used during refinement.

(Fig. S3), whereas significant differences are observed
in the GDP-bound-state structures (Fig. S4).
Changes in conformation of switch I region
2+

Superimposition of the Gαi1·GDP·Mg , Gαi1·
GTPγS·Mg2+, Gαi1-T329A·GDP and Gαi1-T329A·
GTPγS·Mg2+ structures shows striking differences
in the conformations of the switch I region (Fig. 3a).
The T329A replacement on the α5 helix allosterically induces an extensive outward movement of the
switch I region away from the nucleotide in the
GDP-bound state of the mutant Gαi1-T329A compared with the GDP-bound state of WT Gαi1. This
conformational change leads to an overall increase
in the catalytic pocket size, thereby destabilizing the
bound nucleotide to facilitate faster GDP release.
Interestingly, the switch I regions in the activated
forms of the mutant Gαi1-T329A·GTPγS·Mg2+ and
WT Gαi1·GTPγS·Mg2+ exhibit identical conforma-

tional states. Switch I is tightly positioned in close
proximity to the nucleotide, probably due to the
bound Mg2+ divalent cation in the catalytic pocket.
Hence, the T329A substitution affects the conformational state of the switch I region only in the
GDP-bound form. An electrostatic potential surface
rendering of Gαi1-T329A·GDP and WT Gαi1·GDP·
Mg2+ structures also highlights extensive outward
movement of the switch I region, allowing access
for a possible exit route of the bound GDP (Fig. 3b).
Changes in GDP interactome within the catalytic
pocket
The T329A substitution also induced structural
changes in several key amino acid side chains in the
catalytic pocket (Fig. 3c and d). Foremost is an
inversion (∼ 180°) of the guanidinium side chain of
R178, thereby preventing H-bonding interactions
with the oxygen of the α- and β-phosphate on GDP
demonstrated in the WT Gαi1·GDP·Mg2+ crystal
structure. This conformational flip of R178 causes a
loss of stabilization of the bound GDP. The dramatic
movement of switch I in the Gαi1-T329A mutant also
orients the side chain of K180 away from the
catalytic pocket (Fig. 4a). The other residues participating in electrostatic interactions with the guanine ring of GDP (N269, D272, K270 and A326) have
similar orientations in the Gαi1-T329A mutant and
the WT Gαi1, although shorter H-bonding distances
in the mutant promote stronger interactions with the
bound GDP. Also, unlike the case in WT Gαi1, the
side chains of R178 and L273 in the Gαi1-T329A
mutant seem to be involved in hydrophobic interactions with the guanine ring along with K270 and
T327. In WT Gαi1, the GDP ribose engages its 2′- and
3′-hydroxyl groups in an H-bond network with the
backbone carbonyl groups of L175 and R176. These
stabilizing interactions are substituted by the single
side-chain hydroxyl group of S151 in the Gαi1-T329A
mutant, resulting in weaker H-bonding potential
(Fig. 3c and d). Thus, despite apparent gains in
hydrophobic interactions, the loss of favorable
electrostatic and H-bonding interactions in Gαi1T329A destabilizes the bound GDP, resulting in a
faster rate of release from the catalytic pocket.
Loss of Mg2+ from the catalytic pocket in the
Gαi1-T329A·GDP structure
Mg2+ was absent from the catalytic pocket in the
crystal structure of Gαi1-T329A·GDP (Fig. S2b
and c). Two key residues of the Mg2+ coordination
sphere in WT Gαi1·GDP·Mg2+, T181 (on the switch I
region) and S47 (on the α1 helix), display considerable structural alterations upon substitution of T329
(Fig. 4a). T181 moves away from the Mg2+ -binding
site due to the extensive outward movement of the
switch I region. The S47 side chain also orients away
from the Mg2+-binding site, disrupting the favorable
interaction present in WT Gαi1. The displacement of
nucleotide in the catalytic pocket also compromises
the favorable interactions between the β-phosphate
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and bound Mg2+ (Fig. 4a). The integration of these
changes essentially dismantles the Mg2+ coordination sphere in the Gαi1-T329A mutant, and the loss
of bound Mg2+ further decreases the stability of the
bound GDP. In the WT Gαi1·GDP·Mg2+structure
(PDB code 1BOF), several water molecules populate
the catalytic pocket, with water molecules W801,
W802 and W803 forming part of the octahedral
coordination sphere of Mg2+. These water molecules
are completely absent from the catalytic pocket of
the Gαi1-T329A·GDP structure (Fig. 4b), further
corroborating the loss of Mg2+ from the catalytic
pocket. Other proximal residues, including the
highly conserved D200, which is part of the
conserved DXXG sequence motif found in all the
regulatory G proteins of the Ras superfamily, adopt
similar side-chain conformations in the Gαi1-T329A
mutant and WT proteins.
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1n 1998, Coleman and Sprang solved structures of
WT Gαi1 in the presence of different concentrations
of Mg2+.40 They showed that the Mg2+-binding site
in the catalytic pocket of WT Gαi1 has 70% occupancy at 10 mM Mg2+ concentration and 100%
occupancy at 100 mM Mg 2+ or above in the
crystallization buffer.40 To address the issue of
Mg2+ binding, we solved the structure of the GDPbound form of the Gαi1-T329A mutant with 10 mM
Mg2+ in the crystallization buffer. The structure still
revealed a complete absence of Mg2+ from the
catalytic pocket, which was consistent with our
primary crystallographic data set at 2 mM Mg2+. We
also saw similar secondary-structural and side-chain
orientations in the crystals grown at 10 mM MgCl2,
as in the structure from the crystal with 2 mM Mg2+
(data not shown). This confirms the observation that
the T329A mutation indeed disrupts the Mg2+

Fig. 3 (legend on next page)
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coordination sphere in the catalytic pocket. The
absence of Mg2+, in conjunction with other destabilizing structural changes, facilitates the release of
bound GDP from the catalytic pocket, explaining the
increase in release rates of GDP from the mutant
Gαi1 proteins.
To investigate the influence of Mg 2+ on the
kinetics of the nucleotide-exchange process, we
performed the GTPγS-binding assay on the WT
and mutant Gαi1 proteins as a function of Mg2+
concentration. Interestingly, the results showed that
the rates of exchange depended significantly on the
concentration of Mg2+ present in the reaction buffer.
In general, increasing Mg2+ concentration decreased
the rate of GDP release (Fig. 4c). The greatest
decrease in the rate of exchange as a function of
increasing concentrations of Mg2+ was observed for
the WT Gα i1 . The effect of increasing Mg 2+
concentration can be rationalized by our earlier
structural observations. The high concentration of
Mg2+ might induce order in the structure and
stabilize the GDP-bound state. This would make
the rate of nucleotide exchange slower at higher
concentrations of Mg2+. The induction of similar
structural changes due to increasing Mg2+ concentration was also shown earlier by Coleman and
Sprang.40 Interestingly, the rate of nucleotide exchange for the slower-exchange mutants (Q52A,
V332A, Q52A/T329A) was also influenced by the
concentration of Mg 2+ present in the reaction
mixture. This may be due to a partially intact Mg2+
coordination sphere where binding of Mg2+, albeit
with lower affinity, might stabilize the bound
nucleotide. The rates of nucleotide exchange for the
rapid-exchange mutants Gαi1-T329A and Gαi1F336A are, by and large, unaffected by increasing
Mg2+ concentrations. This substantiates the structural findings related to the disruption of the Mg2+
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coordination sphere in the Gαi1-T329A·GDP structure as noted above. We thus propose that the
accelerated rate of the activation process in the
mutants is coherently coupled in part to the loss of
Mg2+ from the catalytic pocket. In receptor-induced
nucleotide exchange, the receptor might possibly be
inducing similar structural rearrangements to facilitate a faster nucleotide exchange.
As stated earlier, the superimposition of the static
secondary-structural elements in the crystal structure of the Gαi1-T329A·GTPγS·Mg2+ and WT Gαi1·
GTPγS·Mg2+ complexes revealed an r.m.s.d. of only
0.29 Å. There were no observable significant
secondary-structural differences between these two
structures (Fig. S3). This highlights the fact that the
activated state is well ordered and almost identical
for WT Gαi1 and the Gαi1-T329A mutant. The
mutation affects only the less ordered GDP-bound
form of the protein, inducing an increased rate of
nucleotide exchange. The presence of an intact Mg2+
coordination sphere in the activated form leads to
tight ordering of the switch I region, which is
conformationally more dynamic in the GDP-bound
form. The residues that constitute the GTPγSbinding domain have identical orientation with
minimal conformational differences. The nucleotide
positioning in the catalytic pocket is more definitive
and static, with complete overlap between the
respective nucleotides in the mutant and WT Gαi1
structures (Fig. 4d).
Thermodynamics and kinetics of the activation
process
The mutations of the α5 helix residues cause
disruption of certain key electrostatic interactions
within the Gα subunit. The influence of the mutation
on the rate of activation suggests that the mutation

Fig. 3. Switch I movement and changes in GDP interactome within the catalytic pocket. (a) The T329A mutation on the
α5 helix allosterically induces an extensive outward movement of the switch I region of Gαi1-T329A·GDP (green) in
comparison to the switch I regions of WT Gαi1·GDP·Mg2+ (salmon) (PDB code 1BOF), Gαi1-T329A·GTPγS·Mg2+ (orange)
or WT Gαi1·GTPγS·Mg2+ (blue) (PDB code 1ASO). This movement of a key structural determinant in Gαi1-T329A·GDP
leads to changes in the orientation of side chains of the residues lying along the switch I region in the Gαi1-T329A·GDP in
comparison to other forms of Gαi1. (b) A zoom into switch I consisting of electrostatic potential surface of Gαi1T329A·GDP and WT Gαi1·GDP·Mg2+ shows extensive movement of the switch I corresponding region on the proteins.
The outward movement of switch I in the mutant exposes an exit route readily available for the bound nucleotide, which
could facilitate faster rates of nucleotide exchange. However, in WT Gαi1, switch I is rigidly positioned to act as a lid on the
exit channel, thereby limiting the kinetics of the nucleotide-exchange process. The residues interacting with the guanine
ring (N269, D272, K270 and A326) are the same in both (c) the mutant and (d) the WT Gαi1, although the H-bond
stabilizing interactions are slightly stronger (due to closer proximity of interacting ends) in the mutant. In the T329A
mutant, additional residues, namely, R178, L273, T327 and K270, are involved in hydrophobic interactions with the
guanine ring through their side chains than in WT Gαi1. In WT Gαi1, the ribose ring of GDP engages the 2′- and 3′hydroxyl groups in a H-bonding network with the backbone carbonyls of L175 and R176, whereas this bicentric
stabilizing interaction is replaced by a single side-chain hydroxyl group of S151 in T329A, contributing to the decreased
stability of the nucleotide in the pocket. The α- and β-phosphates interact with multiple amino acid side chains and
backbones. A crucial H-bonding interaction between the oxygen atoms of the α- and β-phosphates on GDP and the
protonated side chain of R178 is lost in the mutant, contributing further to the decrease in the stability of the bound
nucleotide. The flipping of the R178 side chain outside the pocket also contributes to a larger pocket size in comparison to
WT Gαi1, where this interaction is tightly regulated. These effects of the mutation at a distance are tremendous, and
overall cause the loss of Mg2+ from the binding pocket. The lack of Mg2+ in turn disrupts multiple electrostatic interactions
with amino acid residues, such as S47 and T181, along with the oxygen atoms present on the β-phosphate of GDP. The
T329A mutation overall lowers the activation barrier of nucleotide exchange by allosterically modulating the orientation
and general conformation of the residues constituting the GDP interactome.
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might be affecting the activation energy for the
nucleotide-exchange process. In order to analyze
quantitatively the effect of mutation on the activation energy, we performed GTPγS-binding assays
over a linear temperature gradient. The fluorescence
enhancement of W211 due to activation was
monitored and rates were calculated. Experiments
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were performed for the WT Gαi1 and Gαi1-T329A
mutant and kapp values were calculated for each
data set at different temperatures. A plot of ln k
versus 1/T was fit to the Arrhenius equation to give
activation energies for both WT and mutant. The
analysis revealed that the barrier for activation of the
mutant is lower by 5.1 kcal/mol than that of the WT

Fig. 4 (legend on next page)
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(Fig. S5a). This implies that the T329A mutation
causes allosteric modulation of residues defining the
catalytic pocket, which leads to destabilization of
interactions involved in GDP binding. The net effect
is a lowering of the activation threshold, thereby
resulting in faster rates of nucleotide exchange.
We performed isothermal titration calorimetry
(ITC) to analyze the effect of amino acid replacement
on the apparent binding affinity of the nucleotide
ligand and its influence on the nucleotide-exchange
process. ITC experiments, in principle, give the net
change in the enthalpy for this exchange reaction
(Fig. S5b). The binding of GTPγS to the Gαi1-T329A
mutant was more exothermic than GTPγS binding
to WT Gαi1 (data not shown). The crystal structures
of Gαi1-T329A·GTPγS·Mg2+ and WT Gαi1·GTPγS·
Mg2+ are almost identical, with an r.m.s.d. of 0.29 Å.
Thus, the final GTPγS-bound states of the two
complexes can be assumed to have the same energy
level on a reaction profile diagram. However, the
crystal structure of the GDP-bound form of the Gαi1T329A mutant displays significant conformational
changes that destabilize its GDP-bound state.
Hence, transition from the energetically higher
GDP-bound state should give larger reaction enthalpy. Our ITC data are in excellent agreement with
this rationale. The high activation barrier for the WT
protein makes the process of spontaneous basal
nucleotide exchange slow and unfavorable, although we observe strong binding constants for α5
helix mutants Gαi1-T329A, Gαi1-Q52A/T329A and
Gαi1-V332A (Fig. S4b). The loss of favorable interactions caused by each α5 helix amino acid
replacement promotes faster release of the bound
GDP, which creates a nucleotide-free pocket readily
available for GTPγS binding. This observation is in
excellent agreement with the kinetic analysis of the
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exchange process for different mutants as shown
earlier. Hence, the ITC experiments along with the
Arrhenius analysis show that thermodynamic gain
also contributes to faster rates of nucleotide exchange for the mutants in comparison to the WT
protein.

Discussion
Over the years, several hypothetical models have
been proposed to explain receptor-induced G
protein activation. One model elucidates the role
of the Gβγ subunit as a “lever” to reorient a cognate
exit route in Gα during receptor-promoted GDP–
GTP exchange. The β3–α2 loop or the “lip” of this
contact surface (between Gα and Gβγ subunits) and
switch I occlude the exit route for GDP. The
receptor-mediated exchange promotes alterations
in this region to facilitate the activation of G
proteins.8,41 Alternatively, a “gear-shift” model has
also been proposed where R⁎ binds to Gα and
induces a hinge motion at the Gα N-terminal tail.
This leads to tight packing of the Gα–Gβ subunits,
and the N-terminal tail of the Gγ subunit is engaged
to displace the Gα helical domain. The opening of
the cleft between the GTPase domain and the helical
domain allows for GDP release.42
Mutations of the α5 helix residues of Gt facing into
the protein cause a multifold increase in the basal
rate of nucleotide exchange.26,27 This suggests that
the α5 helix comprises a functional microdomain in
G proteins that affects basal nucleotide release rates
and mediates receptor-catalyzed nucleotide exchange at a distance from the nucleotide-binding
pocket. Interestingly binding to Gβγ or the receptor
is largely unaffected by these mutations. In 2006,

Fig. 4. Changes in catalytic pocket residues in Gαi1-T329A and WT Gαi1 and loss of Mg2+. (a) A superposition of the side
chains of residues in close proximity with GDP and those forming the coordination spheres of Mg2+ in the WT
Gαi1·GDP·Mg2+ and Gαi1-T329A·GDP structures reveals some key differences. The protonated side chain of R178 involved
in forming H-bonding interactions with the oxygen of the α- and β-phosphate on GDP in the WT Gαi1·GDP·Mg2+ rotates
by almost 180° in T329A, thus nullifying this stabilizing interaction. Extensive movement of switch I leads to flipping of the
K180 side chain away from the catalytic pocket into a more solvent-exposed environment. A key residue of the Mg2+
coordination sphere, T181, orients away from the Mg2+ binding site as well. The side chain of S47, a direct Mg2+-binding
ligand, undergoes a conformational switch orienting it away from the Mg2+ binding site. All other proximal residues adopt
a side-chain conformation in the mutant similar to that observed in the WT protein. Concomitantly, the T329A substitution
also leads to the displacement of the nucleotide in the catalytic pocket, indicative of the disruptions in the cooperative Hbond network within the catalytic pocket in the mutant. (b) A superposition of the WT Gαi1·GDP·Mg2+ (green) structure
with the Gαi1-T329A·GDP structure (salmon) shows distinct organization of the water molecules within the catalytic
pocket. The mutant structure shows absence of Mg2+ coordinating water molecules, namely, W801, W802 and W803,
further substantiating the observation of loss of Mg2+ from the catalytic pocket. (c) Coleman and Sprang showed that with
increasing concentrations of Mg2+, WT Gαi1 undergoes conformational changes inducing order in the structure reminiscent
of the activated WT Gαi1·GTPγS·Mg2+ state.40 The rate of nucleotide exchange for the WT Gαi1 protein and the slowexchange mutants (Q52A, V332A and Q52A T329A) is very much dependent on the concentration of Mg2+ present in the
reaction buffer, possibly due to the influence of a completely or partially intact Mg2+ coordination sphere stabilizing the
bound nucleotide. The rates of exchange for the rapid-exchange mutants, T329A and F336A, remain by and large
unaffected by increasing Mg2+ concentrations, substantiating the structural determinants, consistent with the disruption of
the Mg2+ coordination sphere in the Gαi1-T329A·GDP structure as shown above. (d) Unlike the GDP-bound state, the
residues aligned along the catalytic pocket involved in both electrostatic and hydrophobic interactions with the bound
nucleotide in the GTPγS-bound state are much more static. The side-chain orientations are similar or identical, with no
displacement of the bound nucleotide in either the Gαi1-T329A·GTPγS·Mg2+ or WT Gαi1·GTPγS·Mg2+. These results show
that even if the rates of nucleotide exchange are different, post-exchange a higher degree of order is restored in the
structure, which is independent of amino acid substitution on the α5 helix.
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Hubbell and coworkers conducted a site-directed
spin-label EPR study of α5 helix residues and
suggested that R⁎-stimulated activation causes a
rigid-body movement of the α5 helix, which
perturbed the β6–α5 loop and thereby decreased
GDP stability in the catalytic pocket.28 In addition,
allosteric changes at the Gα–Gβγ interface triggered
by interactions with R⁎ were observed, along with
significant changes even in the dynamics of residues
(A300 on the α4 helix) distant to the receptor or the
Gα–Gβγ interface.29,30 An alternative hypothesis
suggested that the receptor first engages Gβγ and
then triggers the GDP release by interacting with
the CT of Gα in a “sequential” manner.43,44 All of
these studies suggest a potential important role for
the α5 helix of Gα in the activation pathway. The
receptor would engage the CT of Gα (connecting
to the α5 helix) to induce conformational changes
facilitating the release of bound GDP from the
catalytic pocket.
In the absence of R⁎, the CT is unstructured and
becomes mainly helical upon binding to the activated
receptor.45,46 This binding also induces conformational rearrangement within the receptor.33 However, intriguingly, the CT interacts with the receptor
primarily through its backbone atoms, which suggests that the CT alone cannot provide specificity and
selectivity to the binding event coupled to G protein
activation. In contrast to this observation, Conklin et
al. earlier demonstrated through a series of experiments that only a minimum of three amino acid
substitutions in the C-terminal region switches the
receptor specificity of Gαq to that of Gαi, highlighting
the contribution of CT.47 However, in Gαi2 and Gt,
the last eight residues are identical, but the α2adrenergic receptor only activated Gαi2 selectively.48
All these observations suggest that the CT alone
cannot be the sole determinant of R⁎–G protein
specificity, and other regions of the α-subunit along
with contributions from the Gβγ subunit49 must
provide elements that contribute to the overall
selectivity of this interaction.
The α5 helix of Gα is directly proximal to the CT
and is highly structured, pointing directly from the
N-terminal portion of CT into the nucleotide-binding
pocket. Therefore, we hypothesized earlier that α5
might be a key structural element in transmitting the
signal of Gα binding to R⁎ to the nucleotide-binding
pocket. This hypothesis was supported by the results
of mutagenesis experiments showing that amino acid
substitutions in the α5 helix resulted in dramatically
enhanced rates of nucleotide exchange even in the
absence of receptor. Mutagenesis of Gt26,27 and
follow-up computational molecular dynamics
studies50 suggested that a receptor-induced movement of the α5 helix of the Gα subunit might affect the
local structure of the GDP-binding pocket via the α1
helix and β2 and β3 strands. Although biophysical
studies of the A326S Gαi1 mutant suggested that it
might be a mimic of the receptor-bound activated
state, a follow-up crystal structure of Gα i1 A326S·GDP showed that its GDP-binding pocket
was no different from that of WT Gαi1.23
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Structural studies on the Gαi1-T329A mutant
presented here show extensive movement of the
switch I region and disruption of the Mg 2+
coordination sphere within the catalytic pocket.
There are also drastic changes in the conformations
of side chains of residues lining the catalytic pocket,
also resulting in decreased stability of the bound
GDP nucleotide. Interestingly, the residue R178
even in the structure of the heterotrimer (PDB code
1GG2) adopts a conformation where it is oriented
away from the catalytic pocket, as shown in Fig. S6.
As shown by Abdulaev et al., Gα adopts a
“preactivated” conformation when associated with
Gβγ.51 An altered conformation of R178 might
contribute to acquiring this state. These changes
concomitantly cause the destabilization and displacement of the bound nucleotide.
Also, the results from the cell-based in vitro SEAP
assay (Fig. 2b and c) show that ligand-stimulated
inhibition is much stronger for the mutants in
comparison to the WT protein. This must be possible
only because the mutant, similar to WT protein, can
interact with the receptor and the Gβγ subunit. As
shown in Fig. S7, both WT and Gαi1-T329A subunits
can interact with Gβγ subunit in vitro, leading to
substantial inhibition of activation. The observation
and rationalization of these changes in the Gαi1T329A mutant suggest that the T329A replacement
has stabilized a structural intermediate along the
activation pathway. The structure of the mutant
subunit provides a plausible insight into the
mechanism of nucleotide exchange and allows us
to explain convincingly the allosteric effect of the α5
helix on the basal rate of exchange.
We did not observe any substantial movement of
the α5 helix itself or of the nucleotide-interacting
β6–α5 loop within the structures, probably because
the structure of the Gαi1-T329A mutant represents
an intermediate along the activation pathway and
not a true transition state in the exchange process.
We presume that a transient movement of α5 along
with other contributing conformational changes
must occur earlier in the process, which could not
be trapped in the crystal structure of the T329A-Gαi1
mutant. In support of this explanation, a recent
molecular dynamics simulation reported by
Scheerer et al. shows that the α5 helix might act as
a transmission rod that undergoes both translation
and rotation upon engagement of G protein by the
activated receptor.52
Recently, Johnston and Siderovski solved the
crystal structure of the WT Gαi1·GDP subunit
bound to two peptides corresponding to the Nterminal region of the third intracellular loop of the
D2-dopamine receptor and a Gβγ surrogate peptide
(KB-752).22 Each of these peptides can act as a Gα
guanine nucleotide exchange factor (GEF). Their
work showed that binding of the peptides to the
GDP-bound form displaces the β6 strand away from
the α4 helix and toward the α5 helix from its
position in the unbound protein. The Gαi1-T329A
replacement described here promotes a similar
movement of the β6 strand in the GDP-bound
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structure (Fig. S8), which further supports the
hypothesis that the mutation most likely traps an
intermediate along the activation pathway.
Based on our analysis, we propose a sequential
release model for G protein activation (Fig. 5).
Initially, the activated receptor interacts with the
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heterotrimer (Gαβγ) and induces a helical conformation into the unstructured CT of the α-subunit.
This binding event translates to an activation signal,
which we propose is transmitted to the catalytic
pocket via the α5 helix. During activation, the switch
I region of the α-subunit undergoes extensive

Fig. 5. A proposed sequential release model of G protein activation by GPCRs. The prototypical GPCR opsin (salmon)
complexed with the C-terminal (CT) peptide (residues 340–350) from transducin (Gt) (green) (PDB code 3DQB) is depicted
as a ribbon diagram in a cartoon. The heterotrimeric G protein subunits Gα (gray), Gβ (light pink) and Gγ (blue) are
shown as a complex (PDB code 1GG2) with Gαi1·GDP replaced with the mutant Gαi1-T329A·GDP structure. The α5 helix
of Gαi1 is highlighted in red. Since the CT is not resolved in the structure of the heterotrimer, the G protein is docked to the
active receptor (R⁎) as suggested by Scheerer et al.33 Upon G protein activation, switch I (S1, dark pink) and switch II (S2,
light green) of the α subunit undergo conformational changes. The switch I region is highlighted to show the extent of
movement. In our proposed model of the G protein activation cycle: (1) The receptor first engages the CT of the α subunit,
which brings the α5 helix directly to the surface of R⁎. (2) Receptor binding along with docking of the Gββγ subunit
facilitates allosteric structural modulation of the α subunit to cause an outward movement of its switch I region. (3) These
accumulating conformational changes disrupt the Mg2+ binding site in the catalytic pocket leading to its dissociation. (4)
The loss of Mg2+ and structural rearrangements of key residues (S47, T181, R178) overall destabilizes the bound GDP and
facilitates its faster release from the catalytic pocket. (5) The transient intermediate of empty pocket Gαβγ bound to R⁎ is
formed. GTP and Mg2+ rebind to Gα leading to the dissociation of the heterotrimer into the Gα and Gβγ subunits. Finally,
the bound GTP is hydrolyzed to GDP + Pi and the inactive Gα·GDP subunit can reassociate with Gβγ to initiate another G
protein activation cycle. The structure of the T329A mutant, which shows an increased rate of receptor-independent GDP
release, may represent an intermediate that mimics the Mg2+ free state of the G protein during the activation cycle.
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outward movement away from the catalytic pocket,
as seen on comparison of Gαi1-T329A·GDP and
Gαi1·GDP·Mg2+ estructures. This spatial rearrangement of switch I coupled to conformational changes
in the side chains of key residues (S47, T181, R178)
lining the catalytic pocket together disrupt the
coordination sphere of Mg2+ . The loss of Mg2+
along with the accumulating conformational
changes destabilizes the bound GDP, which can
now be exchanged for GTP at a much more rapid
rate to accelerate G protein activation. This activation triggers the dissociation of the heterotrimer into
the Gα and Gβγ subunits, rendering them available
for interacting with their respective downstream
effectors.
As expected, the kinetics of the overall process of
nucleotide exchange is modulated by the presence of
Mg2+. However, the rapid-exchange mutants (Gαi1T329A and Gαi1-F336A) show an increased rate of
activation independent of the concentration of Mg2+.
This can be rationalized by the absence of a
coordination sphere for Mg2+ in the crystal structure
of Gαi1-T329A. However, as seen in WT Gαi1, GTPγS
binding assays with the slow-exchange mutants
(Gα i1 -Q52A, Gα i1 -V332A, Gα i1 -Q52A/T329A)
show a decrease in the rate of activation with
increasing concentration of Mg2+, probably due to
a partially intact Mg2+ coordination sphere in the
catalytic pocket. This model suggests the existence of
an “allosteric switch,” meaning that a transient
ternary complex with a finite lifetime should exist
between GDP-bound G protein and R⁎ complex, as
suggested earlier by Heck and Hofmann using a
kinetic analysis.53 The alternate model would be a
so-called hit-and-run model, where R⁎ and GDP
binding to Gα would be mutually exclusive. Our
structural studies suggest, in fact, a transient state
between R⁎·G[GDP-Mg2+] and R⁎·G[empty], namely, R⁎·G[GDP- ], where Mg2+ has exited and GDP
remains, causing destabilization of the GDP-binding
pocket.
G proteins comprise a superfamily consisting of
both the heterotrimeric and small monomeric G
proteins.54,55 Similar to heterotrimeric G proteins,
small G proteins also undergo conformational
changes in switch regions upon activation. Binding
to GTPγS induces order in both switch I and switch
II regions.56,57 Recently, Thomas et al. solved the cocrystal structure of a plant small G protein Rop4
(Rho of plants) in complex with the catalytic PRONE
domain of RopGEF8.58 The structure of this never
previously observed ternary complex of Rop4,
PRONE domain and GDP suggested a general
mechanism of small G protein activation. Namely,
Rop4 binding to RopGEF8 causes displacement of
Mg2+ through steric hindrance of its binding site,
moves switch I away from the nucleotide and
pushes switch II toward the conserved phosphatebinding P-loop. The extended movement of the
switch I region further facilitates the sequential exit
of Mg2+ followed by GDP from the catalytic pocket,
leading to accelerated exchange of nucleotide. Our
structural studies of a heterotrimeric G protein α-
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subunit mutant also highlight the disruption of the
Mg2+ coordination sphere and movement of the
switch I region with concomitant destabilization of
the bound nucleotide. These independent, yet
obviously related, observations hint at a similar
shared mechanism of activation for the two subclasses of G proteins, heterotrimeric G proteins and
small, single-subunit G proteins.
In summary, our results provide novel structural
insights toward understanding the mechanism of
nucleotide exchange by heterotrimeric G proteins.
The structural studies reported here, supplemented
with biophysical data, demonstrate a critical dependence of basal nucleotide exchange rate on Mg2+. As
observed in the high-resolution crystal structure of
the Gα i1-T329A mutant, with an amino acid
replacement in the α5 helix, movement in the switch
I region disrupts the coordination sphere of Mg2+
and increases the effective size of the nucleotidebinding pocket. These changes, in association with
the conformational changes of other binding pocket
residues, result in overall destabilization of the
bound GDP, leading to rapid exchange of GDP for
GTPγS. The complete conservation of residues T329
and F336 across different classes of G protein αsubunits suggests a critical role of these residues
(Fig. S9). Furthermore, our mutational analysis
suggests that similar mechanisms of activation
might be utilized for the different α-subunits. We
believe that the novel mechanistic aspects highlighted here, along with the observations from other
relevant studies on related systems, allow a greater
understanding of the allosteric mechanism of
nucleotide exchange by G proteins.

Materials and Methods
Reagents
GDP sodium salt and GTPγS tetralithium salt were
purchased from Sigma-Aldrich (St. Louis, MO). The
fluorescent GTPγS analogue, mant-GTPγS was purchased
from Jena Biosciences (Jena, Germany). The His6-tagged
mutants of WT Gαi1 were generated by site-directed
mutagenesis using the high-fidelity thermostable DNA
polymerase Pfu (Stratagene, CA). All crystallographic
reagents were purchased from Hampton Research (Aliso
Viejo, CA). All reagents and chemicals used were of
highest available purity.
Construction, expression and purification of
Gαi1 proteins
The DNA fragment containing the WT rat Gαi1 subunit
(residues 1–354) was amplified by PCR and cloned into the
pET28a(+) expression vector (Amersham Biosciences,
Piscataway, NJ) with the BamHI and NotI restriction
sites. The vector was used to transform BL21 (DE3) cells to
express an N-terminal His6-tag WT Gαi1 protein containing
a PreScission protease site directly after the His6-tag. The
same construct served as a template for introducing sitespecific mutations in the protein with the QuickChange
system (Stratagene, La Jolla, CA) according to the
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manufacturer's protocol. The mutations were confirmed by
DNA sequencing (DNA Sequencing Facility, Genelink, NJ).
The WT and the mutants were expressed in BL21 (DE3)
cells grown in the presence of kanamycin (50 μg/ml). Cells
were grown at 37 °C to A600 nm of ∼0.7 and then induced
with 400 μM isopropyl-β-D-thiogalactoside (IPTG) (US
Biological). The culture was then grown overnight at 17 °C
at an agitation speed of 180 rpm. Cells were harvested by
centrifugation, and the resulting pellets were resuspended
on ice in a buffer containing 50 mM Tris–HCl (pH 8.0),
150 mM NaCl, 2 mM MgCl2, 10 μM GDP, 50 mM βmercaptoethanol, bovine lung aprotinin (20 mg/ml), 2 mM
PMSF and complete EDTA (ethylenediaminetetraacetic
acid)-free protease inhibitor cocktail tablets (Roche). The
cells were snap-frozen in liquid nitrogen and stored at
−80 °C. For purification, the cells were thawed on ice and
lysed with a French press (Avestin). The lysate was spun for
90 min at 16,500 rpm. The resulting supernatant fraction
was filtered through a 0.45-μm filter (Nalgene) and loaded
onto a nickel–nitrilotriacetic acid (Ni–NTA) Superflow
resin column (GE Healthcare) that was equilibrated with
buffer A [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM
MgCl2, 10 μM GDP, 50 mM β-mercaptoethanol]. The
protein-loaded resin was washed with buffer A and the
bound protein was eluted, using a gradient of buffer B
(buffer A supplemented with 500 mM imidazole). The
eluted protein fractions were pooled, extensively dialyzed
against buffer A and cleaved with 1:1000 A280 unit of
glutathione S-transferase PreScission protease for 48 h in
order to remove the N-terminal his-tag. The sample was
then loaded onto a Ni–NTA column to separate the cleaved
protein from the cleaved His-tag and any uncleaved
fraction. Next, the protein solution was loaded onto a
glutathione Sepharose 4B column (GE Healthcare) to
separate the glutathione S-transferase fusion PreScission
protease protein from the cleaved protein. The resin was
equilibrated with buffer A. The resin was first washed in
buffer A and the bound PreScission protease was eluted
using a gradient of buffer B (buffer A supplemented with
20 mM reduced glutathione). SDS-PAGE was used to test
the purity of the chromatography fractions. Thereafter, the
appropriate fractions were pooled and concentrated to a
volume of less than 5 ml and loaded onto a Superdex 200
26/60 column (GE Healthcare) that was equilibrated in
buffer C [50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM
MgCl2, 10 μM GDP, 2 mM DTT]. After elution, the
protein-containing fractions were pooled, concentrated to
N 50 mg/ml, snap-frozen in liquid nitrogen and stored at
−80 °C. The average yield for WT Gαi1 and each mutant
was N 10 mg/l of culture.
Fluorescence-based kinetic assays
Time-based fluorescence measurements were performed in a SPEX Fluorolog-2 spectrofluorometer (SPEX
Industries, Edison, NJ) at 25 °C. WT Gαi1 was incubated in
the reaction buffer [50 mM Tris–HCl (pH 8.0), 150 mM
NaCl, 2 mM MgCl2 and 1 mM DTT] for 5 min with
constant stirring. GTPγS (178 μM) was added to the
reaction mixture with WT Gαi1 (178 nM) and the relative
increase in intrinsic fluorescence (λex = 295 nm, λem =
340 nm) was measured as a function of time. The same
procedure was carried out for all Gαi1 mutants. Mg2+dependent nucleotide exchange rates were determined by
varying the concentration of Mg2+ in the reaction buffer.
Pseudo-first-order exchange rates were determined by
fitting the data to an exponential association curve, Y = Y0 +
a[1 − exp(−kappt)], using Sigma Plot 10.0, where kapp is the
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apparent rate constant and t is the time in seconds. The t1/2
values were calculated using t1/2 = (ln 2)/kapp. The pseudofirst-order kinetic analysis was valid due to the presence of
excess GTPγS in the reaction mixture. The data are
reported as the average value obtained from three to five
experiments. The GTPγS-binding assay was also done
with a linear temperature gradient from 5 to 35 °C with the
same method. A kapp was calculated for each temperature
step at intervals of 5 °C by pseudo-first-order kinetic
analysis. The activation energy for reaction Ea was
calculated using kapp = A exp[-Ea/(RT)] for the Arrhenius
analysis, where A is the preexponential factor, Ea is the
activation energy of the exchange reaction, R is the
universal gas constant (8.314 J mol− 1 K− 1) and T is the
temperature in kelvins. For mant-GTPγS binding assays,
Gαi1 protein samples (178 nM) were incubated for 5 min
(same buffer as the GTPγS binding assay) at 25 °C,
followed by the addition of mant-GTPγS (300 nM). FRET
was monitored by exciting the intrinsic Trp fluorescence at
295 nm and measuring the mant-GTPγS fluorescence from
310 to 540 nm. In all cases, blank spectra containing buffer
alone were subtracted from the final spectra.
Cell-based assay of Gαi1-T329A
The EE-tagged WT and constitutively active (GTPase
deficient) human Q204L expression constructs were
obtained from the Missouri S&T cDNA Resource Center†.
The T329A point mutation was generated with sitedirected mutagenesis and confirmed by sequencing.
HEK293 cells (ATCC) were maintained in Dulbecco's
modified Eagle's medium (Invitrogen) with 10% (v/v)
fetal calf serum (FCS) at 37 °C and 5% CO2. For the SEAP
assay described below, cells were plated in 10-cm dishes
and transiently transfected with pCRE-SEAP (BD Biosciences) and pcDNA3.1(+) control, WT Gαi1 or mutantGαi1 expression constructs using Lipofectamine Plus
(Invitrogen). Briefly, 3.5 μg of total DNA (0.5 μg of
pCRE-SEAP + 3 μg of G protein expression vector) was
complexed with 10 μl of PLUS reagent and 17 μl of
Lipofectamine reagent and incubated for 15 min at room
temperature before addition of the DNA–lipid mixture to
cells. Cells were plated 24 h after transfection at a density
of 20,000 cells per well in poly-D-lysine-coated 384-well
plates. Cells were serum-starved in 0.1% FCS overnight
and subjected to the SEAP assay, which was performed as
described previously with some modifications to employ a
384-well format. About 48 h after transfection, cells were
left untreated (basal) or stimulated with FK for 6 h in 0.1%
FCS. Briefly, 2 μl of culture medium supernatant fractions
were transferred to white 384-well low-volume ProxiPlate
(PerkinElmer) containing 5 μl of dilution buffer [150 mM
NaCl and 40 mM Tris–HCl (pH 7.2)] and heat inactivated
at 65°C for 20 min (to heat inactivate the endogenous
alkaline phosphatase). Equal volumes (7 μl) of assay buffer
(2 M diethanolamine, 10 mM MgCl2, 20 mM L-homo-Arg,
adjusted to pH 9.8), reaction solution containing enhancer
solution (Tropics, Bedford, MA) and 0.4 mM SEAP
chemiluminescent substrate (Tropics) were added to
each well. Luminescence was quantified 15 min after
substrate addition with an EnVision Multimode Plate
Reader (Perkin Elmer). To allow comparison between
different experiments and to assess the effect of different
mutant G proteins, data were normalized relative to signal
obtained in mock-transfected cells in the presence of
12.5 μM FK, defined as 100%. Dose response experiments
† www.cdna.org
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were performed with FK ranging from 0.2 to 25 μM.
Assays were performed in triplicate and data were
analyzed using Origin 7.0 software.
Crystallization and structural determination
The protein stock solution of Gαi1-T329A·GDP at
120 mg/ml in storage buffer (50 mM Tris–HCl, 150 mM
NaCl, 2 mM MgCl2, 10 μM GDP, 2 mM DTT) was diluted
to 10 mg/ml using the dilution buffer [50 mM EPPS
(pH 8.0), 1 mM EDTA, 2 mM MgCl2, 5 mM GDP, 5 mM
DTT]. Crystals of Gαi1-T329A bound to GDP were
obtained by the hanging-drop vapor-diffusion method in
1.8–2.1 M (NH4)2SO3 and 100 mM sodium acetate (pH 5.9–
6.3), as described earlier by Sprang and coworkers.59
Crystals of size 0.2 mm × 0.5 mm × 0.5 mm formed in 5–7
days at 20 °C in the space group I4 (a = b = 120.4 Å,
c = 69.8 Å, α = β = γ = 90°) with one Gαi1-T329A·GDP
molecule in the asymmetric unit. Crystals for Gαi1T329A·GDP at 10 mM MgCl2·6H2O in the dilution buffer
were grown under similar conditions and showed the
same space group. A similar strategy was used to grow
crystals of Gαi1-T329A·GTPγS·Mg2+ by preparing a
solution of 10 mg/ml by incubating the protein stock
for 60 min with 5 mM GTPγS in storage buffer instead of
GDP. The Gαi1-T329·GTPγS·Mg2+ complex crystallized in
the space group P3221 (a = b = 78.93 Å, c = 105.62 Å) with
one Gαi1-T329A·GTPγS·Mg2+ molecule in the asymmetric
unit. For data collection at 100 K, crystals were
transferred to well solution supplemented with 20%
glycerol and 2.5 M (NH4)2SO3 for ∼ 30 s followed by
immersion in liquid nitrogen. The native data sets were
collected at beam line NE-CAT (24ID) of the Advanced
Photon Source (APS) at Argonne National Laboratory.
The data sets were indexed and processed using
HKL200060 and Mosflm.61 The structures of Gαi1T329A·GDP and Gαi1-T329A· GTPγS·Mg2+ complexes
were determined by molecular replacement using only
the Cα backbone from 1BOF (WT Gαi1·GDP·Mg2+) and
1AS0 (Gαi1-G42V·GTPγS·Mg2+ ) structures as search
models for Phaser in the CCP4 suite‡. Thereafter, CNS
was utilized to obtain simulated annealing generated
models for both GDP- and GTPγS-bound states of Gαi1T329A. Finally, model building was performed in Coot,62
wherein nucleotide and Mg2+ were fitted into the
observed densities with refinement conducted by
Refmac5 in CCP4 as well as a combination of rigidbody, simulated annealing, energy minimization, and Bfactor protocols in CNS.63 The structural superpositions
were done using SSM superposition for Cα carbon
backbone in Coot. All structural images were made
with PyMOL§ unless otherwise indicated. The ligand
coordination images for GDP and GTPγS were made
using Ligplot.64
PDB accession numbers
Structure factors and coordinates are deposited in the
Research Collaboratory for Structural Bioinformatics
protein database with PDB codes 3FFA (Gαi1-T329A·
GTPγS·Mg2+) and 3FFB (Gαi1-T329A·GDP) for the respective structures.

‡ http://www.ccp4.ac.uk
§ http://www.pymol.org

895

Acknowledgements
Use of the APS is supported by the U.S. Department of Energy, Office of Science, Office of Basic
Energy Sciences, under W-31-109-Eng-38. Use of the
Northeastern Collaborative Access Team (NE-CAT)
beam line at Sector 24 is based on research
conducted at the NE-CAT beam lines of the APS,
which is supported by award RR-15301 from the
National Center for Research Resources at the
National Institutes of Health. Purified Gβ1γ2 subunit was a generous gift of Xin-Yun Huang of
Cornell–Weill Medical College. We thank Ethan P.
Marin and K. Christopher Min for helpful discussions on crystallographic and structural analysis.

Supplementary Data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1016/
j.jmb.2009.08.043

References
1. Gilman, A. G. (1987). G proteins: transducers of
receptor-generated signals. Annu. Rev. Biochem. 56,
615–649.
2. Birnbaumer, L. (1993). Heterotrimeric G proteins.
Molecular diversity and functional correlates. J. Recept.
Res. 13, 19–26.
3. Birnbaumer, L. (1992). Receptor-to-effector signaling
through G proteins: roles for beta gamma dimers as
well as alpha subunits. Cell, 71, 1069–1072.
4. Birnbaumer, L., Abramowitz, J. & Brown, A. M.
(1990). Receptor-effector coupling by G proteins.
Biochim. Biophys. Acta, 1031, 163–224.
5. Oldham, W. M. & Hamm, H. E. (2006). Structural basis
of function in heterotrimeric G proteins. Q. Rev.
Biophys. 39, 117–166.
6. Oldham, W. M. & Hamm, H. E. (2008). Heterotrimeric
G protein activation by G-protein-coupled receptors.
Nat. Rev. Mol. Cell Biol. 9, 60–71.
7. Johnston, C. A. & Siderovski, D. P. (2007). Receptormediated activation of heterotrimeric G-proteins:
current structural insights. Mol. Pharmacol. 72, 219–230.
8. Bourne, H. R. (1997). How receptors talk to trimeric G
proteins. Curr. Opin. Cell Biol. 9, 134–142.
9. Hamm, H. E. (1998). The many faces of G protein
signaling. J. Biol. Chem. 273, 669–672.
10. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A.,
Motoshima, H., Fox, B. A. et al. (2000). Crystal
structure of rhodopsin: a G protein-coupled receptor.
Science, 289, 739–745.
11. Cherezov, V., Rosenbaum, D. M., Hanson, M. A.,
Rasmussen, S. G., Thian, F. S., Kobilka, T. S. et al.
(2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled
receptor. Science, 318, 1258–1265.
12. Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M.,
Kobilka, T. S., Thian, F. S., Edwards, P. C. et al. (2007).
Crystal structure of the human beta2 adrenergic Gprotein-coupled receptor. Nature, 450, 383–387.
13. Noel, J. P., Hamm, H. E. & Sigler, P. B. (1993). The 2.2
Å crystal structure of transducin-alpha complexed
with GTP gamma S. Nature, 366, 654–663.

Heterotrimeric G Protein GDP Release Mechanism

896
14. Lambright, D. G., Noel, J. P., Hamm, H. E. & Sigler,
P. B. (1994). Structural determinants for activation of
the alpha-subunit of a heterotrimeric G protein.
Nature, 369, 621–628.
15. Mixon, M. B., Lee, E., Coleman, D. E., Berghuis, A. M.,
Gilman, A. G. & Sprang, S. R. (1995). Tertiary and
quaternary structural changes in Gi alpha 1 induced
by GTP hydrolysis. Science, 270, 954–960.
16. Sunahara, R. K., Tesmer, J. J., Gilman, A. G. & Sprang,
S. R. (1997). Crystal structure of the adenylyl cyclase
activator Gsalpha. Science, 278, 1943–1947.
17. Kreutz, B., Yau, D. M., Nance, M. R., Tanabe, S.,
Tesmer, J. J. & Kozasa, T. (2006). A new approach to
producing functional G alpha subunits yields the
activated and deactivated structures of G alpha
(12/13) proteins. Biochemistry, 45, 167–174.
18. Raw, A. S., Coleman, D. E., Gilman, A. G. & Sprang,
S. R. (1997). Structural and biochemical characterization of the GTPgammaS-, GDP·Pi-, and GDP-bound
forms of a GTPase-deficient Gly42→Val mutant of
Gialpha1. Biochemistry, 36, 15660–15669.
19. Wall, M. A., Coleman, D. E., Lee, E., Iniguez-Lluhi, J. A.,
Posner, B. A., Gilman, A. G. & Sprang, S. R. (1995). The
structure of the G protein heterotrimer Gi alpha 1 beta 1
gamma 2. Cell, 83, 1047–1058.
20. Sondek, J., Bohm, A., Lambright, D. G., Hamm, H. E.
& Sigler, P. B. (1996). Crystal structure of a G-protein
beta gamma dimer at 2.1Å resolution. Nature, 379,
369–374.
21. Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P.,
Hamm, H. E. & Sigler, P. B. (1996). The 2.0 Å crystal
structure of a heterotrimeric G protein. Nature, 379,
311–319.
22. Johnston, C. A. & Siderovski, D. P. (2007). Structural
basis for nucleotide exchange on G alpha i subunits
and receptor coupling specificity. Proc. Natl Acad. Sci.
USA, 104, 2001–2006.
23. Posner, B. A., Mixon, M. B., Wall, M. A., Sprang, S. R. &
Gilman, A. G. (1998). The A326S mutant of Gialpha1 as
an approximation of the receptor-bound state. J. Biol.
Chem. 273, 21752–21758.
24. Thomas, C. J., Du, X., Li, P., Wang, Y., Ross, E. M. &
Sprang, S. R. (2004). Uncoupling conformational
change from GTP hydrolysis in a heterotrimeric G
protein alpha-subunit. Proc. Natl Acad. Sci. USA, 101,
7560–7565.
25. Natochin, M., Moussaif, M. & Artemyev, N. O. (2001).
Probing the mechanism of rhodopsin-catalyzed transducin activation. J. Neurochem. 77, 202–210.
26. Marin, E. P., Krishna, A. G. & Sakmar, T. P. (2001).
Rapid activation of transducin by mutations distant
from the nucleotide-binding site: evidence for a
mechanistic model of receptor-catalyzed nucleotide
exchange by G proteins. J. Biol. Chem. 276, 27400–27405.
27. Marin, E. P., Krishna, A. G. & Sakmar, T. P. (2002).
Disruption of the alpha5 helix of transducin impairs
rhodopsin-catalyzed nucleotide exchange. Biochemistry,
41, 6988–6994.
28. Oldham, W. M., Van Eps, N., Preininger, A. M.,
Hubbell, W. L. & Hamm, H. E. (2006). Mechanism of
the receptor-catalyzed activation of heterotrimeric G
proteins. Nat. Struct. Mol. Biol. 13, 772–777.
29. Oldham, W. M., Van Eps, N., Preininger, A. M.,
Hubbell, W. L. & Hamm, H. E. (2007). Mapping
allosteric connections from the receptor to the
nucleotide-binding pocket of heterotrimeric G proteins. Proc. Natl Acad. Sci. USA, 104, 7927–7932.
30. Van Eps, N., Oldham, W. M., Hamm, H. E. & Hubbell,
W. L. (2006). Structural and dynamical changes in an

31.

32.

33.

34.
35.

36.
37.
38.
39.

40.

41.

42.

43.

44.

45.

46.

47.

alpha-subunit of a heterotrimeric G protein along the
activation pathway. Proc. Natl Acad. Sci. USA, 103,
16194–16199.
Preininger, A., Funk, M., Meier, S., Oldham, W.,
Johnston, C., Adhikary, S. et al. (2009). Helix dipole
movement and conformational variability contribute
to allosteric GDP release in Gi subunits. Biochemistry,
48, 2630–2642.
Koenig, B. W., Kontaxis, G., Mitchell, D. C., Louis, J. M.,
Litman, B. J. & Bax, A. (2002). Structure and orientation
of a G protein fragment in the receptor bound state from
residual dipolar couplings. J. Mol. Biol. 322, 441–461.
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J.,
Krauss, N., Choe, H. W. et al. (2008). Crystal structure
of opsin in its G-protein-interacting conformation.
Nature, 455, 497–502.
Fahmy, K. & Sakmar, T. P. (1993). Light-dependent
transducin activation by an ultraviolet-absorbing
rhodopsin mutant. Biochemistry, 32, 9165–9171.
Coleman, D. E., Berghuis, A. M., Lee, E., Linder, M. E.,
Gilman, A. G. & Sprang, S. R. (1994). Structures of
active conformations of Gi alpha 1 and the mechanism
of GTP hydrolysis. Science, 265, 1405–1412.
Insel, P. A. & Ostrom, R. S. (2003). Forskolin as a tool for
examining adenylyl cyclase expression, regulation, and
G protein signaling. Cell. Mol. Neurobiol. 23, 305–314.
Levitzki, A. (1987). Regulation of adenylate cyclase by
hormones and G-proteins. FEBS Lett. 211, 113–118.
Gupta, A., Decaillot, F. M. & Devi, L. A. (2006).
Targeting opioid receptor heterodimers: strategies for
screening and drug development. AAPS J. 8, E153–E159.
Durocher, Y., Perret, S., Thibaudeau, E., Gaumond,
M. H., Kamen, A., Stocco, R. & Abramovitz, M.
(2000). A reporter gene assay for high-throughput
screening of G-protein-coupled receptors stably or
transiently expressed in HEK293 EBNA cells grown
in suspension culture. Anal. Biochem. 284, 316–326.
Coleman, D. E. & Sprang, S. R. (1998). Crystal
structures of the G protein Gi alpha 1 complexed
with GDP and Mg2+: a crystallographic titration
experiment. Biochemistry, 37, 14376–14385.
Rondard, P., Iiri, T., Srinivasan, S., Meng, E., Fujita, T. &
Bourne, H. R. (2001). Mutant G protein alpha subunit
activated by Gbeta gamma: a model for receptor
activation? Proc. Natl Acad. Sci. USA, 98, 6150–6155.
Cherfils, J. & Chabre, M. (2003). Activation of G-protein
Galpha subunits by receptors through Galpha-Gbeta
and Galpha-Ggamma interactions. Trends Biochem. Sci.
28, 13–17.
Nanoff, C., Koppensteiner, R., Yang, Q., Fuerst, E.,
Ahorn, H. & Freissmuth, M. (2006). The carboxyl
terminus of the Galpha-subunit is the latch for
triggered activation of heterotrimeric G proteins.
Mol. Pharmacol. 69, 397–405.
Herrmann, R., Heck, M., Henklein, P., Kleuss, C.,
Hofmann, K. P. & Ernst, O. P. (2004). Sequence of
interactions in receptor-G protein coupling. J. Biol.
Chem. 279, 24283–24290.
Dratz, E. A., Furstenau, J. E., Lambert, C. G., Thireault,
D. L., Rarick, H., Schepers, T. et al. (1993). NMR
structure of a receptor-bound G-protein peptide.
Nature, 363, 276–281.
Kisselev, O. G., Kao, J., Ponder, J. W., Fann, Y. C.,
Gautam, N. & Marshall, G. R. (1998). Light-activated
rhodopsin induces structural binding motif in G
protein alpha subunit. Proc. Natl Acad. Sci. USA, 95,
4270–4275.
Conklin, B. R., Farfel, Z., Lustig, K. D., Julius, D. &
Bourne, H. R. (1993). Substitution of three amino acids

Heterotrimeric G Protein GDP Release Mechanism

48.

49.

50.

51.

52.

53.

54.

switches receptor specificity of Gq alpha to that of Gi
alpha. Nature, 363, 274–276.
Cerione, R. A., Staniszewski, C., Benovic, J. L.,
Lefkowitz, R. J., Caron, M. G., Gierschik, P. et al.
(1985). Specificity of the functional interactions of the
beta-adrenergic receptor and rhodopsin with guanine
nucleotide regulatory proteins reconstituted in phospholipid vesicles. J. Biol. Chem. 260, 1493–1500.
Kleuss, C., Scherubl, H., Hescheler, J., Schultz, G. &
Wittig, B. (1992). Different beta-subunits determine Gprotein interaction with transmembrane receptors.
Nature, 358, 424–426.
Ceruso, M. A., Periole, X. & Weinstein, H. (2004).
Molecular dynamics simulations of transducin: interdomain and front to back communication in activation
and nucleotide exchange. J. Mol. Biol. 338, 469–481.
Abdulaev, N. G., Ngo, T., Zhang, C., Dinh, A.,
Brabazon, D. M., Ridge, K. D. & Marino, J. P. (2005).
Heterotrimeric G-protein alpha-subunit adopts a
“preactivated” conformation when associated with
betagamma-subunits. J. Biol. Chem. 280, 38071–38080.
Scheerer, P., Heck, M., Goede, A., Park, J. H., Choe,
H. W., Ernst, O. P., Hofmann, K. P. & Hildebrand,
P. W. (2009). Structural and kinetic modeling of an
activating helix switch in the rhodopsin-transducin
interface. Proc. Natl. Acad. Sci. USA, 106, 10660–10665.
Heck, M. & Hofmann, K. P. (2001). Maximal rate and
nucleotide dependence of rhodopsin-catalyzed transducin activation: initial rate analysis based on a
double displacement mechanism. J. Biol. Chem. 276,
10000–10009.
Vetter, I. R. & Wittinghofer, A. (2001). The guanine
nucleotide-binding switch in three dimensions. Science,
294, 1299–1304.

897
55. Wennerberg, K., Rossman, K. L. & Der, C. J. (2005). The
Ras superfamily at a glance. J. Cell Sci. 118, 843–846.
56. Wittinghofer, F. (1998). Ras signalling. Caught in the
act of the switch-on. Nature, 394(317), 319–320.
57. Cherfils, J. & Chardin, P. (1999). GEFs: structural basis
for their activation of small GTP-binding proteins.
Trends Biochem. Sci. 24, 306–311.
58. Thomas, C., Fricke, I., Scrima, A., Berken, A. &
Wittinghofer, A. (2007). Structural evidence for a
common intermediate in small G protein-GEF reactions. Mol. Cell, 25, 141–149.
59. Coleman, D. E., Lee, E., Mixon, M. B., Linder, M. E.,
Berghuis, A. M., Gilman, A. G. & Sprang, S. R. (1994).
Crystallization and preliminary crystallographic
studies of Gi alpha 1 and mutants of Gi alpha 1 in
the GTP and GDP-bound states. J. Mol. Biol. 238,
630–634.
60. Minor, Z. O. a. W. (1997). Processing of X-ray
diffraction data collected in oscillation mode. Methods
Enzymol. 276, 307–326.
61. Leslie, A. G. W. (1992). Recent changes to MOSFLM
package for processing film and image plate data. Joint
CCP4 + ESF-EAMCB Newslett. Protein Crystallogr. 26.
62. Emsley, P. & Cowtan, K. (2004). Coot: model-building
tools for molecular graphics. Acta Crystallogr., Sect. D:
Biol. Crystallogr. 60, 2126–2132.
63. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano,
W. L., Gros, P., Grosse-Kunstleve, R. W. et al. (1998).
Crystallography & NMR system: a new software suite
for macromolecular structure determination. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 54, 905–921.
64. Wallace, A. C., Laskowski, R. A. & Thornton, J. M. (1995).
LIGPLOT: a program to generate schematic diagrams of
protein-ligand interactions. Protein Eng. 8, 127–134.

Figure S1. mant-GTPγS uptake by α5 helix mutants. Fluorescently-labeled nucleotide
(mant-GTPγS) was used to do FRET studies for monitoring rates of nucleotide exchange.
The α5 helix mutants Gαi1-T329A (top left), Gαi1-F336A (top middle), Gαi1-V332A (top
right), Gαi1-(Q52A T329A) (bottom middle) and Gαi1-Q52A (bottom right) all show
overall fast rates of nucleotide exchange in comparison to WT Gαi1 protein (lower left
panel).

Figure S2. The T329A mutation and model building. The crystal structure of
heterologously expressed Gαi1-T329A shows (a) density for alanine at the 329 position in
its protein sequence confirming the correctly characterized and crystallized protein.
Simulated Annealing OMIT-maps were generated for Gαi1-T329A•GDP while omitting
GDP from the analysis and for Gαi1-T329A•GTPγS•Mg2+ while excluding GTPγS and
Mg2+. A 2Fo-Fc simulated annealing OMIT-map contoured at 2σ for (b) Gαi1T329A•GDP (green) and (c) Gαi1-T329A•GTPγS•Mg2+ (yellow) is shown. The structures
for WT Gαi1•GDP (salmon) and WT Gαi1•GTPγS•Mg2+ (blue) are also superimposed.
The fit of the final model into the electron density is presented for the critical regions
close to the nucleotide for each structure. The nucleotide interacting β6/α5 loop is shown
in yellow. The residues corresponding to Switch 1 and Mg2+ coordination sphere are
shown in (d) pink for Gαi1-T329A•GDP and shown in (e) blue for Gαi1T329A•GTPγS•Mg2+.

Figure S3. Structural changes in the GTPγS-bound form of WT Gαi1 and Gαi1T329A structures. (A) The catalytic pocket of the GTPγS•Mg2+ bound (activated) form
of Gαi1-T329A shows the expected conservation of residues involved in the interaction
with both diphosphate and triphosphate nucleosides. The presense of Mg2+ also promotes
a greater degree of order and coordination density within the catalytic pocket, increasing
the overall stability of the state. (B) A superposition of the WT Gαi1-GTPγS•Mg2+ and
Gαi1-T329A-GTPγS•Mg2+ structures shows almost identical secondary structures. There
are also no observable differences in the orientation of the bound nucleotide.

Figure S4. Structural changes amongst the GDP-bound forms of WT Gαi1 and Gαi1T329A. The superposition of WT Gαi1•GDP and Gαi1-T329A•GDP shows key structural
differences. A zoom into the Ras domain (top) (and removal of the a3 helix for clarity)
reveals the displacement observed in the β6 strand between the structures. A zoom into
the catalytic pocket (below) shows a drastically altered switch 1 conformation between
the WT Gαi1•GDP and Gαi1-T329A•GDP structures. The superposition also shows the
bound Mg2+ in the WT Gαi1•GDP structure along with key residues, namely R178 and
T181, lining the catalytic pocket. A small displacement in position of the bound
nucleotide can also be observed.

Figure S5.

Thermodynamics analysis of the activation process. (A) In order to

analyze quantitatively the effect of mutation on the activation energy for the nucleotide
exchange process, we performed GTPγS-binding assays over a linear temperature
gradient. The fluorescence enhancement of W211 due to activation was monitored and
rates were calculated. Experiments were performed for the WT Gαi1 and Gαi1-T329A
mutant and kapp values were calculated for each data set at different temperatures. A plot
of lnk versus 1/T was fit to the Arrhenius equation to give activation energies for both
WT and mutant T329A Gαi1. The analysis revealed that the barrier for activation of the
mutant was lower by 5.1 kcal/mol compared to the WT.
Isothermal titration calorimetry (ITC) was performed to analyze the effect of
amino acid replacement on the apparent binding affinity of the nucleotide ligand and its
influence on the nucleotide exchange process. (B) ITC experiments of the binding of
GTPγS to three mutant Gαi1 subunits are shown along with their calculated
thermodynamic parameters. The binding of GTPγS to the Gαi1-T329A mutant was more
exothermic than GTPγS binding to WT Gαi1 (data not shown), possibly because it does
not exchange as rapidly as the mutants. The crystal structures of Gαi1T329A•GTPγS•Mg2+ and WT Gαi1•GTPγS•Mg2+ are almost identical, with an r.m.s.d. of
0.29 Å. Thus, the final GTPγS-bound states of the two complexes can be assumed to
have the same energy level on a reaction profile diagram. However, the crystal structure
of the GDP-bound form of the Gαi1-T329A mutant displays significant conformational
changes that destabilize its GDP-bound state. Hence, transition from the energetically
higher GDP-bound state should give larger reaction enthalpy. Our ITC data are in
excellent agreement with this rationale. The high activation barrier for the WT protein

makes the process of spontaneous basal nucleotide exchange slow and unfavorable,
although we observe strong binding constants for Gαi1-T329A. Since both the GTPγSbound states of the WT Gαi1 and Gαi1-T329A proteins show almost identical structures,
the higher affinity of Gαi1-T329A can be explained by the initial lower affinity for the
bound GDP. The loss of favorable interactions caused by the α 5 helix amino acid
replacement promotes faster release of the bound GDP. This creates a nucleotide-free
pocket readily available for GTPγS binding. The initial higher affinity of WT Gαi1 for
GDP explains its lower binding affinity for GTPγS, resulting in lower enthalpy of
reaction. The kinetically slower mutants Gαi1-Q52A/T329A and Gαi1-V332A display
lower apparent binding affinities for the triphosphate ligand than does Gαi1-T329A,
suggesting that replacements of Q52 and V332 destabilize the GDP-bound state to a
lesser extent than the T329A replacement.
ITC was performed at 25°C (298 K) using a MicroCal VP-ITC (MicroCal,
Northhampton, MA) calorimeter. Protein samples were dialyzed against the titration
buffer (50 mM Tris-HCl, pH8.0, 150 mM NaCl, 2 mM MgCl2, 10 µM GDP, 1 mM TCEP
(Tris-(2-carboxyethyl) phosphine)). Three buffer exchanges (each 4 hrs or more) were
done to remove DTT from the protein stock. GTPγS was not dialyzed due to its small
size. The GTPγS stock solution was prepared using the final dialysis buffer for the
protein solution. Both the experimental protein and GTPγS samples were thoroughly
degassed. Contents of the sample cell were stirred continuously at 280 rpm during the
experiment. A typical titration of Gαi1 mutants with GTPγS involved 50 injections each
of 5 µ l of GTPγS solution (500 µ M) into a sample cell containing 1.4 ml of WT or
mutant Gαi1 (50 µM). The heat of dilution of the titrant (GTPγS) was subtracted from the

titration data for base-line correction. The base line-corrected data were analyzed with
MicroCal OriginTM 6.0 software to determine the enthalpy (ΔH), association constant
(Ka), and stoichiometry of binding (N). Thermal titration data were fit to single site
binding model and thermodynamic parameters Δ H, Kd and entropy change (ΔS) were
obtained from the fits to the model. The parameters were calculated based on three or
more independent titration experiments. Each numerical value reported is the mean
experimental value ± S.E.M from three independent data sets. Gαi1-T329A displays
highest affinity for GTPγS in comparison with Q52A T329A and V332A mutant Gαi1
subunits. WT Gαi1 could not be tested because of its low affinity for the nucleotide and
its very slow basal GTPγS uptake rate.

Figure S6. Differential orientation of R178 residue. A superposition of α-subunits
from WT Gαi1•GDP•Mg2+ (PDB Code 1BOF) (Coleman & Sprang, 1998), WT
Gαi1•GDP•Mg2+ (from the heterotrimer complex) (PDB Code 1GG2) (Wall et al, 1995)
and Gαi1-T329A•GDP structures show differential orientation of the R178 residue. In the
WT Gαi1•GDP•Mg2+ structure R178 points into the catalytic pocket making electrostatic
interactions with the α- and β-phosphates of GDP whereas in the heterotrimer the R178 is
flipped outwards by 900 away from the catalytic pocket. Even in the Gαi1-T329A•GDP
structure the R178 residue flips away by almost 1800 and moves away from the catalytic
pocket.

Figure S7. Inhibition of G protein activation in the presence of Gβγ. WT G protein αsubunit or the T329A-Gαi1 in the GDP bound form are mixed with equimolar (178nM
each) quantities of Gβ1γ2 and AlF4- uptake is monitored by measuring the fluorescence
enchancement. Both WT and T329A-Gαi1 exhibit decrease in the fluorescence
enhancement observed in the presence of Gβ1γ2 in comparison to the α -subunits alone
suggesting a direct interaction between these difference components of the heterotrimeric
G proteins.

Figure S8. Structural changes facilitating nucleotide exchange. The structure of WT
Gαi1•GDP bound to two peptides (KB-752 and D2N) which interact with different
regions of the protein and synergistically cause an increase in the nucleotide exchange
rates, apparently acting as GEFs (guanine-nucleotide exchange factors) was recently
solved (Johnston & Siderovski, 2007) (PDB code 2hlb). Superimposition of the α5-β6-α4
domain of WT Gαi1•GTPγS•Mg2+, WT Gαi1•GDP•Mg2+, Gαi1-T329A•GDP and WT
Gαi1•GDP/KB-752/D2N shows a similar orientation of β6 strand for the T329A mutant
as observed by Siderovski et al. Unlike the case of T329A, the β6 strand in the active and
inactive forms of WT Gαi1 do not undergo any conformational changes.

Figure S9. Sequence alignment of C-terminal residues of Gα subunits. The sequence
alignment of the last 31 residues of various α -subunits comprising the P-loop, α 5 helix
and CT shows high degree of conservation. The residues T329 and F336 in WT Gαi1
show 100% conservation across various classes of α -subunits. The sequence alignment
was generated using the software clustalW.
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